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The de novo synthesis of genes is emerging as a powerful tool in biotechnology. The
ability to synthesize genes of any desired sequence opens the door to seemingly unlimited
research possibilities.

Major advances have been made recently in de novo gene

synthesis, with Polymerase Chain Assembly (PCA) routinely used to construct functional
sequences from short single-stranded oligonucleotides.
techniques are lacking in speed and fidelity.

However, current PCA

Additionally, substantial undesired

reactants/products are present in the final reaction. A novel process and accompanying
workstation has been developed that incorporates rapid PCA synthesis coupled with
subsequent affinity purification of the synthesis mixture.

The system enables fast and

accurate PCA synthesis and isolation of the full length DNA of interest.

In the synthesis step, the desired sequence is assembled and PCR amplified in a fast
thermocycler to generate a high yield of product with minimal runtime and errors. A
traditional 2-step PCA-PCR approach is utilized to assemble and amplify the full-length
gene. Alternatively, integration of PCA and PCR into a single rapid reaction is also
employed, working reliably up to about 1 kb. For the synthesis of genes longer than 1.5
kb, a convergent rapid synthesis strategy is proposed in which the full-length sequence is
assembled by a series of synthesis steps from smaller fragments. In this work, a variety
of genes ranging from 600 bp up to 3.8 kb in length are synthesized by rapid PCA
techniques.

The second section of the workstation employs two affinity columns to isolate the desired
full-length product from shorter unwanted reactants/products inherent in the PCA

reaction. During PCR amplification, labels are incorporated into the desired product on
both ends via PCR primers. Undesired products contain only one of these labels, or no
label at all. The first column interacts with one of the labels to partially purify the
mixture. The intermediate product is then subsequently purified via the second column to
isolate the full-length sequence. An initial prototype workstation was developed, while
the 2nd generation instrument consisted of process refinements using two antibody
columns for immunoaffinity purification.
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1 Background and Motivation for the Gene Synthesis
Workstation
Ever since the double-helix structure of DNA was first described by Watson and Crick
(1953), scientists have wondered what the possibilities might be with the knowledge of
genetic instructions. Can DNA sequences be modified or created a priori to produce a
desired function, even unnatural?

By knowing the desired output, the ability to

synthesize genes by programming a genetic code opens the door to possibilities limited
only by man’s imagination and cunning.

While many DNA syntheses rely on modification of existing natural sequences to alter
functionality, the concept of de novo synthesis of gene sequences no longer constrains
genetic coding to those based in nature. In some views a blessing, technical challenges
still abound for facile synthesis of gene sequences, knowingly or unknowingly good or
bad.

Additionally, the moral and ethical implications of gene synthesis cannot be

ignored, especially as scientists move forward with creating ever longer gene sequences.
Just recently, Gibson and others (2008) synthesized a 582,970bp genome for
Mycoplasma genitalium, the smallest free-living organism.

Despite a rapidly growing gene synthesis biotechnology sector, fast and accurate
synthesis of moderate gene fragments is still in relative infancy. High error rates are just
one of many difficulties that plague DNA synthesis. Since one error in a synthesized
gene sequence can destroy the desired functionality of the expressed protein, a high
fidelity process is needed that minimizes post synthesis manipulation to correct the error
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or reduces the burden of screening error-riddled products to isolate an error-free
sequence.

The primary motivation for this work is to develop a novel workstation platform called a
Gene Synthesis Workstation for rapid and high-fidelity synthesis of gene sequences of
moderate length. At the core of the workstation is a rapid thermocycler, which facilitates
expedited synthesis and reduction of introduced errors in the synthesis process. Since
gene synthesis within a thermocycler typically leads to a myriad of products, it is usually
necessary to take the polymerase chain reaction (PCR) end-product through a purification
step to increase the ratio of desired product to undesired products prior to further
processing. During the polymerase chain assembly (PCA) process, only a few copies of
the full length gene are constructed against a large background of shorter
oligonuculeotides.

Traditionally, PCA is followed by primer-mediated PCR

amplification to selectively amplify the full length product.

However, undesired

oligonucleotides from the assembly are still significantly present in the PCR product as
some are linearly amplified.

A secondary aspect of the workstation is to provide a novel alternative chromatography
based purification system to isolate the desired full-length gene resulting from the PCRbased gene synthesis.

Typically, gel purification is employed which consists of

conducting gel electrophoresis to separate the PCR product mixture by molecular weight.
The desired product band (section of gel at a certain molecular weight) is manually cut
from the gel and then a kit is used to purify the product from the gel slice. However,
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band cutting and clean-up can be time consuming due to the manual nature of the
technique.

For the synthesis of longer DNA, multiple DNA constructs need to be

assembled, purified, and ligated. Manual separation of tens or even hundreds of each
DNA constructs (each with different lengths) can be tedious and manually intensive. In
the alternative chromatography section, synthesis products are purified through a serial
arrangement of two columns which exploit binding of artificial labels that have been
incorporated into the synthesis products.

The chromatography section of the workstation is not necessarily meant to completely
replace gel purification for the synthesis of all genes. Rather, it is meant as an option
available to researchers conducting gene synthesis. This is even true for the specifics of
the PCA synthesis described herein. Given the infinite diversity of sequences and lengths
that one may desire to synthesize, it is clear that one single technique may not be superior
to others for all cases. Specific techniques or variations or combinations thereof may be
optimal for any given sequence. While the rapid thermocycler PCA synthesis can be
viewed as generally superior in terms of thermal damage in comparison to slow
thermocyclers, it and the chromatographic purification should be viewed as one of many
options. Molecular biologists should select from all available tools depending on the
specifics of the gene sequence to be synthesized.

1.1 The Polymerase Chain Reaction (PCR)
The Polymerase Chain Reaction (PCR) is one of the most valuable techniques available
to molecular biologists. Discovered by Kary Mullis in 1983 (Rabinow 1996), PCR
creates billions of copies of target DNA amplicon from just a few starting templates using

4
thermal cycling. At the core of the process is the polymerase enzyme. Double-stranded
DNA (dsDNA) is first denatured into single stranded DNA (ssDNA) within a
thermocycler. Typically two primers, i.e. short synthetic oligonucleotides of about 20
base pairs, are employed which target specific sequences of the template. When the
temperature is lowered in the thermocycler (to about 60°C depending on the melting
temperature of the primers employed) after denaturation, the primers anneal to the
complementary template sequences. Polymerase enzymes then bind to the 3’ end of the
annealed primers. Deoxyribonucleotides (dNTP’s) are present within the PCR mixture,
and are thereby added to the 3’ end of the primer complementary to the template.
Typically, the thermocycler temperature is then raised to around 72°C for optimal
extension activity of the polymerase.

At the end of the temperature cycle is the

construction of two new dsDNA. When the cycling is repeated over multiple cycles, the
constructed amplicons are exponentially amplified, theoretically doubling every cycle. A
simplified schematic of one PCR cycle is illustrated in Figure 1-1. One method for
detection of the PCR products is agarose gel electrophoresis, in which the molecular
weight of the DNA amplicon is compared to a reference ladder.

5
1 Template dsDNA

1) Denature
Primers

Polymerase

2) Anneal

3) Extension

2 dsDNA amplicons formed

Figure 1-1 Simplifed schematic of one PCR cycle.
Refer to text for description. The template DNA at the beginning of the process may
either be starting DNA template (exterior sequence shaded in grey and removed for
clarity) or amplicon constructed in a previous cycle.

1.2 Gene Synthesis Techniques
A plethora of synthesis options are available which rely on basic molecular biology
techniques (see Czar and others (2009) for an in-depth review). Three of the most
common techniques are phosphoramidite synthesis, ligase chain reaction (LCR), and
polymerase chain assembly (PCA). Automated phosphoramidite synthesizers routinely
create short (~15-100 bp) nucleotide sequences because elongation efficiencies and selfcomplementarity lower the yields of longer sequences. Integrated DNA Technologies
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(Coralville, IA) commercially offers “ultramers”--synthetic oligonucleotides up to 200bp
in length (Allen and others 2009). While phosphoramidite synthesis is the method of
choice for synthesis of short ssDNA sequences, such as PCR primers, it is impractical for
synthesis of longer dsDNA sequences exhibiting biological functionality. In this respect,
phosphoramidite synthesis is utilized to construct the building blocks for LCR and PCA.
In the LCR technique, a mixture of oligos are denatured and annealed together under
stringent conditions. A DNA ligase is present to ligate the oligos into dsDNA. LCR is
limited in its usage due to the slow reaction rate, and PCA is still typically required for
final synthesis assembly.

The first description of the polymerase chain assembly (PCA) method to create longer
synthetic genes from overlapping short oligonucleotides is commonly attributed to
Stemmer and others (1995). In essence, it is a variation of the PCR process in which a
thermo-stable DNA polymerase is used to “stitch” together shorter oligonucleotides.
Overlapping oligonucleotides are subjected to PCR thermocycling and polymerase
extension to form the gene of interest. Stemmer and others (1995) assembled a 1.1kb βlactamase encoding gene and a 2.7 kb plasmid from short 40mer oligonucleotides. PCA
or variations thereof have been frequently used to synthesize genes from a few hundred to
many kilobases (Mehta and others 1997; Smith and others 2003; Gao and others 2004;
Mamedov and others 2007). PCA also is a means to create synthon precursors that can
be utilized to create even larger constructs (Kodumal and others 2004).

Recently,

Gibson and others (2008) synthesized a 582,970 bp Mycoplasma genitalium genomes

7
using recombination techniques from 5-7kb overlapping “cassettes” assembled from ~104
oligonucleotides of ~50bp in length each.

A)
Denature & Anneal

X

B)

Extend

C)

+ initial short oligos from A
Denature & Anneal

D)

X

+ products from B

Extend

E)

Desired full-length gene

+ initial short oligos from A + products from C

Figure 1-2 Illustration of the PCA process for a simple 4 oligo assembly.
“X” denotes oligo hybridizations that are unproductive.

An illustration of the PCA process is shown in Figure 1-2. During the PCA process, a
mixture of oligos is subjected to the same temperature cycling as in PCR amplification.
Neighboring oligos that are complementary to one another hybridize during the annealing
step. The polymerase then extends the oligos to completion. Note that the polymerase
only is effective in extending from the 3’ end, meaning that many of the hybridizations
that occur are unproductive. The newly formed dsDNA is then denatured into ssDNA.
During the next annealing step, these longer products may now hybridize to new
neighboring sequences. After repeated cycling, the oligos continually increase in length
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until the full-length dsDNA is constructed. As the maximum number of full-length
products is limited by the amount of outermost oligos and the process is fairly inefficient,
a relatively small amount of full-length product is obtained against a large background of
unwanted products.

These unwanted products from inner oligos are obviously a

necessary evil—the starting oligos must be present for PCA but they become a nuisance
once the full-length product is constructed.

Typically, PCA is followed by PCR

amplification of the full-length gene to increase its amount relative to unwanted products.
In a separate reaction using an aliquot of the PCA product, PCR primers are employed to
exponentially amplify the full-length gene.

1.3 PCA Synthesis Using a Rapid Thermocycler
As noted previously, the cornerstone of the workstation is the utilization of a rapid
thermocycler to perform PCA. Almost all prior PCA research has used “heat-block”
thermocyclers with slow ramp rates, with typical run-times for PCA synthesis around 1 to
3 hours.

Similar run-times are needed when follow-up PCR is done to selectively

amplify the full-length gene. The development herein is based upon the initial work of
Mamedov and others (2007), in which rapid PCA was conducted in the PCRJet®
(Quintanar and Nelson 2002) to construct the endothelial protein-C receptor and
thrombin receptor genes. The PCRJet® is a rapid thermocycler which exploits high heat
transfer rates by forcing heated or room temperature compressed air over small diameter
glass capillaries. Total runtimes in the PCRJet® are decreased to about 10-20 minutes for
each PCA and PCR step.
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Figure 1-3 Picture of the PCRJet rapid thermocycler
The PCRJet is used for the PCA and PCR steps in the workstation.

While a beneficial reduction in run-times using a faster thermocycler is obvious, the real
importance of rapid PCA lies in the minimization of errors produced in the assembly
process. By minimizing the times spent at elevated temperatures, thermal damage to the
DNA is minimized. Pienaar and others (2006) demonstrate that errors due to thermal
damage primarily arises from exposure of ssDNA to elevated temperatures via A+G
depurination, oxidative damage of guanine to 8-oxoG and cytosine deamination to uracil.
With standard thermocyclers, typical hold times at denaturation are 10 to 30 seconds, not
including the cumulative time to reach the set-point is large due to the slow ramp rates of
these instruments.

In the compressed air thermocycler, the time spent at elevated

temperatures is on the order of a few seconds. Thus, PCA with a rapid thermocycler is
used as a basis for this work as it provides superior synthesis of products with high
fidelity and functionality.

The thermostable DNA polymerase from Thermococcus

kodakaraensis (KOD) is also employed in this work. KOD polymerase is attractive for
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its fast extension rate and proof-reading activity in which it may correct base pair errors
(Griep and others 2006).

1.4 Application of Affinity Purification to PCA Gene Synthesis
Affinity chromatography, especially immunoaffinity chromatography, has grown
considerably in use over the past several decades.

The first application of affinity

chromatography is commonly attributed to Starkenstein (1910) while the first antibodyantigen immunocapture separations were developed in the 1930’s (d’Allesandro and
Sofia 1935; Landsteiner and van der Scheer 1936). Briefly, affinity chromatography is a
separations technique which relies on the attractive (affinity for) intermolecular forces
between a ligand and receptor.

The target molecule, in this case the full-length

synthesized gene, may be isolated if it possesses a target that is preferentially captured by
the introduced ligand. Immunoaffinity chromatography relies on the affinity between
antibody and antigen. Due to the nature of antibody-antigen binding, immunoaffinity
purification is in general highly specific.
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A

B

C

D

Figure 1-4 Simple illustration of affinity chromatography.
A) A mixture of compounds is introduced to immobilized ligands. B) Target molecules
bind specifically to ligand sites while others are washed through. C) An elution buffer is
applied to the immobilized ligand. D) Target molecules are eluted from the immobilized
ligand.

In standard PCA synthesis, there are not unique parts of the full-length gene that can be
readily exploited by affinity separations. The labels must be incorporated into the fulllength gene by adding labels to the PCR primers, attached at the 5’ end. After the fulllength gene has been assembled, new primer-derived copies of the full-length gene
(existing as double-stranded DNA, dsDNA) that are formed during the PCR amplification
will possess a label on each end. Partially extended PCA products that are linearly
amplified will possess one of the labels, but not both. Thus, the two-label full-length
gene is unique to the mixture, and can thereby be isolated by using a two-column serial
purification.
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There are several benefits of the automated purification over manual gel purification.
First, the procedure has the potential to be faster than gel purification (i.e. < 30 minutes
compared to ~1-2 hours). Second, one need not be concerned with introducing synthetic
DNA errors due to UV damage as in gel purification, as any aliquots to gels need not be
directly used for cloning. Additionally, the automation of purification may reduce the
labor burden thereby increasing the throughput potential for multiple gene synthesis by
PCA. Lastly, affinity purification may be more effective than gel purification in isolating
the desired full-length gene as gel purification offers fairly low resolution. One may
expect a better quality purified fraction with affinity separation, thereby aiding cloning
efforts, as it is very likely that positive clones will possess the full-length insert and
thereby reduce the amount of screening needed.

1.5 Introduction to the Workstation Process
To advance the gene synthesis field, a novel process and accompanying workstation has
been developed that incorporates rapid PCA synthesis coupled with affinity purification.
The system enables fast and accurate PCA synthesis and isolation of the full length DNA
of interest, enabling facile cloning and expression. In the synthesis step, the desired
sequence is PCA assembled and PCR amplified in a fast thermocycler to generate a high
yield of product with minimal runtime and errors.

A traditional 2-step PCA-PCR

approach is utilized to assemble and amplify the full-length gene. Alternatively,
integration of PCA and PCR into a single rapid reaction is also employed, working
reliably up to about 1 kb. The second step in the PCR workstation employs two columns
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to isolate the desired full-length product from shorter unwanted reactants/products.
During PCR amplification, labels are incorporated into the dsDNA product on both ends.
The first column interacts with one of the labels to partially purify the mixture. The
intermediate product mixture is then subsequently purified further via the second column.
A schematic of the workstation process is shown in Figure 1-5.

a) Input Sequence
Design Oligos
F0

F1

F2

F24

F25

b) Oligonucleotide units
R0

R1

R23

R24

R25

Polymerase Chain Assembly
c) PCA product mixture

PCR with labeled outer primers
d) Labeled PCR
product mixture

Column 1 Purification
e) Intermediate product

Column 2 Purification
f) Final product

Figure 1-5 Schematic of the rapid gene synthesis workstation
A serial two-column purification is employed after gene synthesis.
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1.6 Developmental Objectives
While others have broken ground in the field of PCR-based gene synthesis, the field is
still searching for improved methods. The speed and high fidelity that can be achieved
by rapid thermocycling has been described (Mamedov and others 2007), but has by and
large gone unappreciated. New demonstrations of gene synthesis by rapid PCA, along
with the construction of even longer gene sequences by the technique, are of great
importance to wider adoption. The objectives of this work are outlined below:
1. Demonstrate the robustness and repeatability of rapid PCA gene synthesis for a
variety of different genes.

As the specific sequences of each gene play a

significant impact on synthesis success, it is of critical importance that rapid PCA
is proven as a robust technique.
2. Develop proof-of-concept for affinity purification platform and method using two
columns in series to isolate genes synthesized by rapid PCA.

The proof-of-

concept represents the first ever demonstration of the process.
3. Develop a technique that combines PCA assembly and PCR amplification into a
single step procedure to even further reduce thermocycling runtimes and the labor
requirements to produce the desired gene in high yield.
4. Further develop the chromatography section with improved performance and
characteristics based upon the proof-of-concept findings.

Immunoaffinity

purification using two antibody columns are preferred.
5. Develop a novel rapid PCA method that enables synthesis of longer gene
sequences. The longest gene synthesized by Mamedov and others (2007) using
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rapid PCA was a 1,548 bp thrombomodulin gene from a pool of 77
oligonucleotides.

The process and workstation steps are demonstrated for a variety of synthetic genes. In
Chapter 2, four different genes were synthesized in an initial proof-of-concept
workstation. Chapter 3 investigates a novel technique that integrates PCA and PCR steps
in a single rapid thermocycling process. Chapter 4 presents development of a next
generation instrument with refined processes and hardware. In Chapter 5, a long 3.8 kb
gene sequence was synthesized to challenge the next generation workstation and
demonstrate a convergent synthesis approach.

To construct longer genes that are

otherwise not amenable to direct synthesis, the sequence may be segmented into smaller
fragments that are synthesized in parallel in 1st round PCA-PCR. 2nd round integrated
PCA-PCR is performed to join the fragments into the full-length gene. The process is
demonstrated for the synthesis of the 3.8 kb gene sequence by utilizing either 2 or 4
smaller fragments. Provided in an appendix, chimeric gene sequences integrating two
encoding regions for two different proteins were explored.

Chapter 6 provides an

analysis of the research and direction for future work.
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2 Proof-of-Concept for the Workstation
To demonstrate the rapid PCA synthesis coupled with affinity purification process
described in Chapter 1, a proof-of-concept workstation was developed.

The system

enables fast and accurate PCA synthesis, ending with isolation of the full length DNA of
interest. In the synthesis section, a rapid 2-step PCA assembly with subsequent PCR
amplification technique is used to generate a high yield of product with minimal runtime
and errors. During PCR amplification, labels are incorporated into the dsDNA product
on both ends. The second step in the PCR workstation employs two affinity columns to
isolate the desired full-length product from shorter unwanted reactants/products. The
first column interacts with one of the labels to partially purify the mixture.

The

intermediate product mixture is then subsequently purified further via the second column.
Four genes were constructed and purified using the workstation to demonstrate the
approach.

2.1 Introduction
2.1.1 Rapid PCR-based synthesis
For a background into gene synthesis by PCR, please refer to Chapter 1. The first section
of the workstation is a rapid compressed-air thermocycler, the PCRJet® (Quintanar and
Nelson 2002; Whitney 2004). The rapid thermocycler is utilized for the PCA and PCR
steps of the workstation process. The PCRJet® accommodates up to eight 1.5 mm outer
diameter glass capillaries (part # 04929292001, Roche Applied Science, Indianopolis,
IN). Each capillary can hold up to 25 µl of reaction mixture.
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Figure 2-1 Picture of the PCRJet rapid thermocycler

The PCRJet® (see Figure 2-1) is one of the fastest PCR thermocyclers built to date.
Briefly, the instrument forces heated or room temperature compressed air at high velocity
over the glass capillaries. The high heat transfer of the forced convection is coupled to
the fast equilibrium characteristics of the small diameter capillaries. This results in
heating and cooling rates in excess of 10°C/sec with only a few seconds of hold time
required at the set-point temperature for the PCR mixture to reach the desired
temperature. In conjunction with the fast thermocycler, KOD polymerase is employed
for its particularly suitable high fidelity and fast extension rates (Griep and others 2006)
to give very short runtimes of about 10 minutes.

To test the robustness of the prototype workstation, four different genes were selected.
The details of the four genes and the primer sequences used are listed in Table 2-1.
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Table 2-1 Genes synthesized in the proof-of-concept workstation.

2.1.2 Purification of synthetic genes
The second section of the synthesis workstation is tasked with purification of the reaction
products to isolate the desired full-length dsDNA of interest.

A schematic of the

prototype workstation is shown in Figure 2-2.
2-way Valves

Column #1

B (elution buffer)

A (wash buffer)

S (sample)

Pump

3-way Valve

2-way Valves

Column #2

D (elution buffer)

C (wash buffer)

I (intermediate)

Pump

3-way Valve

F (final product)

W (waste)

Figure 2-2 Schematic of the prototype affinity chromatography station.
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One commonly used interaction is the streptavidin-biotin (or biotin analog) system
(Hofman and others 1980; Fudem-Goldin and Orr 1990; Hirsch and others 2002).
Iminobiotin is an attractive analog due to the reversible binding and elution
characteristics

at

modified

pH

values.

Additionally,

the

thymidine

analog

bromodeoxyuridine (BrdU) antibody-antigen systems also find common use in
immunoaffinity separations, especially for in vivo labeling (Haider and others 1997;
Kobayashi and others 1998; Urbach and others 1999; Artursson and Jansson 2003;
Walters and Field 2006).

Thus these two labels are employed in the prototype

workstation as demonstration of the concept.

2.2 Materials & Methods
2.2.1 Design of Oligonucleotides
The Gene2Oligo computer program of Rouillard and others (2004) was used to design
assembly oligonucleotides and optimize melting temperatures of the hybridization units.
Oligonucleotides at either 50 or 100 μM in nuclease-free water were obtained from
Integrated DNA Technologies (Coralville, IA).

2.2.2 Polymerase Chain Assembly Conditions
The synthesis of the genes was performed in accordance with the work of Mamedov and
others (2007). Equimolar PCA was carried out in 25 µL reaction volumes as listed in
Table 2-2.
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β-lactamase
pUC19ori
200μM
200μM
dNTPs
MgSO4
4mM
4mM
0.4mg
/
mL
0.4mg / mL
Non-acetylated BSA
KOD
hot
start 0.5U / 25 μL 0.5U / 25μL
reaction
reaction
polymerase
1X
1X
KOD Reaction Buffer
Reagent

PCR Protocol

Hot start
Denaturation
Annealing
Elongation
# of Cycles
Final extension

β-lactamase
Temp
Time
(°C)
(s)
94
30
94
2
56
10
10
72
30
72
25

pUC19ori
Temp
Time
(°C)
(s)
94
30
94
2
56
10
72
10
30
25
72

Thrombomodulin
200μM
5mM
2mg / mL
0.5U / 25 μL reaction
1X

Thrombomodulin
Temp
Time
(°C)
(s)
94
30
92
2
60
15
72
7
30
72
20

EPCR-1
200μM
4mM
0.4mg / mL
0.5U / 25 μL
reaction
1X
EPCR-1
Temp
(°C)
92
92

Time
(s)
30
1

68

4

30
-

-

Table 2-2 Polymerase Chain Assembly conditions.

2.2.3 PCR Amplification Conditions
PCR amplification using regular or labeled primers was carried out in 25 µL reaction
volumes as listed in Table 2-3. PCR was performed on aliquots of either the assembly or
affinity purification products.
PCR Protocol
PCR Protocol

Hot start
Denaturing
Annealing
Elongation
# of Cycles
Final extension

β-lactamase
Temp Time
(°C)
(s)
94
30
94
2
55
3
72
10
30
72
25

pUC19ori
Temp
(°C)
94
94
55 / 56 3
72
30
72

Time
(s)
30
2
3
10
25

h-TM
Temp
(°C)
92
92
60
72
40
72

Time (s)
30
2
3/24
15
20

EPCR-1 1
Time
Temp
(°C)
(s)
92
30
92
1
60
2
72
4
35
72
20
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MgSO4

β-lactamase
200μM
0.5μL / 25μL
reaction
4mM

pUC19ori
200μM
0.5μL /
reaction
4mM

Non-acetylated BSA

0.4mg / mL

0.4mg / mL

KOD
hot
start
polymerase
KOD Reaction Buffer
Forward primer
Reverse primer

0.5U
/
25μl
reaction
1X
0.6μM / 0.7μM 2
0.6μM / 0.7μM 2

0.5U
/
25μl
reaction
1X
0.5μM - 0.7μM 3
0.5μM - 0.7μM 3

Reagent

dNTPs
Synthetic DNA

25μL

h-TM
200μM
2μL / 25μL
reaction
5mM
0.4 – 2.0 mg
/ mL 4
0.5U / 25μl
reaction
1X
0.6μM
0.6μM

1

EPCR-1
200μM
0.7μL / 25μL
reaction
4mM
0.4mg / mL
0.5U /
reaction
1X
0.7μM
0.7μM

25μl

Table 2-3 PCR amplification conditions.
1: PCR amplification of purified product was performed using 1 μl template with pH adjusted
to 7 by adding 1.06 μl of Tris base.
2: Unlabelled PCR of PCA product: 0.6μM each.

Labelled PCR of PCA product or

unlabelled PCR of purified product: 0.7μM each
3: Unlabeled amplification of PCA product was done using 0.7μM of each primer at 55°C
annealing temperature. Labeled amplification of PCA product was done using 0.5μM of
each primer at 56°C annealing temperature. Unlabeled amplification of purified product
was done using 0.6μM of each primer at 56°C annealing temperature.
4: BSA concentrations were 2.0 and 0.4 mg/mL for labeled and unlabeled amplifications,
respectively. Annealing times were 3 and 2 seconds for labeled and unlabeled
amplifications, respectively.

2.2.4 Labeling of synthesis products
The forward and reverse primers used for PCR amplification were labeled with
iminobiotin and BrdU labels attached to their 5’ ends, respectively. During the PCR
amplification step of PCA synthesized product, the polymerase-extended primers contain
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the labels. The labeled primers were obtained from IBA GmbH (Göttingen, Germany),
while regular primers were obtained for Integrated DNA Technologies (Coralville, IA).

2.2.5 BrdU and Iminobiotin affinity columns
Chicken polyclonal antibody against BrdU (anti-BrdU Pab) was purchased from
Immunology Consultants Laboratory, Inc. (Newberg, OR). Activated NHS-Sepharose
resin was purchased from Sigma Chemical Company (St. Louis, MO). The anti-BrdUPab was coupled to the NHS-Sepharose resin per the protocol supplied by the
manufacturer. Briefly, the resin as supplied was drained and washed with 1 M ice-cold
HCl and decanted. The resin was subsequently washed with approximately 10 column
volumes of 0.1 M sodium bicarbonate, 0.5 M NaCl, pH 8.0 buffer (ligand coupling
buffer) prior to antibody coupling. The target antibody was dissolved in 0.1 M sodium
bicarbonate, 0.5 M NaCl, pH 8.0 buffer (ligand coupling buffer), mixed with decanted
resin at a volume ratio of 3:1 and placed on an end-to-end rotator in a cold room (4°C).
Upon completion of the antibody coupling step, the supernatant was drained and excess
reactive groups on the resin were blocked with 1M ethanolamine, pH 8.0 for 1-hour at
room temperature. Upon completion of the blocking step, the resin was sequentially
washed with 0.1 M sodium bicarbonate, 0.05 M Tris-HCl, 0.5 M NaCl, pH 8.0 and 10
mM Tris-HCI, 50 mM NaCI, pH 7.4. Unless used immediately, the antibody coupled gel
was stored at a neutral pH in the presence of 0.05% NaN3 at 2°C to 8°C.

For the iminobiotin affinity capture, its well-known interaction with streptavidin was
employed. Ready to use 1ml HiTrap Streptavidin HP columns were purchased from GE
Healthcare (part # 17-5112-01, Piscataway, NJ).
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2.2.6 Affinity Purification Hardware
The hardware layout of the affinity workstation is in accordance with Figure 2-2. The
affinity chromatography section is comprised of pumps, valves, tubing, columns, reagent
/ buffer vessels and the necessary electronics and software to control all of these
components. The components were assembled on a vertical breadboard using perforated
sheet metal to maximize flexibility and different arrangements for prototyping as needed.
A picture of the prototype workstation is shown in Figure 2-3.

Figure 2-3 Picture of the Prototype workstation using a vertical breadboard.
The components follow that of the schematic in Figure 2-2. The power supply and
custom printed circuit board are located on the right.
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The key hardware components of the system are described briefly below:

Pumps. There are two pumps present in the prototype affinity section, one pump
for each column. The displacement diaphragm pumps (model # 120SP24104TE, Bio-Chem Valve Inc., Boonton, NJ) are factory calibrated to 10 µL per
pump stroke (at zero back-pressure) at a rate of up to 2 Hz (1.2ml per minute
max). The actual flow rates of the pumps were calibrated to account for the
tubing lengths and backpressure of the system. Higher flow rate pumps are
also available. Bio-Chem Valve components were chosen for the chemical
inertness of the internal components and attractive pricing compared to other
pump designs.

2-way valves. The station has six normally closed 2-way valves. These micro
isolation valves (model # 038T2S24-32-4, Bio-Chem Valve Inc.) provide a
compact method to direct fluid flow.

3-way valves. There are two 3-way isolation valves in the station (model #
075T3MP42-32, Bio-Chem Valve Inc.). Each 3-way valve selects the direction
for the fluid to flow downstream of the columns – either directed towards the
next stage or towards a waste container.

Tubing & Fittings. The pumps and valves are connected with chemically inert
PTFE tubing (part # PTFE1030, Western Analytical Products, Wildomar, CA).
This replaceable and sterilizable tubing has a 0.030” inner diameter and 1/16”
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outer diameter. Various PTFE and PEEK fittings and connectors connect the
workstation components (Western Analytical Products, Wildomar, CA).

Reagent vessels. Several reagent vessels are used by the station for tubing priming,
column washing and pH control. The buffer vessels were 50 mL centrifuge
tubes (model # 2553, CLPdirect, San Diego, CA), while the feed and
intermediate vessels were 5ml tubes, both as a matter of convenience.

Affinity columns. A 1 mL HiTrap Streptavidin HP column (part # 17-5112-01, GE
Healthcare, Piscataway, NJ) was used for the iminobiotin capture. A custom
anti-BrdU Pab (Immunology Consultants Laboratory, Inc., Newberg, OR) was
coupled to NHS-sepharose resin (Sigma Chemical Company, St. Louis, MO).
The resin was prepared and packed in a Tri-corn 5/20 glass column (part # 284064-08, GE Healthcare, Piscataway, NJ).

Power supply. A 24V DC power supply capable of delivering 60W is used to
power the pumps and valves (model # MAP55-1024, Power-One, Camarillo,
CA).

Controller card. A custom printed circuit board (PCB) was built to trigger the
pumps and valves (MIS Engineering, Lincoln, NE). This PCB allows for either
manual control with push buttons or with an external computer control via 5
VDC inputs.
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The manual control option was used to prime the system; all tubing and affinity
purification columns were filled with the proper initial buffer. Automated control was
used to then perform the pump and valve control for the actual affinity purification. A
KPCI-3107 board (Keithley Instruments) was interfaced to the controller card to run the
automated protocol. A simple Visual Basic 6.0 software interface was written by Dr.
Scott Whitney to control valve settings and operating the pumps at each programmed step
by sending digital outputs to the custom printed circuit board.

2.2.7 Purification Methods
Typical purification procedures are described here. Unless otherwise specified, all
experimentation was performed following these protocols.
•

The binding buffer A for the anti-BrdU column was 10mM Tris-HCl, 50mM
NaCl, pH 7.4.

•

The elution buffer B for the anti-BrdU column was 20mM Tris-HCl, 500mM
NaCl, pH 7.5.

•

The binding buffer C for the Streptavidin column was 50mM ammonium
carbonate, 500mM NaCl, pH 10.0.

•

The elution buffer D for the Streptavidin column was 50mM ammonium acetate,
500mM NaCl, pH 4.0.

The affinity workstation was initialized by priming lines with the respective solutions.
The intermediate vessel was preloaded with 3 mL of 1x binding buffer (C) and the
sample vessel loaded with 200 μL of labeled PCR product mixture and 1200 µL sterile
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distilled water. The high amount of feed product was used to overcome dilution and gel
sensitivity considerations; smaller feed amounts (i.e. 25 µL) may also be employed.
Pumping was set at 1 Hz for an approximate flow rate of 0.6 mL/min. The software was
programmed to run the following sequence:
• Equilibrate columns and tubing with respective binding buffers A and C
• Load in sample mixture S to anti-BrdU column
• Wash BrdU column with binding buffer A
• Elute intermediate product from BrdU column with elution buffer B
• Load intermediate mix I to streptavidin column
• Wash streptavidin column with binding buffer C
• Elute final product F from streptavidin column with elution buffer D

To adequately characterize the purification characteristics, the protocol for the four genes
was performed in a semi-automated fashion. Samples for binding, washing, and elution
fractions for both columns were collected manually in approximately 200 µl increments
from the respective outlet tubing into 1.5 ml microcentrifuge tubes for gel analysis.

To fully demonstrate the automated protocol, purification with the β-lactamase synthetic
gene was conducted once the protocol was sufficiently optimized.

The automated

protocol was completed in 33 minutes at the conservative 0.6 ml / min flow-rates.

2.2.8 Gel Electrophoresis
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For the electrophoresis gels, typically 8 µL of each PCA or PCR sample or 30 µL of each
affinity chromatography fraction were run on 1.0% agarose gel stained with ethidium
bromide at 10V/cm in TAE buffer.

2.2.9 Cloning and Sequencing
The synthetic genes were gel-purified using a Gel Elute Extraction Kit (Qiagen Inc.,
Valencia, CA). Purified DNA was ligated to TOPO vector using Zero Blunt® TOPO®
PCR Cloning Kit (Invitrogen, Carlsbad, CA). The ligated plasmid was transformed into
competent cells of E. coli strain TOP-10 (Invitrogen); ten positive clones were selected.
Purified plasmids from selected clones were sequenced at the University of NebraskaLincoln sequencing facility (CEQ8000 DNA Sequencer, Beckman Coulter, Fullerton,
CA) using vector and gene specific primers.

2.3 Results & Discussion
The application of the prototype workstation to the synthesis and purification of βlactamase, pUC19ori, TM and EPCR-1 are elaborated below. The four genes were
successfully assembled from 52, 36, 77 and 35 synthetic oligonucleotides, respectively.
In other testing with unlabelled product, some non-specific binding was observed with
the anti-BrdU column (results not shown), suggesting that the full-length gene purity in
the final effluent may be partially compromised if undesired iminobiotin-labelled
products are non-specifically bound to the anti-BrdU column in the first stage. However,
the four labeled genes tested did not show any significant background present.
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2.3.1 929 bp puc19 B-lactamase sequence

Figure 2-4 PCA, PCR and Affinity Purification of the pUC19 β-lactamase gene.
A: PCA & PCR products- Lanes (M) 100bp DNA ladder (NEbiolabs); lane 1: PCA
product; lane 2: PCR product with unlabeled primers; lane 3: PCR product with labeled
primers.
B: Semi-automated Affinity Purification- Lanes (M) 100bp DNA ladder (NEbiolabs);
lane 1: labeled PCR product (8 μL); lane 2: wash sample from BrdU column (30 μL);
lane 3: intermediate elution product from BrdU column (30 μL); lane 4: wash sample
from streptavidin column (30 μL); lane 5: final elution product from streptavidin column
(30 μL).
C: PCR of Affinity Purification Product- Lanes (M) 100bp DNA ladder (NEbiolabs); lane
1: 929bp PCR of the affinity purification product.
D: Fully Automated Affinity purification- Lanes (M) 100bp DNA ladder (NEbiolabs);
lane1: PCR product with labeled primers (feed); lane 2: Final Elution Product; lane 3:
929bp PCR of the Affinity Purification Product.

32
The assembly product and PCR amplification (with both regular and labeled primers) of
the assembly product is shown in Figure 2-4A. The success of the PCA is confirmed by
the presence of the correct size full length bands from the PCR amplifications. Note that a
significant smear is present in the PCR steps due to a complex mixture of 1) carryover
and linear amplification of short assembly oligonucleotides and 2) duplex formation of
different length single stranded DNA with complementary sequence regions.

Samples from wash/elution fractions of the affinity purification protocol are Figure 2-4B.
As expected, the intermediate elution product from the anti-BrdU column has both the
full-length product present along with undesired shorter products that possess the BrdU
label but not the iminobiotin label. Subsequent purification of this intermediate through
the streptavidin column results in only the full length product with both labels in the
elution fraction. The absence of visible bands in the streptavidin wash step is attributed to
the high dilution of the intermediate product. The slight upward shift of the final product
is due to the high salt present in the elution buffer. The purity of the affinity purification
product and its correct size was confirmed by subsequent PCR (Figure 2-4C). Sampling
of the affinity purification steps interrupted the protocol and resulted in a semi-automated
process.

To demonstrate the robustness of the workstation, the protocol was run in fully automated
mode—sampling was only done at the final elution step. The eluted product and its PCR
amplification of the automated procedure are shown in Figure 2-4D. The success of the
automated procedure provides evidence that the affinity purification approach may be

used as an alternative to gel purification.
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Gel purification typically requires about 2

hours to conduct gel separation and then recover the desired band from the gel slice. In
contrast, the fully automated protocol required 33 minutes for completion.

The

comparison is not necessarily clear-cut as the affinity purification is at higher cost and
additional processing steps may be needed depending on downstream objectives. Yet,
the additional advantage is that the affinity chromatography does not expose the
synthesized DNA to UV damage.

2.3.2 612 bp endothelial protein C receptor sequence

Figure 2-5 PCA, PCR and affinity purification of the Endothelial Protein C Receptor
gene.
A: PCA & PCR products- Lanes (M) 100bp DNA ladder (NEbiolabs); lane 1: PCA
product; lane 2: PCR product with unlabeled primers; lane 3: PCR product with labeled
primers.
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B: Semi-automated Affinity Purification- Lanes (M) 100bp DNA ladder (NEbiolabs);
lane 1: labeled PCR product (8 μL); lane 2: wash sample from BrdU column (30 μL);
lane 3: intermediate elution product from BrdU column (30 μL); lane 4: wash sample
from streptavidin column (30 μL); lane 5: final elution product from streptavidin column
(30 μL).
C: PCR of Affinity purification Product- Lanes (M) 100bp DNA ladder (NEbiolabs); lane
1: final elution product; lane 2: PCR of the affinity purification product.

The assembly product and PCR amplification (with both regular and labeled primers) of
the assembly product is shown in Figure 2-5A. The success of the PCA is confirmed by
the presence of the correct size full length bands from the PCR amplifications. A
secondary non-specific band was obtained with regular primers (Figure 2-5A, lane 2),
despite optimization attempts. As with the other genes, a significant smear is present in
the PCR steps.

Samples from wash/elution fractions of the affinity purification are shown in Figure 25B. As expected, the intermediate elution product from the anti-BrdU column has both
the full-length product present along with undesired shorter products that possess the
BrdU label but should not contain the iminobiotin label. Subsequent purification of this
intermediate through the streptavidin column results in the full length product with both
labels in the elution fraction. The absence of visible bands in the streptavidin wash step is
attributed to the high dilution of the intermediate product. The slight upward shift of the
final product is due to the high salt of the elution buffer. The anti-BrdU wash gel lane
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(Figure 2-5B, lane 2) was corrupted—other gels have shown this product to look similar
to the labeled PCR product lane (results not shown).

The purity of the affinity purification product and its correct size was confirmed by
subsequent PCR with regular primers (Figure 2-5C). The non-specific amplification of
undesired products is attributed to PCR and not the purification performance (compare to
Figure 2-5A, lane 2).

2.3.3 615 bp puc19 ori sequence

Figure 2-6 PCA, PCR and affinity purification of the pUC19 Origin of Replication gene.
A: PCA & PCR products- Lanes (M) 100bp DNA ladder (NEbiolabs); lane 1: PCA
product; lane 2: PCR product with unlabeled primers; lane 3: PCR product with labeled
primers; lane 4: PCR product with labeled primers (new reverse primer).
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B: Semi-automated Affinity purification- Lanes (M) 100bp DNA ladder (NEbiolabs);
lane 1: Iminobiotin-labeled PCR product (8 μL); lane 2: Elution product from
streptavidin column (30 μL); lane 3: Concentrated elution product.
The assembly product and PCR amplification (with both regular and labeled primers) of
the assembly product is shown in Figure 2-6A. The success of the PCA is confirmed by
the presence of the correct size full length bands from the PCR amplification with regular
primers (Figure 2-6A, lane 2). Efficient PCR with labeled primers was problematic
(Figure 2-6A, lane 3). The first labeled primer set yielded a smeared band at
approximately the correct size, and the poor yield was unattractive for purification
testing. PCR with mixing of labeled/unlabeled primers showed correct amplification
with both forward primers, but only in combination with the regular reverse primer
(results not shown). This suggested that the reverse BrdU-labeled primer might be the
culprit; a replacement was ordered from the supplier. However, the result was similar
using the new primer (Figure 2-6A, lane 4).

Due to the difficulties with the BrdU-labeled primer, a single column purification with
streptavidin was employed to partially purify the gene. First, the PCA product was
amplified using the iminobiotin-labeled forward primer and the regular reverse primer
(Figure 2-6B, lane 1). The affinity purification workstation and software were
reconfigured to run only the streptavidin column section. The purified elution product is
shown in Figure 2-6B, lane 2. Note the slight upward shift due to high salt as seen with
the other genes.
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With only one column used in the purification, it is expected that impurities will still be
present—those which possess the labeled 5’ end but may or may not be the desired fulllength product. The product should be similar to the intermediate in the tandem
purification scheme. To reveal the presence of impurities (along with confirming the
correct length by gel mobility), a purification kit was used on the elution fraction per
manufacturer’s protocol (Cat # A9281, Promega Corporation, Madison, WI). The
concentrated elution product is shown in Figure 2-6B, lane 3. As anticipated, a
background of undesired products still exists after the single column purification.

2.3.4 1548 bp human Thrombomodulin sequence

Figure 2-7 PCA, PCR and affinity purification of the human Thrombomodulin gene.
A: PCA & PCR products- Lanes (M) 1kb DNA ladder (NEbiolabs); lane 1: PCA product;
lane 2: PCR product with unlabeled primers; lane 3: PCR product with labeled primers.
B: Semi-automated Affinity Purification- Lanes (M) 1kb DNA ladder (NEbiolabs); lane
1: labeled PCR product (8 μL); lane 2: wash sample from BrdU column (30 μL); lane 3:
intermediate elution product from anti-BrdU column (30 μL); lane 4: wash sample from
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streptavidin column (30 μL); lane 5: final elution product from streptavidin column (30
μL).
C: PCR of Affinity purification Product- Lanes (M) 1kb DNA ladder (NEbiolabs); lane1:
PCR product with labeled primers (feed); lane 2: PCR of the affinity purification product.
The assembly product and PCR amplification (with both regular and labeled primers) of
the assembly product is shown in Figure 2-7A. The success of the PCA is confirmed by
the presence of the correct size full length bands from the PCR amplifications. Note that a
significant smear is present in the PCR steps due to a complex mixture of 1) carryover
and linear amplification of short assembly oligonucleotides and 2) duplex formation of
different length single stranded DNA with complementary sequence regions.

Samples from wash/elution fractions of the affinity purification protocol are shown in
Figure 2-7B. As expected, the intermediate elution product from the anti-BrdU column
has both the full-length product present along with undesired shorter products that
possess the BrdU label but not the iminobiotin label. The absence of visible bands in the
streptavidin wash step is attributed to the high dilution of the intermediate product. The
absence of any visible product in the streptavidin elution sample is likely attributable to
low binding efficiency of the labels and the detection sensitivity of the gel. However, the
presence of desired product was confirmed by subsequent PCR (Figure 2-7C) on the
elution fraction.

2.3.5 Synthesis Rates, Cloning, and Sequencing
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Table 2-4 Summary of the four assembled genes.

Assembly times and error rates for the four genes are summarized in Table 2-4. All four
genes were synthesized at rates that exceed 4,000 bp/hr. Note the difference in the
synthesis rates of the pUC19 origin of replication and the EPCR gene, both of which are
of comparable length. Due to the differences in their oligonucleotide sets (from which
they are assembled), the pUC19 origin of replication required a lengthier assembly
protocol than the EPCR gene. All error rates for the four different genes were below 1
error/kb, calculated after sequencing of ten clones each. The EcoRI digests of ten clones
obtained from the purified β-lactamase product are shown in Figure 2-8.

The gel

indicates that the full-length gene insert was present in all clones. The presence of the
full-length insert in all ten clones was confirmed by sequencing.

Figure 2-8 EcoRI restriction enzyme digest of 10 clones.
Lane M1: 1kb DNA ladder (NEbiolabs); Lane M2: 100bp DNA ladder (NEbiolabs); lane
1-10: EcoR1 digest of ten clones (10µL each)
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2.4 Conclusion
The primary objective of demonstrating feasibility of the synthesis and purification
platform has been met. Four different genes were constructed rapidly and with high
fidelity in the PCRJet® thermocycler. A fully automated purification was performed on
the synthesized β-lactamase gene, indicating that the serial affinity purification approach
may serve as an alternative to gel purification. Tempered success was obtained for the
three other genes tested. Thrombomodulin also performed rather well, with the exception
of low yield in the final effluent that was below the gel detection limit.

PCR

amplification of the final effluent clearly demonstrated that the full-length TM gene was
present. For pUC19 ori and EPCR, difficulties arose in PCR amplification, thus limiting
the clarity of purification results obtained.

However promising, process refinements are recommended such that the robustness of
the platform in all respects is increased. The up-front thermocycler hardware is welldeveloped, yet the PCA and PCR reaction conditions may be further optimized for
specificity, yield, and runtimes. While the initial affinity purification system served its
purpose, a next generation should seek to address present concerns, both in hardware and
processes. For example, in testing the purification setup with unlabelled PCR products,
the anti-BrdU column did exhibit some non-specific binding (results not shown). If some
of these non-specific products contain the iminobiotin label, they will be captured by the
streptavidin column and eluted in the desired final effluent. Some impurities in the final
effluent are not necessarily lethal to the success of the process. Rather, the objective with
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any purification technique is to increase the relative signal of the desired product against
undesired products.
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3 Gene synthesis by integrated polymerase chain assembly
and PCR amplification
In traditional PCA, equimolar concentrations of single stranded DNA oligonucleotides
are repeatedly hybridized and extended by a polymerase enzyme into longer dsDNA
constructs, with relatively few full-length sequences being assembled. Thus, traditional
PCA is followed by a second primer-mediated PCR reaction to amplify the desired fulllength sequence to useful, detectable quantities. Integration of assembly and primermediated amplification steps into a single reaction using a high-speed thermocycler is
shown to produce similar results. For the integrated technique, the effects of oligo
concentration, primer concentration, and number of oligonucleotides are explored. The
technique is successfully demonstrated for the synthesis of two genes encoding EPCR-1
(653 bp) and pUC19 β-lactamase (929 bp) in under 20 minutes.

However, rapid

integrated PCA-PCR was found to be problematic when attempted with the TM-1 gene
(1509 bp).

Partial oligonucleotide sets of TM-1 could be assembled and amplified

simultaneously, indicating that the technique may be limited to a maximum number of
oligonucleotides due to competitive annealing and competition for primers.

3.1 Introduction to the concept of integrated PCA-PCR
PCA is a variation of the PCR process in which many oligonucleotides (“oligos”) are
repeatedly hybridized, extended by a polymerase, and denatured. The desired gene
sequence is segmented into short phosphoramidite synthesized oligo sequences of ~15 to
100 bp in length. The oligo design is typically aided by an oligo design software
program (Rouillard and others 2004).

Using PCR thermocycling, the oligos are

hybridized to one another and undergo polymerase chain extension to construct longer
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dsDNA. After repeated thermal cycling, the desired full-length sequence is assembled.
In traditional equimolar PCA, relatively little full-length dsDNA is completely assembled
during the PCA process. Thus, PCA is usually followed by a second primer-mediated
PCR amplification of the full length template to produce useful (and detectable)
quantities of the synthetic gene.

The ability to conduct PCA and primer-mediated amplification simultaneously is highly
attractive due to reduced labor, reagents, and instrument time. A more subtle advantage
of the integrated technique is that a reduction of synthetic errors attributable to thermal
damage can be logically assumed from fewer thermal cycles (Pienaar and others 2006).
Chen and others (1994) described PCR based de novo gene synthesis of a 779 bp
bacteriorhodopsin gene. Chen and others (1994) employed purified 70 to 100-mers with
~20 bp overlap between neighboring oligos, along with short outer oligos (primers). In
single reactions, they assembled gene fragments from either 4 or 12 oligos, with outer
primers providing for PCR amplification.

Barnes and Frawley (2003) used

approximately picomole amounts of each 40-mer per 100 μL reaction volume (i.e. ~1 nM
to 10 nM concentration each oligo). Outer primers were present at 200 nM each. Using
integrated PCA-PCR, Barnes and Frawley (2003) constructed a 731 bp gene and a 2187
bp gene. However, their recommended thermal cycler parameters were denaturation at
93°C for 1 minute and annealing/extension at ~55°C for 20 minutes over 20-25 cycles.
Given these long annealing times, the Barnes and Frawley method yields runtimes of
about 7-10 hours. Tian and others (2004) coined the term PAM (polymerase assembly
multiplexing) for spiked outer primers combined with the oligo pool to perform
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integrated PCA-PCR. Using PAM (2 μL oligo mixture, 400 nM each primer) coupled
with a highly discriminating oligonucleotide selection method, 21 ribosomal genes were
synthesized, cloned, and sequenced. Selected error-free genes were combined using
sequential PAM reactions to yield a 14.6 kb operon.

Gao and others (2004) presents a unique thermodynamically balanced inside-out (TBIO)
synthesis scheme to conduct PCA with gradient oligo concentrations. Sense strand oligos
are used only in the C-terminal half and anti-sense strand oligos are only used in the Nterminal half with the innermost oligos overlapping. The oligo concentrations were
increased step-wise from 40 nM (innermost oligos) to 200 nM (outermost oligos). TBIO
proceeds from the “inside-out” with each consecutive cycle growing strands outwards
from the low concentration innermost oligos to the outermost oligos. This is in contrast
to traditional PCA in which assembly occurs throughout the oligos in every cycle.
However, this TBIO technique was limited to a maximum of six oligo pairs in a single
PCR and thereby required repetitive PCR steps to synthesize longer genes.

A rapid integrated PCA-PCR technique has been developed using short annealing times
(~10 seconds), a high-speed thermocycler, and fast KOD polymerase. Using the rapid
technique, genes can be assembled and amplified in high yield in under 20 minutes. Wu
and others (2006) explored key parameters in a conventional PCR thermocycler for their
one-step simplified gene synthesis approach.

Wu and others (2006) explored key

parameters in a conventional PCR thermocycler for their one-step simplified gene
synthesis approach (integrated PCA-PCR). Polymerase selection, oligo concentration,
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and ratio of outer primers were tested for three different genes (209, 777, and 936 bp).
Similarly, we have focused our efforts on exploring several key variables that are
important to the development of a rapid technique—the number of thermal cycles, the
concentration of oligonucleotides, and the concentration of outer primers. As noted by
Wu and others (2006), KOD polymerase performs better than Taq or Pfu enzymes for
integrated protocols. Also, the fast extension rate of KOD (Greip and others 2006) is
well-suited to rapid thermocycling, and is thus used in our experiments. In instances
where the rapid protocol failed, the Barnes and Frawley (2003) protocol was attempted
using a conventional block cycler.

First, oligo concentration strongly influences integration of assembly and amplification.
PCA usually employs high concentrations (25 nM to 100 nM) of each oligo for assembly,
whilst followup PCR on an aliquot has a lower oligo background (~5 nM). Oligo
concentrations must be high enough to enable efficient (and feasible time-scale) PCA.
However, PCA oligos/shorter products are complementary to the full-length template and
some compete for the primer pool during PCR amplification. So, one must at the same
time provide a low oligo background concentration that will minimally interfere with
amplification efficiency. Reconciling the oligo concentrations between the two steps is
paramount to integrating PCA-PCR. Second, the concentration of primers (or outer
oligos) affects the outcome of the integrated technique. Third, as the number of oligos
present in the reaction mixture increases both the assembly and PCR amplification
become more difficult.

While there is no theoretical limit on the assembly or
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amplification process, there is a practical limit on the number of oligos that can be used
robustly for the technique.

To investigate the integrated PCA-PCR technique, three genes were selected as
representative candidates: a 653 bp gene containing the endothelial protein C receptor
(EPCR) sequence, a 929 bp gene sequence encoding the pUC19 β-lactamase gene, and a
1509 bp gene sequence encoding the thrombomodulin-1 (TM-1) gene. All three of these
genes have been previously shown to work well under the traditional two-step approach
(Mamedov and others 2007; TerMaat and others 2010).

3.2 Materials & Methods
Oligonucleotides spanning the templates coding the EPCR gene, pUC19 β-lactamase
gene, and TM-1 gene were designed from cDNA sequences (GenBank accession nos.
L35545, L09137, and BC035602, respectively). The Gene2Oligo computer program of
Rouillard and others (2004) was used to design the assembly oligos. Oligos and primers
were obtained from Integrated DNA Technologies (Coralville, IA) at 50 μM in nucleasefree water.

Thermocycling protocols were performed in a rapid compressed air PCRJet®
thermocycler (Quintanar and Nelson 2002) using glass capillaries. All reaction volumes
were 25 μl with the following reagents fixed: 200 μM of each dNTP, 5 mM MgSO4, 400
μg/ml non-acetylated BSA, and 0.5 unit KOD hot-start polymerase from Novagen
(Madison, WI) in 1x manufacturer’s buffer.

All thermocycling protocols had fixed
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conditions of a 30 s hot start at 94°C, denaturation of 94°C for 2 s, extension of 72°C for
10 s, and a final extension at 72°C for 15 s. The number of cycles and annealing
conditions were varied. Traditional PCA: 20 or 30 cycles with annealing conditions of
56°C for 10 s. Each reaction contained 0.1 μM of each oligonucleotide. Followup PCR:
20 or 35 cycles with annealing conditions of 56°C for 3 s, and each reaction contained 1
μl PCA product template and 0.7 μM of each primer.

All reaction products were

electrophoresed on 1% agarose gels stained with ethidium bromide using 6 μl of each
product.

For the integrated PCA-PCR experiments, a variety of thermocycling conditions and
reaction compositions were used. The standard conditions for the integrated PCA-PCR
experiments were 40 cycles with annealing conditions of 56°C for 10 s. Each standard
reaction contained 10 nM of each oligonucleotide and 0.7 μM of each primer. For oligo
concentration experiments, 1 nM to 100 nM of each oligo were employed, with an
additional 1 nM sample with 30 s annealing time. For primer concentration experiments,
0 μM to 1.5 μM each primer were employed. To investigate the number of integrated
PCA-PCR cycles, 20 to 50 cycles were used. For integrated PCA-PCR experiments with
the TM-1 oligo set, the number of oligos present in each reaction was varied from 46 to
76 oligos. The thermocycling conditions were 70 cycles with annealing at 62°C for 15 s.
Each reaction contained 5 nM of each oligonucleotide along with an additional 700 nM
each outer oligo.
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The protocol described by Barnes and Frawley (2003) was attempted with the βlactamase and TM-1 oligo sets. Klentaq1 Polymerase and Rockstart buffer from DNA
Polymerase Technologies (St. Louis, MO) were employed in the reaction mixture along
with 1.3M betaine (Sigma Aldrich) and (20, 10, or 5) nM of each oligo. A conventional
block thermocycler was used to execute the 20 minute annealing time protocol.

3.3 Results & Discussion
3.3.1 Number of Cycles
Figure 3-1 shows integrated PCA-PCR of EPCR (Figure3-1A) and β-lactamase (Figure
3-1B) using 20 to 50 cycles. The left lanes of each gel show the equimolar PCA and
followup PCR, respectively, for the traditional two-step approach with 30 cycles of PCA
and 35 cycles of PCR. The right lanes of Figure 1b show the equimolar PCA and followup PCR for β-lactamase with 20 cycles each. As expected, the amplification of the
desired product increased up to a maximum along with the number of thermal cycles.
With the use of a rapid thermocycler, the 40 cycle protocol was completed in 19.2
minutes, and was used for further reactions. However, one can see that a high yield of
product can be obtained in 30 cycles (14.5 minutes).
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Figure 3-1 Traditional 2 step PCA/PCR and Integrated PCA-PCR vs. # of cycles.
(A) EPCR gene. lane 1: Equimolar PCA with 30 cycles; lane 2: Followup PCR with 35
cycles; lanes 4 thru 10: Integrated PCA-PCR vs. # of cycles. (B) β-lactamase gene. lane
1: Equimolar PCA with 30 cycles; lane 2: Followup PCR with 35 cycles; lanes 4 thru 7:
Integrated PCA-PCR vs. # of cycles; lane 9: Equimolar PCA with 20 cycles; lane 10:
Followup PCR with 20 cycles. Lanes (L): 100bp DNA ladder (NEbiolabs).

3.3.2 Effect of Oligo Concentration
The integrated technique using 1 nM to 100 nM each oligo was tested for both EPCR
(Figure 3-2A) and β-lactamase (Figure 3-2B). The right lane of each gel represents a 1
nM of each oligo sample with the annealing time increased to 30 seconds. For both
genes, 100 nM did not yield any distinguishable product from the background. For 25
nM reactions, EPCR showed a band at the correct molecular weight while β-lactamase
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did not. Both genes had strong product amplification at 10 nM and 5 nM. The 1 nM
EPCR sample with 30 second annealing had an extremely faint band, while 10 second
annealing product did not. The reverse situation was observed for 1 nM β-lactamase
samples.

Figure 3-2 Effect of oligo concentration on Integrated PCA-PCR.
(A) EPCR gene. (B) β-lactamase gene. Lanes 2 thru 6: (100, 25, 10, 5, and 1) nM of
each oligo, respectively. Lane 8: 1 nM of each oligo with 30 second annealing time.
Lanes (L): 100bp DNA ladder (NEbiolabs).

The concentration of oligonucleotides is paramount to simultaneous assembly (PCA) and
amplification (PCR) in a single reaction.

As can be seen in Figure 3-2, the oligo

concentration of 100 nM typically employed in the traditional two-step PCA and
followup PCR is unsuitable for use in the integrated approach.

While 25 nM of each
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oligo did yield product in the case of the 653 bp EPCR gene, it did not in the case of the
longer 929 bp β-lactamase sequence. Only when the oligo concentrations were about 5 to
10 nM did the integrated technique show high yield of the desired product in a single
step. This is in good agreement with the findings of Barnes and Frawley (2003) with
their long annealing time integrated protocol. Interestingly, Wu and others (2006) was
able to obtain the desired product at higher concentrations up to 100 nM, but only for
short genes with few oligos. At 5 nM, Wu and others (2006) had only the 209 bp gene
construct visible product. In exploring oligo concentrations, both the conventional and
rapid techniques became less forgiving as the number of oligos present increased. 5 nM
to 10 nM concentration of each oligo is recommended as close to optimal for rapid
integrated PCA-PCR.

Further reduction of oligo concentrations to 1 nM resulted in little to no product. This
indicates that the optimum of around 5 to 10 nM drops off sharply. In essence, proper
assembly is intermittent at 1 nM or lower concentrations and is not advisable. There is
no theoretical minimum on the necessary oligo concentrations for PCA per se, as it is
conceivable that only one strand of each oligo would be needed. However, the oligos
become so dilute within the reaction mixture that the probability of correct hybridization
at each cycle becomes miniscule. This is exacerbated by the fact that, upon later cycles,
these sparse intermediate products must hybridize. Thus, the propagation of assembly is
contingent upon intermediate product concentrations that are considerably less than 1
nM.

As intermediate assembly products are at extremely low (or non-existent)
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concentrations, even the longest of annealing times may be insufficient to promote
continued assembly.

3.3.3 Effect of Primer Concentration
The effect of primer concentrations (0 to 1.5 μM) is shown in Figure 3-3 (EPCR: Figure
3-3A, β-lactamase: Figure 3-3B). Wu and others (2006) specified a primer to assembly
oligo ratio, but the impression is that absolute primer amounts may have more weight to
integrated PCA-PCR techniques than a primer ratio. Note that primers can be replaced
by simply spiking the outer assembly oligos (with consideration given to optimal
annealing temperatures). The maximum amount of full-length product attainable clearly
depends on the amounts of the outer primers. With no primers present, no distinct band
at the expected size was visible for either gene while primer concentrations of 0.1 µM did
produce weak amplification.

0.4 µM to 0.7 µM of each primer provided good

amplification of the product. High primer concentrations of 1 µM or more also produced
good results. Just as in regular PCR, high primer concentrations can cause increased
probability of misannealing and thereby inhibit the desired amplification.

Thus,

concentrations of primers or outer oligos of about 0.4 to 0.7 µM each is recommended.
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Figure 3-3 Effect of primer concentration on Integrated PCA-PCR.
(A) EPCR gene. (B) β-lactamase gene. Lanes 2 thru 6: (0 (none), 0.1, 0.2, 0.4, 0.7, 1.0,
and 1.5) μM each primer, respectively. Lanes (L): 100bp DNA ladder (NEbiolabs).

3.3.4 Limitations arising from number of oligonucleotides
When rapid integrated PCA-PCR was attempted on TM-1 (76 oligos, 1509 bp), no
desired amplification product was visible on the gel (results not shown). Numerous
adjustments to TM-1 oligo concentrations, primer concentrations, and increased number
of cycles did not alter the outcome (results not shown). We hypothesized that integrated
PCA-PCR may be practically limited to a maximum number of oligos. Thus, the number
of oligos used within the reaction was decreased to investigate the point at which the
integrated technique failed.
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Figure 3-4A shows the resulting products using the TM-1 oligo set for 46 to 76 oligos.
The 76 oligo reactions are the full-length 1509 bp gene, while fewer oligo reactions result
in shorter products (partial gene sequence). All oligos were set at a concentration of 5
nM. An additional 700 nM each outer oligo employed in lieu of primers. The optimal
annealing conditions were found to be 62°C for 15 s since longer oligos were used. The
number of cycles was increased to 70 to maximize yield. As can be seen from the figure,
the amount of amplified product decreases as the number of oligos increases and
integrated PCA-PCR fails to produce a distinct product at about 60 to 66 oligos. The
decreased band intensity for 56 oligos is due to a compromise in annealing temperatures
(not optimal) for the oligo set. Figure 3-4B shows the traditional equimolar PCA and
follow-up PCR products using the full TM-1 oligo set. The desired band at ~1509 bp is
visible after completion of the two step approach.
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Figure 3-4 Traditional 2 step PCA/PCR and Integrated PCA-PCR vs. # of oligos using
the TM-1 oligo set.
(A) Integrated PCA-PCR using different # of oligos from the TM-1 oligo set. Lanes 2
thru 8: 46, 50, 56, 60, 66, 70, and 76 total oligos, respectively. (B) Equimolar PCA (lane
2) with follow-up PCR (lane 3) of the full TM-1 gene 76 oligo set. Lanes (L): 100bp
DNA ladder or 1kb DNA ladder (NEbiolabs).

The use of integrated PCA-PCR to assemble longer genes is possible given the findings
of Barnes and Frawley (2003). To see if the TM-1 gene could be assembled with longer
annealing times, we increased the annealing times from 10 seconds up to 14 minutes in
the compressed air thermocycler. In no case was the integrated PCA-PCR technique
successful for the TM-1 gene. Negative results (not shown) were also found for another

76 oligo set that was available in our lab.
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Follow-up PCR was performed and

demonstrated that the oligos had assembled full-length templates, but never reached an
efficient amplification phase. The exact integrated PCA-PCR protocol described by
Barnes and Frawley (2003) was then attempted with the β-lactamase and TM-1 oligo sets
using a conventional block thermocycler. In Figure 3-5, a discernable band was visible
after 25 and 37 cycles for β-lactamase with 5 nM each oligo. However, none of our
experiments with the TM-1 oligo set were successful even with the same reaction
conditions. Followup PCR of the 25 cycle products revealed that β-lactamase was indeed
fully assembled but TM-1 was not (results not shown). While we certainly cannot rule
out the possibility of success as we did not use PAGE-purified oligos or KlentaqLA
polymerase mix, the TM-1 gene was not simultaneously assembled and amplified in any

(A) β-lactamase

5 nM

10 nM

20 nM

L

5 nM

10 nM

20 nM

L

of our reactions.

(B) TM-1

Figure 3-5. Integrated PCA-PCR products after 37 cycles using a modified Barnes and
Frawley Protocol.
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(A) β-lactamase using either 20, 10, or 5 nM each oligo. (B) TM-1 using either 20, 10, or
5 nM each oligo. L: 100bp or 1kb ladder (New England Biolabs)

Logically, both PCA and PCR amplification become more difficult as the number of
oligos and gene length increase. Given the failure of the integrated technique on TM-1
but the success of the 2-step approach, it is fair to say that the 2-step approach is more
robust. In general, one would expect such a result, as two separate steps facilitate the use
of different oligo concentrations. In equimolar PCA, higher oligo concentrations (25 nM
to 100 nM) allow for efficient assembly even for longer gene sequences with a large
number of oligos. Follow-up PCR on an aliquot of the PCA product is performed with a
low concentration of background oligos (~5 nM) due to the dilution of the aliquot. This
dichotomy of oligo concentrations is not possible with the integrated approach.

To allow for efficient amplification, the background oligos should be present in minimal
concentrations.

All background oligos are complementary to the full-length PCR

amplification templates.

Thus, these oligos may inhibit polymerase extension by

annealing to the template downstream of the primer. Experiments using Vent polymerase
(New England Biolabs) with strand displacement activity did not result in successful
amplification of TM-1 (results not shown). Additionally, inner oligos that have been
extended to completion on their 3’ end will compete for primers and be linearly
amplified. As the number of oligos in the reaction mixture increase, so does the primer
competition and upstream annealing.

For example, 26 possible forward oligos are

present for β-lactamase. In contrast, 38 forward oligos are present in the full TM-1 set.
As an additional complication, the formation of DNA duplex pairs and gel analysis
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inferences will depend on the relative oligo pool at the last thermal cycle. A distinct band
may not be visible even though a significant amount of the full-length top strand and
bottom strands may be present. It is expected that using 100-mers as described by Chen
and others (1994) instead of 40-mers would likely allow for longer genes to be assembled
and amplified with an integrated technique.

However, PAGE purification of assembly

oligos would be needed to limit unwanted deletion errors in the synthesized product.

3.4 Conclusion
Integration of PCA assembly and primer-mediated PCR amplification into a single
reaction using rapid thermocycling has been demonstrated. Unlike the traditional 2-step
synthesis approach, the concentration of initial oligos must be lowered with an optimum
about 5 nM to 10 nM each oligo. Standard PCR reaction and primer conditions may be
used. The rapid integrated PCA-PCR technique was successful for two genes, a 653bp
EPCR gene (35 oligos) and a 929 bp β-lactamase gene (52 oligos). Annealing times of
10 seconds were found to be sufficient for the technique. Both genes were assembled and
amplified in a single reaction, requiring less than 20 minutes total (for 40 cycles) of rapid
thermocycling to obtain the full-length genes in high yield.

As the number of oligos present within the reaction increases, one must reconcile the
dichotomy of optimal oligo concentrations.

Lower concentrations favor PCR

amplification, but hinder efficient oligo assembly due to extremely dilute intermediate
products. Higher concentrations promote assembly but inhibit PCR amplification of
constructed full-length templates by upstream annealing of complementary oligos and
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competition for primers. For the 1509 bp TM-1 gene synthesis with 76 oligos, we were
unable to obtain a distinct gel electrophoresis product. The long annealing protocol of
Barnes and Frawley (2003) was equally poor for TM-1 but successful for β-lactamase
synthesis. Using partial oligo sets for TM-1, it was determined that about 60 oligos is the
maximum number that can be routinely used for rapid integrated PCA-PCR.
corresponds to about 1200 bp if ~40mers are used.

This

While there is likely some

dependence on the specific TM-1 gene sequence, some insights can be drawn from the
number of oligo results. Above 60 oligos, results may be unsatisfactory or optimization
too laborious and the two-step approach preferable.
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4 Improvements to the Gene Synthesis Workstation
A next generation rapid PCA-based gene synthesis and affinity purification platform has
been developed that generates improved yield and specificity from both sections of the
workstation. While feasibility of combining rapid PCA synthesis and subsequent twocolumn affinity purification of synthesized products was conceptually demonstrated
previously in Chapter 2, several deficiencies and opportunities were identified. In prior
syntheses, the PCA oligo concentration and the amount of PCA product aliquot used for
subsequent PCR were determined to require additional optimization as genes longer than
1 kb presented some difficulties in synthesis. In prior proof-of-concept purification,
some non-specific binding of the BrdU system was observed, in addition to unattractive
intermediate pH adjustment and generally low levels of isolated full-length construct. In
this work, five different target-ligand systems (BrdU, desthiobiotin, digoxigenin, FITC,
and TRITC) were explored to select two of these systems that convey improved levels of
yield and specificity in a desirable process. Digoxigenin and FITC were selected among
the five for use in a simpler yet improved flow-through immunoaffinity process that
directly applies first column effluent to the second column.

A 1.4 kb gene was

synthesized and purified in the next generation workstation as a representative test
sequence.

4.1 Introduction
Polymerase Chain Assembly (PCA) to synthesize genes from a pool of oligonucleotides
was first described by Stemmer and others in 1995.

In brief, short overlapping

oligonucleotides are hybridized together, extended by a DNA polymerase, and then
denatured in a PCR thermocycler—the process is repeated over many cycles to construct

the full-length double-stranded DNA of interest.
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The technique of PCA has been

exploited by other researchers to construct a variety of sequences ranging from a few
hundred bases up to many kilobases in length (Mehta and others 1997; Smith and others
2003; Gao and others 2004; Kodumal and others 2004). PCA was a primary technique to
create 5-7 kb sequences utilized by Gibson and others (2008) to construct a 582,970 bp
Mycoplasma genitalium genome using recombination techniques.

Mamedov and others (2007) applied the use of a rapid compressed air thermocycler
(Quintanar and Nelson 2002, Whitney 2004) to facilitate extremely short runtimes with
high fidelity. The rapid PCA technique was further expanded in Chapter 2 (also see
TerMaat and others 2010) to include affinity purification of the synthesized genes. In
Chapter 2, serial two-column purification was employed to selectively capture the fulllength synthetic gene. BrdU and iminobiotin labels were incorporated into the gene via
amplification primers, thereby facilitating selective capture of labeled DNA in the affinity
columns.

These two affinity systems have been separately employed for protein

purification (Haider and others 1997; Urbach and others 1999; Hirsch and others 2002;
Walters and Field 2006).

However, the application of these systems in a serial

purification arrangement for isolation of synthetic genes was not performed by others to
our knowledge. In Chapter 2, the rapid synthesis and subsequent purification of genes
was investigated using four genes ranging from 612 to 1548 bp.

While combined rapid PCA and affinity purification of synthetic genes was conceptually
demonstrated in Chapter 2, the results presented therein show that the proof-of-concept
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process suffered from several short-comings. The objective of this work was to develop
a next generation synthesis and purification platform that addresses deficiencies and
unknowns arising from the proof of concept research. The foundation of the rapid PCA
synthesis technique was relatively well-developed, yet the optimal conditions of PCA
oligo concentration and subsequent PCR template concentration were not fully
understood. Prior work indicated that as the gene to be synthesized increased in length
(typically greater than 1 kb), the synthesis became very sensitive to these two variables.
However, optimal conditions for these parameters were unknown and the rationale
behind the effects not clearly understood; thus further investigation was undertaken in
this work.

For the purification process, the performance characteristics of the initial anti-BrdU and
Streptavidin ligands, while demonstrating feasibility, were not considered optimal with
respect to the yield and specificity. The BrdU purification did demonstrate some nonspecific binding of unlabelled DNA, thereby resulting in some possible impurities being
present in the isolated product. Due to the binding and elution conditions of the two
columns in the proof-of-concept workstation, an intermediate adjustment step added
some complexity to the system. Lastly, the yield of isolated product in the final effluent
was also identified for improvement. For example, the yield of isolated product after
affinity purification was below the gel detection limit for the TM-1 gene tested therein.
Thus, a considerable portion of the development herein focused on selection and testing
of different purification systems for use in the next generation platform. A total of five
different affinity based systems were compared to select the two top candidates for
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further testing. Additionally, biospecific elution conditions enabled testing of a modified
purification process in which effluent from the first column is directly applied to the
second column.

The scope of this research is summarized in the following key objectives:

•

Elucidate general insight into the optimal PCA oligo concentration and PCR
template aliquot conditions for rapid PCR to be implemented in the workstation.

•

Identify five different affinity purification systems as candidates for
implementation in the purification section of the workstation.

•

Screen the label candidates for any potential inhibition during incorporation of the
labels into amplicons during PCR.

•

Conduct batch testing of label-ligand systems to compare yield and specificity.

•

Determine appropriate elution conditions for the systems, either non-specific salt
elution or biospecific elution using free labels in the elution buffer.

•

Implement two selected candidates in an improved flow-through process with
accompanying instrumentation.

•

Validate the new system for the purification of a 1.4 kb gene sequence.

For this work, a 1.4 kb sequence was primarily employed as a model gene. This gene
sequence was a chimeric gene encoding for both EPCR and TM-2 regions in a single
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sequence joined by a myc linker sequence. By utilizing both inner and outer primers, a
total of three different amplicons could be generated—a 640 bp chimera “A” fragment
(primarily the EPCR section), a 753 bp chimera “B” fragment (primarily the TM-2
section), and a 1377 bp (herein 1.4 kb) full chimeric gene sequence. Please refer to
Appendices 5B and 5C for further details on the chimera sequence, noting that all
references in this chapter of “chimera” or its fragments refer to a modified chimera #2
gene that lacks the His-6 tag (see hybridization map in Appendix 5C.6 for the modified
sequence).

Note that the A and B fragments overlap each other by 16 bp, thus

reconciling the gene lengths. The details of the chimera and its fragments employed in
this work are given in Table 4-1.

Description
Full-length chimera
Chimera A fragment
Chimera B fragment

Length # oligos
1377 bp
77
640 bp
35
753 bp
42

Forward Primer (5'-->3')
ATCTCGAGAAAAGATTTTGTAG
ATCTCGAGAAAAGATTTTGTAG
ATCTGAATAGCGCCGTCG

Reverse Primer (5'-->3')
TAGCGGCCGCTTACTTACC
ACGGCGCTATTCAGATCC
TAGCGGCCGCTTACTTACC

Table 4-1 Details of the chimera gene sequence and its fragments.

For investigation of PCA parameters, the chimera “A” fragment was tested along with the
TM-1 sequence described in Chapter 2.

In PCR inhibition tests, all three chimera

amplicons were tested (A and B with only one labeled primer, full-length with two
labeled primers to elucidate any detrimental interaction). Comparative testing of label
systems by batch purification was performed using the chimera “A” fragment for
consistency. Serial purification, both batch and flow-through, using two labels was
performed with the full-length chimera as no inner labeled primers were procured.
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4.1.1 Improvements to the 2-step PCA process

Two of the most critical parameters in the 2-step PCA-PCR process are the oligo
concentration used in PCA, and the amount of PCA product used in subsequent PCR. In
prior research (Mamedov and others 2007; TerMaat and others 2010), typically smaller
genes were assembled with 100 nM each oligo with 1 µl of this PCA product used as
template for PCR. However, longer synthetic genes were assembled using ~25 nM each
oligo with 2 µl used as template (Mamedov and others 2007). While the assemblies may
have approximately the same total oligo concentrations, it begs several questions: Is
there a general rule of thumb for an optimal oligo concentration? What is the sensitivity
of the 2-step process to oligo concentrations? Is there an optimal aliquot amount for
follow-up PCR? Do the answers to these questions depend on the gene length (or # of
oligos)? It was postulated that, as the gene length (and thereby # of oligos) increases, the
process will become more sensitive to the point of failure, for similar reasons as found in
integrated PCA-PCR. To provide some preliminary insight into these questions, a brief
set of experiments was devised in which the PCA oligo concentration, and the subsequent
PCA product aliquot for PCR, were varied for two genes:

the 640 bp chimera A

fragment and the 1548 bp TM-1 gene sequence from Chapter 2.

4.1.2 Investigation of target-ligand affinity systems
The concept of affinity purification as demonstrated in Chapter 2 is not specific to the
BrdU and iminobiotin systems employed therein. Several deficiencies existed in which
correction would be desirable, most notably non-specific binding found with the BrdU
antibodies.

Additionally, demonstration of the process with alternative purification
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systems supports greater generalization of the workstation. The label-antibody systems
that could potentially be employed in the system are seemingly limitless. Antibodies
against all sorts of molecules are theoretically an option, as evidenced by the plethora of
options commercially available. The type of antibody (polyclonal or monoclonal), the
originating host (goat, sheep, chicken, mouse, rabbit, etc), as well as the specific supplier
compound the issue. Lastly, other affinity ligand-target systems can also be considered
for use in the workstation.

However, utilization of antibodies is particularly

advantageous due to their high specificity in general. As exhaustive analysis of all
possible schemes was practically impossible, a highly focused effort was undertaken.

In total, five different candidates were selected for initial testing based upon a prior work
and a survey of literature.

The original BrdU antibody (goat polyclonal antibody,

Immunology Consultants) used in Chapter 2 was retained for testing. For the streptavidin
affinity separation, desthiobiotin was used as a replacement for iminobiotin with the HP
Streptavidin resin (GE Healthcare, Piscataway, NJ). Desthiobiotin has shown to be
eluted using competitive binding with biotin in the elution buffer, whereas biotin binding
is essentially irreversible and iminobiotin purification typically employs pH adjustment
(Hirsch and others 2002). Three other candidates were also selected: Digoxigenin
(DIG), Fluorescein isothiocyanate (FITC), and tetramethyl isothiocyanate (TRITC).
Digoxigenin is a steroid found in the Digitalis plants and is commonly employed as a
hapten (Höltke and Kessler 1990). FITC and TRITC are commonly used fluorescent
labels that may be attached to proteins (Moser and Hage 2006; Hermanson 2008). For
Digoxigenin, FITC, and TRITC, a search of commercial suppliers for antibodies was
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conducted; cost, purity, host, and amount were weighed in the selection. All of the
procured antibodies used were immunoaffinity purified against the antigen, except for the
anti-TRITC which was protein A purified.

The details of the labels and employed

ligands are given in Table 4-2.

Label
CAS #
BrdU
59-14-3
Desthiobiotin 533-48-2
Digoxigenin 1672-46-4
FITC
27072-45-3
TRITC
95197-95-8

Ligand Source
chicken polyclonal
HP Streptavidin
goat polyclonal
goat polyclonal
mouse monoclonal

Ligand Supplier
Immunology Consultants
GE Healthcare
Genetex
Bethyl Labs
Rockland Inc.

Supplier Part #
CBDU-65A-Z
17-5112-01
GTX73152
A150-112A
200-301-246

Table 4-2 Label and ligand details.

To evaluate the labels in an effort to select only two for testing in the next generation
workstation, performance of labeled primers in the PCR process (inhibitory or not) was
the first screening step. Incorporating labels into the oligonucleotide primers for PCR
amplification of the full-length synthetic gene template is necessary to provide targets for
selective purification of the full-length synthetic gene from the oligo pool resulting from
the PCA process.

PCR inhibition due to the labeling of primers was not expected

because of the relatively small size of the molecules and the success already achieved
with BrdU and iminobiotin in the proof-of-concept. However, overlooking this due
diligence step could have had onerous consequences if indeed the selected labels were
inhibitory to PCR. The five candidates were then subjected to a number of batch elution
tests to provide comparative measures of 1) the efficacy of binding, and 2) elution
characteristics under salt and free label in solution conditions.

The total cost

consideration was based on cost of the antibody, the cost of the primer labeling, and the
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cost of the label for inclusion in elution buffers. Lastly, the buffer compatibility between
selected label purification systems was also not overlooked since whatever two
candidates are chosen must work synergistically in the serial purification.

4.1.3 Affinity purification process
Another aspect of the research was to refine the affinity purification section. After
selection of digoxigenin and FITC as the two candidates and demonstration of product
elution from competitive binding with free labels, a revised hardware schematic was
developed for the serial immunoaffinity process. The biospecific elution by free labels
facilitated a simplification of the workstation. The first column (anti-FITC) product
effluent was directly applied to the second column (anti-digoxigenin) as it was not
anticipated that free FITC label would interfere with the binding due to the specificity of
antibody based separations. A schematic of the hardware is shown in Figure 4-1.
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Figure 4-1 Schematic of the next generation affinity section.

4.2 Materials & Methods
4.2.1

Optimization of 2-step PCA-PCR

The TM-1 oligo set (77 oligos, 1548bp) from Chapter 2 and the chimera A oligo set (35
oligos, 640bp) were used as model systems. Oligo concentrations in the PCA step were
either 12.5, 25, 50, or 100 nM each oligo. For each of the PCA products, the aliquot for
PCR amplification was either 0.25, 0.5, 1, 2, or 4 µl. Each 25 µl PCA and PCR reaction
contained the standard reagents of 200 µM each dNTP, 5 mM MgSO4, 400 µg/ml non-
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acetylated BSA, and 0.5 U KOD polymerase in 1x manufacturer’s reaction buffer. For
PCR amplification , 0.7 µM each primer was used. PCA thermocycling conditions in the
PCRJet for both genes were: Hot Start of 94°C for 30 sec; 30 cycles of [94°C for 2 sec,
56°C for 10 sec, 72°C for 10 sec]; and final extension of 72°C for 15 sec.

PCR

conditions were identical except for 1) 40 cycles with 56°C for 3 sec annealing was used
for TM-1, and 2) 30 cycles with 58°C for 3 sec annealing was used for chimera A. PCR
products were analyzed by 1% gel electrophoresis stained with ethidium bromide using
10 µl each product and 12 µl reference ladder.

4.2.2 PCR testing of labels
The chimeric gene sequence of EPCR-myc-TM2 was used as the model sequence. One
advantage of this chimeric gene sequence is that inner primers were previously shown to
be robust to amplify shorter products. Thus, three total amplicons could be tested: 1)
640 bp chimera “A” (primarily the EPCR region) with labeled/regular outer forward
primer and regular inner reverse primer, 2) 753 bp chimera “B” (primarily the TM-2
region) with labeled/regular outer reverse regular/label primer and regular inner forward
primer, or 3) 1.4 kb full chimera with both labeled or regular outer primers to verify no
interaction between labels existed.

Outer primers labeled on the 5’ end with the

respective label or unmodified were obtained from IBA GmbH (Göttingen, Germany).
The labeled primers from IBA GmbH were HPLC-purifed post-labeling to ensure a high
percentage (>95%) of the primers were in fact labeled. Both forward and reverse outer
primers were labeled with each of the five candidates. Regular inner primers were
procured from Integrated DNA Technologies (Coralville, IA).
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First, equimolar PCA was performed to create the three templates for the PCR testing.
Each 25 µl PCA reaction contained 200 µM each dNTP, 5 mM MgSO4, 400 µg/ml nonacetylated BSA, and 0.5 U KOD polymerase in 1x manufacturer’s reaction buffer. The
chimera “A” and chimera “B” assembly utilized 100 nM each oligo, whilst the full
chimera was at 25 nM. PCA thermocycling conditions in the PCRJet were: Hot Start of
94°C for 30 sec; 30 cycles of [94°C for 2 sec, 56°C for 10 sec, 72°C for 10 sec]; and final
extension of 72°C for 25 sec.

As outlined above, the possible combinations of labeled and regular primers were
explored for each of the three amplicons. For chimera “A” and chimera “B”, 1 µl of the
PCA product was used as template for PCR, whilst 2 µl was taken for the full chimera
amplification. 0.7 µM each primer was employed in each PCR reaction. Otherwise the
other reaction components for PCR were the same as for PCA. PCR conditions in the
PCRJet were: Hot Start of 94°C for 30 sec; 35 cycles of [94°C for 2 sec, 58°C for 3 sec,
72°C for 10 sec]; and final extension of 72°C for 25 sec. 1% gel electrophoresis stained
with ethidium bromide was performed loading 10 µl of each PCR product and 12 µl
molecular weight DNA ladders.

4.2.3 Affinity columns
The BrdU antibody and HP Streptavidin ligands from Chapter 2 were retained. The three
new antibodies (for DIG, FITC, and TRITC) were coupled to N-HydroxysuccinimidylSepharose(R) 4 Fast Flow (Sigma Aldrich, 4% highly cross-linked beaded agarose, part #
H8280) to a concentration of 0.5 mg per ml. Briefly, the sepharose resin-isopropanol
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suspension was centrifuged, the isopropanol removed, and then washed with 10 resin
volumes of ice-cold 1 mM HCl. Antibody was placed into 0.1M NaHCO3, 0.5M NaCl,
pH 8.0, and then added to the resin. Coupling was allowed to proceed overnight at 4°C
on an end-to-end rotator.

After centrifuging and removing the supernatant, any

remaining coupling sites were blocked by washing twice in 5 resin volumes of 1.0M
ethanolamine, pH 8.3, and then once in 5 resin volumes of 0.2M Tris-HCl, pH 8.5, with
each step at 1 hour at room temp on an end to end rotator.

The resin was then

equilibrated in protein binding buffer (PBB) by washing five times in 5 resin volumes of
10mM Tris-HCl, 50mM NaCl, pH 7.4. The coupled resins were stored at 4°C in 0.05%
sodium azide.

4.2.4 Batch purification testing
To investigate the binding and elution characteristics, the chimera “A” (EPCR) fragment
was used as the initial test gene. 60 µl of labeled PCR product (with respective label)
was mixed with 180 µl of PBB (10mM Tris-HCl, 50mM NaCl, pH 7.4; application
buffer), and 40 µl of this mixture removed as a feed sample. 100 µl of each resin was
placed in a microcentrifuge tube. After adding the feed to the resin, the 2:1 solution:resin
was placed on an end-to-end rotator at room temperature. After binding, the tube was
centrifuged and the supernatant removed (same procedure for wash and elution steps).
The resin was washed with 200 µl PBB. Elution was attempted using 200 µl aliquots of
elution buffer with a 4 hour incubation time. 30 µl of each fraction was analyzed by 1%
agarose gel electrophoresis with 12 µl of 100bp DNA ladder (New England Biolabs) for
reference. Due to the higher detection sensitivity, gels were stained with GelRed dye
(Biotium, Hayward, CA, part # 41001) rather than the typical ethidium bromide.
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Initial testing with high salt elution: Binding was allowed to proceed overnight. Three
washes were performed. One elution fraction with 20 mM Tris-HCl, 500 mM NaCl, pH
7.4 using was performed with 4 hour elution incubation time.

Testing with free label in elution buffer: Elution buffers with free labels were prepared
with the label at half-maximum solubility, 500 mM NaCl. 1% DMSO (Sigma Aldrich)
was included to increase the solubility of the labels. All free labels were obtained from
Sigma Aldrich (part numbers: BrdU- B5002; biotin - B4501; DIG – D9026; FITC F3651; TRITC – 87918). Binding of Feed was reduced to 1 hour.

2 washes and 2

elution steps were employed with incubation times for elution at 15 minutes each step.

Regeneration testing-

The exact resin aliquots used for free label elution testing of

labeled PCR product were regenerated with 500 µl glycine, pH 2.2 for 10 minutes at
room temperature. The exact same protocol used for free label elution testing was then
carried out.

Non-specific binding testing: Fresh resins were utilized under the same protocol as the
labeled PCR product with free label elution buffer. Regular PCR product devoid of any
labels was used in the feed.

Serial testing with digoxigenin and FITC: The full chimera product labeled with
digoxigenin and FITC (forward and reverse primers, respectively and arbitrarily) was

used for serial batch testing.
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90 µl of this product was mixed with 270 µl PBB; the

additional amount was used in an effort to overcome detection deficiencies especially
after a serial purification. Binding to fresh anti-FITC resin (100 µl) was allowed to
proceed for 1 hour, then washed three times, then eluted three times with FITC free label
elution buffer (15 minutes incubation each elution step). The first two FITC elution
fractions were combined (after saving 30 µl each as samples for gel analysis) and an
equivalent amount of water added to adjust salt concentration. This intermediate feed
was incubated with fresh anti-DIG resin (100 µl) for 1 hour, then washed three times,
then eluted three times with DIG free label buffer (15 minutes incubation each elution
step).

4.2.5 Flow-thru affinity purification hardware
A new enclosure was constructed that was approximately 15” wide x 15” tall x 10” deep.
The electronics (power supply, circuit board, and wiring harnesses) were located in the
rear of the unit and isolated from any fluid paths by way of a middle divider. The
schematic of pumps, valves, columns, fittings, tubing, and vessels according to the layout
were mounted onto the divider wall. A picture of the workstation is shown in Figure 4-2.
Please reference the schematic shown in Figure 4-1.
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Figure 4-2 Picture of the new affinity purification system.

Many of the same components employed in the Chapter 2 workstation were retained in
the next generation workstation. Please refer to Chapter 2 for the details of the pumps,
valves, tubing, custom circuit board, power supply, and buffer vessels. Omnifit 3mm id x
2.5cm precision glass columns (Western Analytical Products, part # 006-CC-03-02-FF)
were employed for both columns.

A digitial input/output terminal board (Keithley

Instruments) and power entry module were mounted at the back wall to allow for the
system electronics to be completely hidden.

Molex mini-fit pins and wall-mount

connectors mounted on the middle divider were employed within wiring harnesses to tidy
up electrical wiring.

A custom-built outer enclosure was constructed from 1/16”

aluminum with hinged plexi-glass front doors, framed with ½” aluminum bar stock. The
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middle divider was employed to separate electronic components from the
chromatography process.

All buffers were placed proximal each other along with the feed. The fluids flow through
a valve manifold consisting of 2-way valves that may be opened during each stage. A
multi-port union consolidates the outputs into a single line. A pump is activated to pull
the selected fluid(s) through valves that are open at each stage, and the fluid is pumped
through the first column.

Three way valves are present at the effluent end of each

column to direct the flow to waste, the second column, or the final effluent. Prior to
direct application of desired FITC effluent to the anti-digoxigenin column, it is necessary
to divert feed loading and wash fractions that contain unwanted digoxigenin-labeled
product to waste.

Therefore, a three-way valve was required to be present in this

configuration between the FITC and digoxigenin columns.

4.2.6 Flow-thru immunoaffinity purification
Initial testing of the flow-thru immunoaffinity workstation was done with the labeled full
chimera sequence. Anti-FITC and anti-digoxigenin antibody resins were each packed
into separate Omnifit glass columns with a bed volume of 170 µl. This amount was
determined to be sufficient, as it represents at least a ten-fold excess of antibody binding
sites to labeled product. Estimating the molecular weight of the igG antibodies at 150
kDa and a concentration of 0.5 mg/ml, this yields approximately 567 picomoles. In the
PCR reaction using 0.7 µM of labeled primer and 100 µl total product as feed, the
maximum amount of label load to the first column is 70 picomoles. Each igG molecule
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has the capacity to bind two antigens in the two Fab fragments. Note that the label
binding burden of the second column is substantially less due to wash-thru of labels and
inefficiencies of first column binding.
volume for simplicity.

However, both columns used the same bed

Sufficient bed volume binding capacity is also justified

empirically from scale-up of batch testing in which 100 µl of resin was used against 60 µl
of PCR product.

The buffer vessels in the workstation were filled with the following buffers:
•

Binding/Wash Buffer (BB): 10mM Tris-HCl, 50mM NaCl, pH 7.4

•

FITC Elution Buffer (fEB): FITC label at max solubility in water with 1%
DMSO, 100mM NaCl

•

Digoxigenin Elution buffer (dEB): DIG label at max solubility in water with 1%
DMSO, 250mM NaCl

•

Regeneration Buffer (RB): 0.1M phosphate buffer, pH 2.5

Note the sixth vessel was not productively used yet filled with water for priming of the
tube.

Prior to installation of the columns, all lines were primed via the software

interface. The respective buffer vessel fluid was primed up to the 7-port union. Binding
buffer was primed into the feed line and all lines downstream of the union. After
installation, the columns were equilibrated with approximately 2 ml of binding buffer.
With the system initialized, the following protocol was used. Please refer to the hardware
schematic shown in Figure 4-1 and the picture of the workstation in Figure 4-2. Effluent
samples of approximately 200 µl were collected.
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1.

Load Feed to FITC column. Mixed 100 µl PCR product with 300 µl BB in
sample Feed microcentrifuge tube. 40 µl was saved as a Feed aliquot for gel
analysis. With VFeed on, pumping set at 20 µl /min (200ms on / 29800ms off per
stroke). When ~20ul left, added 40 µl BB to tube and continued pumping. The
first 200 µl was not collected. Collected samples #1-3 from V3way1 waste.

2.

Wash FITC column. With VBB on, pumping set at 0.3 ml /min (200ms on / 1800
ms off per stroke) for a total of 1.2 ml.

Collected samples #4-9 from V3way1

waste.
3.

Elute FITC column/Bind DIG column. With VfEB on and V3way1 on, pumping set
at 20 µl /min (200ms on / 29800ms off per stroke) for a total of 1.2 ml. Collected
samples #10-15 from V3way2 waste.

4.

Wash DIG column. With VBB on and V3way1 on, pumping set at 0.3 ml /min
(200ms on / 1800 ms off per stroke) for a total of 1.2 ml. Collected samples #1621 from V3way2 waste.

5.

Elute DIG column. With VdEB on, V3way1 on, and V3way2 on, pumping set at 40 µl
/ min (200ms on / 14800 ms off per stroke) for a total of 1.6 ml.

Collected

samples #22-29 from V3way2 collect.
6.

Flush DIG column.

With VdEB on and V3way1 on, pumping set at 0.3 ml / min

(200ms on / 1800 ms off per stroke) for a total of 1.2 ml.
7.

Regenerate columns. With VRB on, pumping set at 0.3 ml / min (200ms on / 1800
ms off per stroke) for a total of 3ml. Repeated for 3ml with V3way1 on.

8.
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Equilibrate columns. With VBB on, pumping set at 0.6 ml / min (200ms on / 800
ms off per stroke) for a total of 6 ml. Varied V3way1 and V3way2 to clear lines.

30 µl of each sample was analyzed by 1% gel electrophoresis using GelRed stain with 12
µl of 1 kb ladder.

4.3 Results & Discussion
4.3.1 Optimization of 2-step PCA-PCR
The results of PCA oligo concentration coupled with PCR aliquot are shown in Figure 43. For the short 640 bp gene, the reactions were insensitive to the variables—high yield
of product was obtained for all samples. However, for the longer 1548 bp gene, the yield
of product became very sensitive to the variables and their interaction. A desired product
band was distinguishable for only a few of the combinations in this case. For the 1548 bp
gene, [25 nM / 2 µl] and [50 nM / 1 µl] yielded the best products, while samples to the
right (next level of PCR aliquot amount) of these optimal values gave strong bands with
slightly reduced yields.
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100

TM-1

Figure 4-3 PCA oligo concentration – PCR aliquot amount reaction sets for the 640 bp
chimera “A” and 1548 bp TM-1 genes.
PCA was performed at either 12.5, 25, 50 or 100 nM each oligo. Aliquots of 0.25, 0.5, 1,
2, or 4 µl were used for PCR.

As expected, the window of acceptable oligo concentrations and PCR aliquots closes as
the gene length increases. Of course, the specific genes employed in the experimental set
highly influence the results. Thus, a quantitative analysis of gel electrophoresis yields
does not provide intrinsic benefit from a design aspect. Note that normalization of the
PCR aliquot to an effective oligo concentration may be more apt. In the TM-1 set for
example, the most distinct product band for each PCA oligo concentration can be seen at
an effective PCR concentration of 2 nM.
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The significance of oligo concentration to integrated PCA-PCR as detailed in Chapter
(also see TerMaat and others 2009) supports that these parameters are also of high
importance to the 2-step process. In integrated PCA-PCR, one must balance the oligo
concentration—it must be sufficient for assembly yet low enough so that exponential
amplification is not greatly inhibited. In the 2-step process, one has considerable control
over the oligo concentrations during each of the separate PCA and PCR reactions. As
noted in Chapter 3, high PCA oligo concentrations are reduced by only taking an aliquot
of the PCA product for follow-up PCR.

Synthesis of shorter genes that do not require a substantial number of oligos (35 in the
case of chimera A) do not require a high initial concentration of each oligo for the
reaction to progress through intermediate products to the full-length gene. Thus, shorter
genes may be assembled over a wide range of assembly oligo concentrations. Since in
these PCA reactions a considerable number of full-length templates are formed, the PCR
aliquot amount is not critical to ensure a sufficient number of templates are present for
amplification.

Under this rationale, one would expect preference for high oligo concentrations and a
relatively large PCR aliquot for longer genes. However, other aspects of the reaction
must be considered in the case of a large pool of oligos.

For PCA, high oligo

concentrations to promote assembly through intermediate products are counter-acted by
inefficiencies arising from the high total oligo concentration. For example, the PCA
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reaction may become “poisoned” by the sheer number of oligos present at 100 nM due to
increased probability of misannealing events, or even polymerase sequestration (Kainz
2000). In the case of TM-1 at 100 nM, the total oligo concentration was 7.7 µM. In
contrast, chimera A at 100 nM was 3.5 µM total oligo concentration. At the other
spectrum end, low concentrations of assembly oligos are insufficient for the assembly to
progress through intermediate products. As the number of oligos in a reaction increases,
the number of intermediate actions that must occur increases along with more dilute
levels of these intermediates. A second aspect that must be considered non-trivial with
longer gene synthesis is the PCR aliquot amount. It is necessary to get a sufficient
number of full-length templates into the PCR amplification reaction (theoretically one
template). At high assembly oligo concentrations, amplification may be inhibited by too
large of an aliquot due to carryover of undesired oligos that are complementary to the
template. Too small of an aliquot in any case will not provide the template required for
amplification. Taking both of these points into consideration, it is understandable why
the assembly oligo concentration coupled with PCR aliquot amount must be balanced for
longer gene synthesis.

From the experiments, some general rules of thumb can be gleaned. In prior research,
shorter genes (< 1 kb) were assembled at 100 nM each oligo. While the facile nature of
these short genes tolerates this concentration, it is in many ways unnecessarily excessive.
Rather than rely on this forgiveness, it is generally recommended that lower oligo
concentrations be employed even for short genes. Therefore, for short and long genes
alike, the PCA concentration / PCR aliquot combinations of [25 nM / 2 µl] or [50 nM / 1

87
µl] are recommended. These findings are relied upon for future work found in Chapter 5.
Genes up to ~1.9 kb were successfully constructed under these conditions. Unsuccessful
attempts at a 2.7 kb gene reaffirmed the difficulties that arise to such an extent that no
distinguishable band can be attained regardless of the parameters employed.

4.3.2 Labeled primer testing
The resulting PCR products employing labeled primers are shown in Figure 4-4.

As

expected, the labeled primers did not affect PCR amplification in the three cases tested
(chimera A and B with single labeled primer, full chimera with combination of two
labeled primers). In all cases, amplicon yield from a labeled primer was essentially
equivalent to PCR amplification with regular primers. Thus, further testing was pursued

Chimera “A”

Chimera “B”

FITC/TRITC

DIG/TRITC

DIG/FITC

DEST/TRITC

DEST/FITC

DEST/DIG

BRDU/TRITC

BRDU/FITC

BRDU/DIG

BRDU/DEST

REG/REG

REG
BRDU
DEST
DIG
FITC
TRITC

REG
BRDU
DEST
DIG
FITC
TRITC

with all five candidates.

Full Chimera

Figure 4-4 PCR inhibition testing using labeled and regular primers.
REG: regular, DEST: desthiobiotin, DIG: digoxigenin. Chimera A: 640 bp; Chimera B:
753 bp; Full Chimera: 1.4 kb.
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4.3.3 Batch purification with high salt elution

TRITC

Figure 4-5 Initial batch testing of the five labels with high salt in the elution buffer with
the 640 bp chimera A sequence.
F: Feed, P: post-binding supernatant, W: Wash step, E: Elution.

The results from the initial conservative protocol with long binding and elution
incubation times reveal several key findings.

In comparing the feed and post-bind

supernatant samples, the amount of labeled product binding to each resin can be inferred.
Of course, it also serves to verify that coupling of the ligands was successful. In this
case, anti-streptavidin, anti-digoxigenin, and anti-FITC resins demonstrated fairly high
quantities of binding. Anti-BrdU and anti-TRITC resins did not demonstrate such high
levels. Although imperfection exists in removing supernatants, the products visible in the
wash steps are indicative of bleed-off of the bound product and weaker binding. In this
respect, anti-TRITC showed that product slowly was lost over wash steps. Lastly and
most importantly for the objective, the presence and amount of product in the elution
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fraction revealed the success of the tested 500 mM NaCl elution buffer. The higher salt
was successful for BrdU elution and TRITC elution (the latter muddled due to product
bleed-off). However, the higher salt elution failed to elute streptavidin, digoxigenin, and
FITC labeled-products, implying that the binding affinity of these ligand-target systems
was relatively strong by comparison.

In the gels, one will notice that the product band is shifted up (appears to be longer
length) in the elution fraction in comparison to the other samples and reference ladder.
This mobility shift is a consequence of the higher salt concentration employed in the
elution fraction. This phenomena is also observed in other samples in this work in which
the salt concentration was altered.

4.3.4 Batch purification with free label elution buffer
The anticipated direction from the beginning of the candidate selection was the use of
free labels in the elution buffer for biospecific elution conditions. This reverse-role
competitive binding mechanism employed was believed to be a preferred method,
especially as it may facilitate a simplified workstation layout via direct application of first
column effluent to the second column. The results of the testing are shown in Figure 46.
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FITC
TRITC
Figure 4-6 Batch testing of the five labels with label in the elution buffer for the 640 bp

chimera A sequence.
F: Feed, P: post-binding supernatant, W: Wash step, E: Elution step.

The results demonstrate that the label elution buffers have succeeded in displacing the
bound labeled DNA.

For all 5 systems, product bands were visible in the elution

fractions upon application of the elution buffer. In most of the cases, product eluted over
both fractions indicating that the accumulation of free label competition gradually
displaces product. In looking at the post-bind supernatant samples in comparison to the
feed, once again desthiobiotin, DIG, and FITC bound significantly with the reduction to 1
hour incubation. Additional elution steps would have likely released more product in
these three cases as the mass balance of all the samples indicate that some product may
still be bound. This is especially true for DIG in which elution was gradual over the two
elution fractions.

Fluorescent background signals are present in FITC and TRITC
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elutions; the FITC background may overlap bands whilst the TRITC label does not
migrate in the gel.

4.3.5 Column Regeneration
The objective was to regenerate the column for repeated use by releasing any bound free
label. Carry-over labeled DNA was highly unlikely as the resins remained incubated
with some elution buffer in between runs. The identical batch purification procedure was
then performed to determine the efficacy of the glycine regeneration. The purification

FITC

E2

E1

W2

W1

P

F

E2

E2

W2

W1

P

DIG

E1

W2

W1

E1
F

E2

E1

W2

W1

P

Desthiobiotin

F

BrdU

P

F

E2

E1

W2

W1

P

F

results after glycine regeneration are shown in Figure 4-7.

TRITC

Figure 4-7 Batch testing of the columns after glycine regeneration using the 640 bp
chimera A sequence.
F: Feed, P: post-binding supernatant, W: Wash step, E: Elution step.
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As can be seen from the gels and in direct comparison to fresh resin testing done in 4.3.4,
binding of the product was greatly reduced in all cases. BrdU, digoxigenin, and FITC
exhibited very slight binding activity as evidenced by an increase in product upon elution
buffer application. Elution bands for FITC were masked by the free label fluorescence.
The performance reduction was either due to the glycine denaturing the antibodies and
rendering them inactive, or the glycine failed to remove the bound free labels from the
binding sites.

As glycine conveys relatively harsh regenerations conditions, an

alternative regeneration buffer of pH 2.5, 0.1 M phosphate buffer was used for further
column regeneration. This buffer has been shown to release bound fluorescein from antiFITC antibodies (Clarke and Hage 2001).

The low pH used typically results in a

conformational change of the ligand, thereby facilitating release of the target.

4.3.6 Non-specific binding testing
In general, it can be assumed that antibody-based binding systems are highly specific for
the target. However, this cannot necessarily be assumed to be unquestionably true,
especially in cases where polyclonal antibodies are employed. Thus, nonspecific binding
using regular (unlabelled) PCR product with fresh resins is shown in Figure 4-8. The
anti-BrdU resin was the only antibody to exhibit visible non-specific binding. This is
supportive of non-specific binding observed in the initial proof-of-concept testing.
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FITC
TRITC
Figure 4-8 Batch testing of the five columns with unlabelled 640 bp chimera A product.
F: Feed, P: post-binding supernatant, W: Wash step, E: Elution step.

4.3.7 Selection & Serial batch testing
After weighing the batch results, anti-digoxigenin and anti-FITC were chosen as the
candidates for further exploration. Anti-BrdU was easily eliminated due to its nonspecific binding and low binding yield of labeled product.

Anti-TRITC was less

attractive due to the weak binding characteristics coupled with high costs of antibody and
free label for the elution buffer, although optimized isocratic conditions may be feasible.
While anti-FITC had very low regeneration with glycine, the proven regeneration buffer
(Clarke and Hage 2001) made it, along with anti-DIG, the most promising candidates.
The gradual elution of DIG-labeled products under free label elution buffer may be
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improved with optimization. Desthiobiotin performed rather well overall and would have
been a justifiable choice. However, regeneration was expected to be problematic since
the biotin-streptavidin exhibits very tight binding affinity.

The use of StrepTactin

Sepharose with HABA (2-(4’-hydroxyphenylazo)benzoic acid) elution or regeneration
may be a useful technique (Müller and Schmidt 2000) if desthiobiotin labeling is
considered in future work.

In this light, the use of iminobiotin may be considered also an attractive option for its pHbased binding/elution protocol and proven regeneration. The iminobiotin pH adjustment
may be particularly advantageous as the second stage in a serial purification arrangement
with an antibody-based system. There are two considerations for this scenario to be
feasible: 1) the labeled product will successfully bind in the first stage under streptavidin
elution conditions so that all products not captured by the first column do not bind to the
streptavidin (i.e. first column binding buffer at pH 4.0), and 2) the elution buffer from the
first column is at the proper binding pH for the streptavidin (i.e. pH 10). If reasonable
validity can be achieved regarding these two aspects, then it would be possible to have
both columns directly in series, or for that matter even a single column packed with two
distinct matrix layers of the respective ligands.

Digressing aside, the initial two labels selected for further testing in the workstation were
the digoxigenin and FITC. The next step was to conduct serial purification with the two
labels in batch processing. As an arbitrary choice, the forward primer was labeled with
digoxigenin, while the reverse primer was labeled with FITC. Initially, digoxigenin was
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used as the first purification step, followed by FITC purification. While a sufficient
amount of purified product was visible in the final effluent, the yield was unimpressive.
A short ~100bp undesired PCR product complicated matters and optimization strategies
for PCA and PCR did little to improve the result. As a consequence, FITC purification
was performed first followed by digoxigenin. This strategy gave slightly better yield in
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the final effluent, and was used in further testing.

DIG

Figure 4-9 Serial batch purification of the labeled 1.4 kb full chimera gene using antiFITC, followed by anti-DIG.
The first two elution fractions of anti-FITC were combined as feed to the anti-DIG resin.
F: Feed, P: post-binding supernatant, W: Wash step, E: Elution step.

The serial purification demonstrated that the process is successful. Note that the nonspecific ~100bp band did compete with the desired product, and bound in greater relative
amounts to the FITC column. Strong elution bands were found in the FITC elution
products (the lower gel fluorescence is due to the free FITC label in the elution buffer).
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For the DIG purification, the feed bound in moderate amount, and clearly yielded the
desired band in the final elution fractions. The upward shift in the elution samples is due
to the higher salt concentration. On a final note, the elution buffers used herein were at
500 mM NaCl, thus the reason why an intermediate adjustment was done. Other testing
(results not shown) has demonstrated that lower salt concentrations are adequate. Thus,
100 mM NaCl in the FITC elution buffer and 250 mM in the DIG elution buffer were
employed in further experiments.

4.3.8 Flow-thru purification
A key refinement to the workstation from the initial proof-of-concept was a simplified
process. In the initial BrdU and streptavidin arrangement, an intermediate pH adjustment
step (and vessel) was utilized in order to adjust BrdU elution product to the proper
binding pH of streptavidin. This intermediate step was a conservative approach rather
than attempting a high pH in the BrdU elution buffer. With two label-antibody based
columns in which free labels are used in the elution buffers, it was deemed unnecessary
to have an intermediate adjustment vessel. The rationale is that the presence of free FITC
label should have no impact on digoxigenin binding due to the biospecific elution
conditions. Thus, it was deemed possible to directly load the anti-FITC elution effluent
to the anti-digoxigenin resin.

That said, the previous batch serial testing included a higher salt concentration for antiFITC elution than the anti-digoxigenin application buffer. While the higher salt would
promote sharper elution, the free label carries the primary elution burden. For the FITC
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label elution buffer, a salt concentration of 100mM NaCl was determined to strike a
balance between elution behavior and sufficient binding to the digoxigenin antibody.
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Figure 4-10 Initial purification of labeled 1.4 kb full chimera using the next generation
workstation.
A: samples # 1-9. B: samples # 10-21. C: samples # 22-29. Please refer to the protocol
for details of the collected samples.

The result shown in Figure 4-10 demonstrate that the initial flow-through immunoaffinity
purification has performed well. One can see that binding to the FITC antibody was
inefficient, but as expected given the batch testing results with chimera. Upon elution
from the anti-FITC column, a significant amount of the full-length product also did not
bind to the anti-digoxigenin antibody, but confirms that FITC binding was successful. It
can be expected that improved yields from both columns is possible with further process

optimization.
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However, a sufficient amount of purified product was obtained in the

final effluent to be visible by gel electrophoresis. Please refer to Chapter 5 for continued
optimization to improve: 1) binding yield of the columns, 2) reduction of bleed-off during
column washing, and 3) regeneration of antibody column activity.

4.4 Conclusions
Extending from the proof-of-concept described in Chapter 2, an improved process and
accompanying workstation for the rapid synthesis and purification of de novo gene
sequences have been developed. Within the upfront rapid PCA synthesis section, the
PCA oligo concentrations and the PCR aliquots were explored. While assembly of
shorter genes was found to be relatively insensitive to these parameters, longer genes (i.e.
above 1 kb) are highly susceptible due to increasing complexity stemming from the oligo
pool. As logically expected, the interaction of these two parameters played an important
role in successful synthesis. As a general guideline, PCA oligo concentrations of 25 to
50 nM each and respective PCR aliquots of 1 to 2 µl appear to provide the best conditions
for routine construction of gene sequences.

An extensive comparison of five different label-ligand systems (BrdU, desthiobiotin,
digoxigenen, FITC, and TRITC) was performed in an effort to improve the purification
of synthesized genes. All five labels were amenable to incorporation into synthetic DNA
via amplification primers, as none of the labels effected any reduction in PCR yield
compared to unlabelled primers. Batch purification studies employing a 640 bp gene
sequence were performed to compare the binding and elution behavior of labeled DNA to
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procured ligands coupled to NHS-sepharose. Of these five candidates, digoxigenin and
FITC were selected for further testing in a serial immunopurification arrangement.

Biospecific elution conditions employing competition from free labels enabled a simpler
yet improved serial purification process in which the product effluent from the first
column could be directly applied to the second column. The serial immunoaffinity
purification was first demonstrated in batch mode using a 1.4 kb chimeric gene sequence.
The process was then implemented in a new flow-through chromatography platform.
The 1.4 kb gene sequence was successfully isolated in the workstation under automated
software control of pumps and valves as validation of the method.

In summary, the refined process and workstation disclosed herein with different labels
than the proof-of-concept clearly demonstrates the generalization of the technique for the
rapid synthesis and purification of gene sequences. Of course, the selected digoxigenin
and FITC labels used in the new immunoaffinity platform are by no means purported to
be paramount to all other affinity systems.

Rather, they represent only improved

alternatives to BrdU and iminobiotin. Given the demonstration in this Chapter and
Chapter 2, it should be clear that the workstation may be modified to accommodate other
affinity systems that one may desire to employ for purification of synthetic DNA.
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5

Convergent synthesis by rapid PCA in the workstation

A novel convergent synthesis strategy using rapid thermocycling has been developed,
facilitating the construction of longer genes.

In the technique, shorter overlapping

fragments are first synthesized from approximately 40 bp assembly oligonucleotides
using rapid 2-step PCA-PCR. These fragments are then stitched together and the fulllength sequence amplified using rapid integrated PCA-PCR. To demonstrate the rapid
convergent approach, synthesis of a 3.8kb gene sequence consisting of a mouse whey
acidic protein and cDNA for human protein C (mWAP-hPC) was undertaken. Synthesis
of the 3.8kb gene was performed by stitching either two fragments (approximately 1.9kb
each) or four fragments (approximately 950 bp each).

The rapid gene synthesis

workstation developed in Chapter 4 was utilized for the parallel synthesis of fragments
and convergent stitching. The application of the immunoaffinity purification section of
the workstation was also explored to determine if this purification provides any distinct
advantages in the convergent strategy. While difficulties arose in the cloning of the
synthetic products, the success of the convergent strategy was demonstrated by correct
gene sizes and direct sequencing of the fragments. The 3.8 kb gene represents by far the
largest gene constructed to date by rapid PCR thermocycling techniques. Provided in the
appendix, rapid PCA was also used to construct two novel chimeric gene sequences
containing domains for both endothelial protein C receptor and thrombomodulin.

5.1 Introduction
5.1.1 Convergent strategy for longer genes
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Polymerase chain assembly (PCA) is a technique for constructing synthetic gene
sequences by polymerase extension of a pool of oligonucleotides utilizing a PCR
thermocycler (Stemmer and others 1995). Since this first description, PCA or variants
thereof have been utilized for the construction of a number of gene sequences ranging
from a few hundred to many kilobases (Mehta and others 1997; Smith and others 2003;
Gao and others 2004). Due to its facilitation of de novo sequence synthesis, PCA has
taken root as a primary technique used in the gene synthesis field (Czar and others 2009).
The use of a rapid thermocycler to yield short synthesis runtimes and high fidelity was
first proposed by Mamedov and others (2007).

A convergent-based synthesis approach using PCA has been achieved by others, but
typically ligation and/or cloning strategies were involved in the convergence. Chen and
others (1994) demonstrated sequential ligation of three synthetic fragments within a
pUC19 vector, in addition to direct PCR-based synthesis of the full-length 770 bp gene.
Kodumal and others (2004) used PCR-based synthesis to generate 500-800 bp synthon
precursors, ligated these precursors together into ~5 kb components, and used cloning to
generate a 32 kb sequence. Recently, Gibson and others (2008) synthesized a 582,970
bp Mycoplasma genitalium genomes using recombination techniques from 5-7kb
overlapping “cassettes” assembled from ~104 oligonucleotides of ~50bp in length each.
To our knowledge, a convergent based approach using PCA (most certainly rapid PCA)
in the multiple convergent steps has not been reported.

105
It is well-known that the larger the gene to be synthesized, the complexity increases with
the number of oligos and the probability of success for direct PCA synthesis is greatly
reduced. The sheer number of oligos required for the direct synthesis of a long gene may
reduce reaction efficiencies, such as via polymerase sequestration (Kainz 2000). The
large number of intermediate product reactions needed to progress towards the full-length
gene also reduces success rates. Another complication that can arise is that hybridization
specificity may be decreased; that is, mis-annealing of oligos may occur as sequences
have increased probability of base pair commonality. This is especially apt for genes in
which repeat sequences are present. The point at which direct PCA synthesis becomes
impossible (or practically so) is dependent on the specific sequence, and could range
from 1 kb (for genes with high sequence commonality, such as high GC content) to 5kb
or more in which unique oligo hybridization units can be designed.

The technique of rapid integrated PCA-PCR developed in Chapter 3 (also see TerMaat
and others 2009) has broader implications than just reducing a two step thermocycling
process into one step. It can also facilitate an improved pathway for the synthesis of
longer gene fragments.

To construct longer genes by polymerase chain assembly,

integrated PCA-PCR may not only be used in the first-round synthesis of shorter (<1 kb)
fragments, but also as a follow-up to join these fragments into larger constructs. Even
though gene synthesis with the technique was problematic in genes greater than 1 kb, the
association is indirect. It is believed that the root cause of the difficulties stemmed from
the number of oligos.

Such an assumption is founded on competitive annealing

arguments—complementary internal oligos bind to the full-length template and inhibit
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exponential amplification. In the extreme, one can imagine only two oligos, each of 1 kb
in length with a hybridization overlap. Rapid integrated PCA-PCR on these two oligos
would seem trivial. In the presence of primers, the two oligos would assemble to create 2
kb dsDNA and be thereby exponentially amplified completely unencumbered by
competitive annealing. Thus, it is possible to apply rapid integrated PCA-PCR to form
larger constructs in certain instances.

For the sake of argument, consider a hypothetical 3kb gene which cannot be constructed
by traditional PCA for the above reasons. Of course, direct integrated PCA-PCR will
certainly not work where a 2-step PCA with follow up PCR has failed. However, an
alternative approach is possible. The full-length sequence can be segmented into smaller
fragments that can be facilely created by direct techniques (traditional 2-step or integrated
PCA-PCR). In the case of the 3kb gene, it could be divided into two 1.5 kb fragments,
three 1 kb fragments, or so on. Neighboring fragments have overlapping hybridization
units to facilitate further assembly.

After the fragments have been successfully

synthesized separately, these fragments can be used as templates for a 2nd round rapid
integrated PCA-PCR.

A schematic of the process is illustrated in Figure 5-1 for

convergent synthesis from a representative 3 fragments.
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a) Input Sequence

Design Oligos and Segment
into N Fragments with overlap

b) Oligonucleotide units for
each fragment

aF0 aF1 aF2

aF24 aF25

cF0 cF1 cF2

cF24 cF25

aR0 aR1

aR23 aR24 aR25

cR0 cR1

cR23 cR24 cR25

Equimolar PCA

bF0 bF1 bF2

bF24 bF25

bR0 bR1

bR23 bR24 bR25

Equimolar PCA

Equimolar PCA

c) PCA products

PCR

PCR

PCR
d) PCR products
(background DNA removed)

Integrated PCA-PCR with outermost primers
(“Stitching”)
e) Final full-length product

Figure 5-1 Schematic of convergent synthesis of a long gene.
Traditional 2-step PCA-PCR for 1st round synthesis of fragments and rapid integrated
PCA-PCR for 2nd round stitching is illustrated.

The advantages of this convergent synthesis strategy are that it enables a reduction in
number of oligos in each reaction while also potentially isolating undesired misannealing oligo combinations from one another. There are a number of variants possible
considering the option to do either equimolar PCA-followup PCR (2-step) or integrated
PCA-PCR during the fragment synthesis, and either one for the 2nd round stitching
reaction. For the fragment synthesis, the two step process is preferable since in most
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cases the fragments need not be shorter than 1kb (see conclusions from Chapter 3) and
that a higher yield and relative purity of the fragments is preferred as templates in the
stitching reaction. Given that typically only a few fragments are needed in the stitching
reaction, integrated PCA-PCR for 2nd round stitching is logical.

This convergent

synthesis strategy may conceivably be extended further to 3rd, 4th, etc. rounds of synthesis
assembly to synthesize even longer constructs, but not explored in this work.

5.1.2 Application of purification to convergent-based synthetic genes
Coupling PCA-based synthesis (traditional or integrated) of fragments with another (or
more) PCA stitching steps presents unique opportunities for the application of the affinity
workstation developed previously. In Chapter 2 and Chapter 4, the affinity workstation
was used as a final step following synthesis of the relatively short genes tested. In
Chapter 4 for example, digoxigenin and FITC were selected for use in the
immunoaffinity workstation. Incorporation of these two labels into the synthetic gene via
amplification primers allowed for isolation of the synthetic gene through a serial
immunocapture purification. Both digoxigenin and FITC have also been employed as
haptens for purification by others (Höltke and Kessler 1990; Moser and Hage 2006).

For longer genes, the workstation may possibly be applied in a similar fashion after
stitching of the full-length gene. As with the shorter genes, a final PCR amplification
with regular primers may be required to retain functionality of the gene for further
processing (i.e. cloning). Alternatively, the intermediate fragments may each be labeled
and purified prior to the final stitching. A comparison of the options is shown in Figure
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5-2. Also note that the affinity purification may also be applied to both the intermediate
fragments and final full-length sequence.

Figure 5-2 Different workstation processes for long gene synthesis from fragments.
(A) Intermediate purification of labeled fragments followed by 2nd round stitching. (B)
Direct stitching of fragments using labeled primers followed by purification of the fulllength gene.

5.1.3 Convergent synthesis of a 3.8kb mWAP-hPC sequence

As a difficult challenge of the rapid PCA workstation and convergent approach, a 3810
bp sequence was selected. This sequence, graciously provided by William Velander,
consists of a 2,424 bp mouse whey acidic protein (mWAP) sequence and a 1386 bp
cDNA sequence for human protein C (hPC). mWAP contains regulatory elements that
can direct cDNA expression at high levels in pig mammary gland, whilst hPC is a
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regulator of hemostasis, making it of great importance to the development of anticoagulation therapies (Velander and others 1992). Similar hybrid gene constructs of
mWAP-hPC developed by Velander and others (1992) have demonstrated high
recombinant hPC expression levels of 1 g per liter in the milk of transgenic pigs. Initial
demonstration of rapid PCA techniques to synthesize a mWAP-hPC sequence is clearly
attractive; future variants of the hybrid construct without reliance on existing sequence
constraints may be an extension of the convergent approach.

The 3.8 kb gene sequence represents by far the largest sequence synthesized to date by
rapid PCA. Direct synthesis of the full-length gene was not possible in the workstation
(results not shown)—thus, the convergent strategy was pursued using 2-step rapid PCAPCR to construct the fragments followed by rapid integrated PCA-PCR. Stitching was
tested from either 2 fragments approximately 1.9kb each in length or 4 fragments
approximately 950bp each in length. Additionally, the flow-through immunoaffinity
purification section of the workstation was utilized as either an intermediate step or final
purification step as illustrated in Figure 5-2. The purpose was to determine the benefit, if
any, of the purification sequence synthesis and yield. To understand the effects of
incubation time and DNA lengths on chromatographic performance with respect to
incubation times, temperatures and the effect of DNA length, batch purification studies
were also conducted. Additionally, batch purification with overnight incubation of the
~1.9 kb fragments was conducted to maximize yield for stitching.

111
Provided as appendix, rapid PCA was employed for the de novo construction of a
chimeric gene sequences encoding for both endothelial protein C receptor (EPCR) and
thrombomodulin (TM). These two ~ 1.4 kb gene sequences serve as additional examples
of the rapid PCA technique. As a demonstration to the convergent strategy, a chimeric
gene was assembled from two fragments.

In this chapter, a chimeric gene or its

fragments was utilized for investigation of chromatographic behavior where noted.

5.2 Materials & Methods
5.2.1 mWAP-hPC: Sequence information and design of oligonucleotides
The 3810bp sequence is given in Appendix 5A.1. The Gene2Oligo program of Rouillard
and others (2004) was employed—the entire sequence was input to generate the complete
hybridization map shown in Appendix 5A.2. Modified Gene2Oligo settings of: Tm
priority mode, 10 nM each oligo concentration, 1 M Na+, and 69 +/- 10°C were required
to generate a reasonable program output. A total of 204 oligos comprised the sequence
set. The oligo set was then segmented into 2 or 4 fragments as outlined in Table 5-1.
Primers were designed for each fragment, with the overlap between fragments simply the
corresponding hybridization units between neighboring oligo sets.

Assembly oligos and

regular primers were obtained from Integrated DNA technologies at 100 µM in nucleasefree water. Labeled primers for each fragment labeled on the 5’ end (digoxigenin on
forward primer and FITC on reverse primer) were obtained from IBA GmbH (Göttingen,
Germany). Note that in certain instances where noted in the text, a modified R4 (R4.1)
was used that lacked “TT” on the 3’ end.

112
Fragment # of oligos Product Size Primers Forward Primer (5'-->3')
Reverse Primer (5'-->3')
1
50
985 bp
F1 / R1 GAATTCTTTCACTGCTAAAACAG GCCCACTGGCTGTTATTC
2
50
936 bp
F2 / R2 GAATAACAGCCAGTGGGC
CCATGTAGAGAGTGTCGGG
3
52
1000 bp
F3 / R3 CCGACACTCTCTACATGGAG
TCCTCTAGGCAGTAATGCG
4
52
943 bp
F4 / R4 GCATTACTGCCTAGAGGAGG
CTAAGGTGCCCAGCTCTT
(1+2)
100
1903 bp
F1 / R2 GAATTCTTTCACTGCTAAAACAG CCATGTAGAGAGTGTCGGG
(3+4)
104
1925 bp
F3 / R4 CCGACACTCTCTACATGGAG
CTAAGGTGCCCAGCTCTT
Full-length
204
3810 bp
F1 / R4 GAATTCTTTCACTGCTAAAACAG CTAAGGTGCCCAGCTCTT

Table 5-1 Assembly details and primers used in the mWAP-hPC synthesis.

5.2.2 mWAP-hPC convergent synthesis
The first step in the convergent approach was to synthesize the 4 fragments (1, 2, 3, and
4) separately or combine into 2 parts ((1+2) and (3+4)) by 2-step rapid PCA-PCR. 2nd
round stitching of fragments by integrated PCA-PCR was performed to construct the full
sequence. Each 25 µl reaction contained the standard reagents of 200 µM each dNTP, 5
mM MgSO4, 400 µg/ml non-acetylated BSA, and 0.5 U hot-start KOD polymerase in 1x
manufacturer’s reaction buffer. The optimal concentration of assembly oligos in the PCA
reaction was determined to be 50 nM each.

For PCR amplification and 2nd round

stitching by integrated PCA-PCR, 0.7 µM each primer was used in accordance with
Table 5-1. 1 µl respective PCA product as template was used for PCR amplification.
For the stitching reaction, 1 µl each of the fragment PCR products was employed (i.e. 4
parts: 1 µl each of 1, 2, 3,and 4; 2 parts: 1 µl each of (1+2) and (3+4)) unless otherwise
noted. Note that the synthesis of longer fragments (1+2+3), (2+3+4), and (1+2+3+4) was
also attempted but not successful.
Table 5-2.

Thermocycling conditions in the PCRJet are given in

113
1,2,3, and 4 fragments
PCA
PCR

Hot Start
# of cycles
Denaturation
Annealing
Elongation
Final Extension

(1+2) and (3+4) fragments
PCA
PCR
94°C for 30 sec
35x
30x
94°C for 2 sec
56°C for 10 sec 56°C for 3 sec 56°C for 10 sec 56°C for 3 sec
72°C for 10 sec
72°C for 20 sec
72°C for 25 sec

Stitching of fulllength sequence
45x
56°C for 10 sec
72°C for 30 sec
72°C for 30 sec

Table 5-2 Thermocycling conditions for the convergent synthesis.

5.2.3 Flow-through Immunoaffinity Purification
A modified protocol to the one presented in Chapter 4 was utilized to purify either a
mixture of the 4 fragments, a mixture of the 2 fragments, or the full-length gene. The
buffer vessels in the workstation were filled with the following buffers:
•

Binding/Wash Buffer (BB): 2.5 mM Tris-HCl, 12.5 mM NaCl, pH 7.4

•

FITC Elution Buffer (fEB): FITC label at max solubility in water with 1%
DMSO, 100 mM NaCl

•

Digoxigenin Elution buffer (dEB): DIG label at max solubility in water with 1%
DMSO, 250 mM NaCl

•

Regeneration Buffer (RB): 0.1 M phosphate buffer, pH 2.5

Note the sixth vessel was not productively used yet filled with water for priming of the
tube.

Prior to installation of the columns, all lines were primed via the software

interface. The respective buffer vessel fluid was primed up to the 7-port union. Binding
buffer was primed into the feed line and all lines downstream of the union. After
installation, the columns were equilibrated with approximately 2 ml of binding buffer.

With the system initialized, the following protocol was used.
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Effluent samples of

approximately 250 µl were collected.

1. Load Feed to FITC column. Mixed 100 µl labeled PCR product with 400 µl BB
in sample Feed microcentrifuge tube. 40 µl was saved as a Feed aliquot for gel
analysis. With VFeed on, pumping set at 20 µl / min (200ms on / 29800ms off per
stroke). When ~20 µl left, added 100 µl BB to tube and continued pumping.
When ~20 µl left again, switched to pure BB microcentrifuge tube for an
additional 500 µl. The first 250 µl was not collected. Collected samples #1-3
from V3way1 waste.
2.

Wash FITC column. With VBB on, pumping set at 40 µl /min (200 ms on / 14800
ms off per stroke) for a total of 1.75 ml.

Collected samples #4-10 from V3way1

waste.
3.

Elute FITC column/Bind DIG column. With VfEB on and V3way1 on, pumping set
at 20 µl /min (200 ms on / 29800ms off per stroke) for a total of 1.5 ml. Collected
samples #11-16 from V3way2 waste.

4.

Wash DIG column. With VBB on and V3way1 on, pumping set at 40 µl /min (200
ms on / 14800 ms off per stroke) for a total of 1.75 ml. Collected samples #17-23
from V3way2 waste.

5.

Elute DIG column. With VdEB on, V3way1 on, and V3way2 on, pumping set at 40 µl
/ min (200 ms on / 14800 ms off per stroke) for a total of 1.75 ml.
samples #24-31 from V3way2 collect.

Collected
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Upon completion, columns that were to be re-used were flushed with 2 ml each of the
respective elution buffer, regenerated with ~6 ml of regeneration buffer, and then
equilibrated with ~6 ml of binding buffer. Where noted, final elution fractions were
combined and concentrated using an Amicon DNA purification kit (part # UFC503096,
Millipore, Billerica, MA) per manufacturer’s instructions with one water wash

5.2.4 Batch immunoaffinity purification
To characterize the binding and elution parameters of the antibody resins, several
different batch experiments were carried out in microcentrifuge tubes:

DNA length effects: An equal volume mixture of FITC-labeled chimera #2 “A” PCR
product (640 bp) and full-length chimera #2 (1377 bp) was prepared. The 100 µl mixture
was mixed with 300 µl binding buffer, 30 µl removed as Feed, and then subjected to
binding to anti-FITC resin on an end-to-end rotator at room temperature. 30 µl aliquots
of the supernatant were removed after 45 min and 90 min.

Binding incubation time and temperature: 70 µl of digoxigenin labeled chimera #2 “A”
PCR product (640 bp) was mixed with 220 µl of binding buffer. After removal of a Feed
aliquot, this Feed was subjected to binding to 100 µl of the anti-digoxigenin resin over
varied time periods at either room temperature (end-to-end rotator) or in a 37°C incubator
(shaking). 30 µl aliquots of the supernatant after centrifugation were removed after 15
min, 30 min, 1 hr, 2 hrs, or 4 hrs.
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Overnight serial batch binding: The mWAP-hPC (1+2) and (3+4) PCR products, both
labeled with Digoxigenin and FITC, were processed separately. 120 µl of PCR product
was mixed with 360 µl binding buffer and added to 150 µl of anti-FITC resin. Binding
proceeded overnight on an end-to-end rotator at room temperature. The microcentrifuge
tube was centrifuged and the post-bind supernatant removed (same procedure after wash
and elution steps). The resin was washed 3 times in 300 µl binding buffer for 10 minutes
incubation. Two elution steps were performed using 300 µl FITC elution buffer, with 4
hours incubation each step. The elution fractions were combined as an intermediate
Feed, and then the procedure repeated for purification with 125 µl of anti-digoxigenin
resin. The final elution fractions were combined and concentrated using an Amicon
DNA purification kit (part # UFC503096, Millipore, Billerica, MA) per manufacturer’s
instructions with one water wash. Stitching of the concentrated products was performed
using primers as described in the text.

5.2.5 Gel Electrophoresis & Purification
PCR products were run on a 1% agarose gel stained with ethidium bromide using 10 µl
each product and 12 µl 1kb ladder (New England Biolabs). Where gel purification was
used, the appropriate band was excised from the gel and processed using a purification kit
(Cat # A9281, Promega Corporation, Madison, WI) for cloning and sequencing. Samples
obtained from affinity purification fractions were analyzed on a 1% agarose gel stained
with GelRed using 30 µl each product and 12 µl 1kb ladder (New England Biolabs).
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5.2.6 Cloning & Sequencing
Cloning and sequencing of each of the 2-fragments (gel-purified) was performed by
GeneWiz, Inc. (South Plainfield, NJ). However, GeneWiz was unable to produce any
colonies using either TA cloning or TOPO blunt-end cloning strategies. To understand
what might be lethal to the cloning, direct sequencing of the PCR products was
performed. See Appendix 5A.3 and 5A.4 for the sequencing results of gene (1+2) and
(3+4), respectively. 1

5.3 Results & Discussion
5.3.1 mWAP-hPC fragment synthesis
The synthesis of the four 950 bp fragments and the two ~1.9 kb fragments by rapid 2-step
PCA-PCR was straightforward. Figure 5-3 shows the resulting PCR products for the
various fragments. High yield was obtained for all PCR products with a minimal amount
of assembly background. Note that the particular products shown in Figure 5-3 were
generated using labeled (digoxigenin and FITC) primers—similar results were also
obtained using regular primers. The 1.9 kb fragments demonstrated excellent yield and
purity given the length of these products. This is indicative of robust assembly oligo
design and supportive of optimal conditions used in the synthesis.

1

The full 3.8 kb gene was first sent to Biomeans, Inc. (Sugar Land, TX) for cloning and sequencing.

However, Biomeans failed to provide any results or evidence the work was conducted.

L
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Figure 5-3 PCR products of the different mWAP-hPC fragments generated by rapid 2step PCA-PCR.
Please refer to Table 5-1 for the respective lengths of the products.

It is important to note that all of similar fragment synthesis reactions were performed in
parallel. That is, the ~950 bp fragments were PCA assembled in separate capillaries in a
single thermocycler run, and the PCR amplification of these fragments was also
performed in a single thermocycling run.

Likewise, side-by-side processing was

performed for the ~1.9kb fragments. This is a consequence of the entire 204 oligo set
having been designed comprehensively and then segregated into fragments with
amplification primers also matched for melting temperature.
temperatures were reasonably similar to one another.

Thus, annealing

This parallel processing

significantly reduces the instrument time required. Coupled with rapid thermocycling
protocols in which each run required only about 20 minutes, the actual thermocycling
time for fragment synthesis becomes insignificant compared to other steps in the
experimental process such as preparation of oligo and reaction mixes.
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5.3.2 Flow-through immunoaffinity purification
The flow-through immunoaffinity workstation was employed to purify labeled
intermediate fragments. In line with parallel synthesis in the thermocyler, the feeds to the
anti-FITC column were equal volume mixtures of labeled PCR products. Purification
fractions for the four ~950 bp fragments are shown in Figure 5-4. The binding to the
anti-FITC column was moderate, as evidenced by comparison of the Feed to the passthrough.

Upon elution from the FITC column and binding to the anti-digoxigenin

column, more pass-through of the full-length product is present. However, a respectable
amount of purified product was obtained in the final elution from the anti-digoxigenin
column.
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Figure 5-4 Flow-through immunoaffinity purification of a 4-fragment (~950 bp)
mixture.
Refer to the materials and methods section for sample details.

Similar chromatographic behavior was obtained for the purification of the two ~1.9kb
fragment mixture feed as shown in Figure 5-5A. However, the binding yield at both
columns was reduced when compared to the 4-fragment purification.

This resulted in

even less purified product yield in the final anti-digoxigenin elution. While yield was
reduced, faint bands are still visible by gel electrophoresis. Therefore, two final elution
fractions (#26 and #27) were combined and processed using an Amicon 30K MW kit to
concentrate the samples. 5 µl of this Amicon product is shown in Figure 5-5B. The
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concentration was successful since the intensity was slightly better than the original 30 µl
elution samples in a reduced volume.

1

2 3 4 5 6 7

8 9 10

11 12 13 14 15 16 17 18 19 20 21 22 23

Amicon

F

24 25 26 27 28 29 30 31

B

A
Figure 5-5 Flow-through purification of a 2-fragment (~1.9 kb) mixture (A) and the
subsequent Amicon concentration (B).
Refer to the materials and methods section for sample details.

The alternative approach of conducting direct stitching of the 3.8 kb band with labeled
primers followed by purification was also tested (Figure 5-6). However, the binding
yield was so poor that no product was visible in the final effluent. Insufficient product
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for gel detection was also the case even after purification and concentration with the
Amicon kit (results not shown). There is some product visible in the FITC elution /
digoxigenin bind (samples #14, 15, and 16). Extrapolation from the reduced yield of 1.9
kb fragments compared to 950 bp fragments provided some justification for this result.
The differing results from the three different gene lengths insinuate that the binding is
perhaps dependent on gene length.

F

1 2 3 4 5 6 7

8 9 10

11 12 13 14 15 16 17 18 19 20 21 22 23

24 25 26 27 28 29 30 31

Figure 5-6 Flow-through purification of the full-length labeled 3.8kb direct stitching
product.
Refer to the materials and methods section for sample details.
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5.3.3 2 round stitching to construct the 3.8kb sequence
Stitching by 2nd round integrated PCA-PCR from fragments is shown in Figure 5-7.
Direct stitching using 1 µl each of unpurified PCR product (from either 4 or 2 fragments)
is shown in Figure 5-7. The desired 3.8 kb band was successfully stitched together in
both cases. Note that for stitching from 4 fragments, there are incomplete side products
at ~1.9 kb (2 of the 4 joined) and ~2.7 kb (3 of the 4 joined) in addition to the 3.8 kb band
(4 of the 4 joined). There is also likely remaining ~950 bp template bands (not joined
whatsoever), but not visible due to conversion of these products into the larger fragments.
Such quantization is an inherent by-product of the stitching from more than 2 fragments.
In the stitching from 2 parts, only the 3.8 kb band (2 of the 2 joined) is distinctly visible.
The lack of a strong band also at the template length of 1.9 kb also indicates a high
conversion efficiency of the stitching.

For reference, in other experiments high yield

was obtained when conducting stitching on 1+2 and 3+4 fragments to yield ~1.9 kb
products (results not shown).
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Figure 5-7 Direct stitching of unpurified labeled PCR products from either 4 fragments
(lane 1) or 2 fragments (lane 2) to produce the 3.8 kb full-length sequence.

One of the hypotheses of the research was that intermediate immunoaffinity purification
of fragments would increase the yield of the stitching reaction. The belief was that the
removal of unwanted background DNA that is complementary to the template would
reduce competitive annealing and increase the stitching efficiency.

However, when

stitching was conducted on the flow-through purified fragments (either 4 or 2 fragments),
the desired 3.8kb band was never visible on the gel despite exhaustive optimization
attempts.

On the surface, this result seems contrary to reason. To understand why purified products
were inferior in stitching to the unpurified products, one must examine the other
parameters important to the stitching process.

Aside from purity of templates, the

concentration of templates is of critical importance, supported extensively by traditional
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PCA theory. An immense difference exists in the amount of template used in the purified
vs. unpurified stitching reactions. Due to the low binding yield at each column stage and
the final product dilution over the elution buffer effluent fractions, stitching from purified
products employed much lower template concentrations. The concentration of final flowthrough effluent product with the Amicon kit improved template concentration, but was
still insufficient for stitching.

To demonstrate the importance of template concentration to the stitching reaction,
different template concentrations were compared using the 2 fragments. 2 µl, 1 µl, 1 µl
of a 10x dilution, and 1 µl of a 100x dilution, for each of the fragments was employed.
The results of the template concentration upon stitching are shown in Figure 5-8. As can
be seen from the results, 1 µl each fragment gave the highest yield while 2 µl resulted in
slightly less yield and conversion of the ~1.9 kb templates. It is clear that dilution of the
templates greatly affected the result—the 10x dilution gave only slight yield whereas the

1 µl 100x dil

1 µl 10x dil

1 µl

2 µl

100x dilution completely failed to yield the desired band.

Figure 5-8 Effect of fragment template concentration on stitching of the 3.8 kb gene.
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At the lower concentrations, a non-specific band at ~600 bp was generated. This nonspecific band was also highly prevalent in stitching reactions from purified products. In a
perfect world, PCR amplification is possible from a single template (or in this case, one
molecule of each fragment). Yet as any PCR practitioner knows, low-copy (especially
single-copy) PCR may have inherent difficulties due to the fragile reactions occurring in
the first few cycles and formation of unwanted primer interactions (Chou and others
1992). The problems are exacerbated in the stitching case—during a cycle two very
dilute template molecules must anneal through diffusion before undesired products from
templates and primers are formed and dominate further cycles. Thus, it is understandable
why the lower template concentrations of purified products fail to yield the full-length
gene despite having higher purity. To prove that purified products result in better yield
than unpurified products when template concentrations are equal, gel-purified and
concentrated (to approximate concentration of PCR products) was compared to
unpurified products utilizing the 4-fragment stitching. As can be seen in Figure 5-9, a
higher yield is obtained for gel-purified fragments. A similar improvement in yield and
purity was obtained in stitching gel-purified 2-fragments compared to unpurified
templates (results not shown).
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1

2

Figure 5-9 3.8 kb stitching comparison of unpurified vs. gel-purified using 4-fragments.
1 µl each of the unpurified PCR products (lane 1) or 4 µl of a combined 4-fragment gel
purification (lane 2) was employed to give similar template concentrations.

Other testing revealed that the F1/R4 combination necessary to amplify the full-length
gene was contributory to the problems at hand. As noted in the materials and methods
section, a modified outermost reverse primer (i.e. R4.1) was deemed to give improved
amplification.

While R4.1 was better than the original R4 at lower template

concentrations, it did not give sufficient improvement to give successful stitching from
immunoaffinity products.

The F1/R3 and F2/R3 primer combination brackets the

stitching point of the 2-fragment reaction; stitching using these primer combinations
showed marked improvement in the desired band yield (results not shown). Since a
shorter product than the full 3810 bp sequence would lack the desired functionality, these
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shorter products only served to separate the complications arising from PCR from the
base hypothesis.

5.3.4 Follow-up batch testing
Due to the low yield of the flow-through immunoaffinity purification and its subsequent
impact on stitching, batch purification testing was performed. In light of the decreased
yield with longer length synthetic genes from flow-through testing, further investigation
of DNA length effects was undertaken.

Using a chimeric gene, direct binding

competition using a equal volume mixture of the 640 bp “A” fragment and 1377 bp fulllength PCR product was performed. The feed and post-binding supernatants after 45 min
and 90 min are shown in Figure 5-10. If length was not a factor, one would expect that
the relative ratios of feed bands to post-binding bands would be constant; that is, both
products would bind in the same relative amounts. However, the shorter 640 bp band
bound in greater amounts than the 1377 bp band, again indicating a binding preference
for the shorter gene. Other batch purification experiments with wash and elution steps
showed more binding and elution yield for the shorter gene. Thus, it is believed that the
gene length does indeed impact the immunoaffinity performance.

90min

45min

F
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Figure 5-10 Comparison of the effect of DNA length on chromatographic binding.
Competitive binding of a 640 bp chimera “A” fragment and a full-length 1377 bp
chimera gene was performed.

The significance of gene length may be rationalized in several ways. At the extreme, the
ligand obviously has a higher affinity for a free label than a label with extra attachments.
This is clear from the utilization of free labels in the elution buffers to competitively
displace bound labeled DNA. The longer the attachment to the free label is, the binding
constant is decreased, although the argument could be made that beyond very localized
attachments the decrease is negligible.

Another consideration is steric hindrance

conveyed by the long DNA chain. It is unlikely, especially with longer sequences, that
the chain exists in linear form.

Rather, the DNA may coil up and may limit the

accessibility of the label to the ligand. Even if the label is at times exposed and does bind
to the ligand, longer chains may increase the disruption of this bond to disassociate the
complex.
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Another drawback of the flow-through system is that the residence time may be
insufficient for the specific antibody columns employed, even under the slow flow rates
employed in the protocol. To investigate, the batch binding over various incubation
times are shown in Figure 5-11. It can be seen that most binding occurs initially and
decreases at each interval, in line with second order reaction kinetics (or pseudo-first
order in the case of a large antibody excess—exact quantitative kinetics plots were not
performed on gel intensities) . To reach reasonably close to equilibrium in which most of
the labeled DNA has bound, around one hour is needed which is not feasible in this flowthrough system. To determine if increased temperature would affect binding rates, the
incubation time experiment was repeated at 37°C (Figure 5-11).

In comparing the

binding behavior at the two different temperatures in Figure 5-11, the increased
temperature did not have a visible impact on the binding rates. Given the nature of the
antibody binding, it is understandable that it may not follow normal Arrhenius rate
kinetics and explain why the binding was not improved at 37°C.

This is in good

agreement with the studies conducted by Lipschultz and others (2002), who found that
antigen-antibody docking can be energetically less favorable at elevated temperatures and
result in a higher apparent off-rate. Thus, aside from increased residence time and
amount of ligand present, there is little leeway to improve the performance of the existing
purification systems.

Room Temp

2hr

1hr

30min

15min

Feed

4hr

2hr

1hr

30min

15min

Feed
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37°C

Figure 5-11 Effect of incubation time on binding amount at room temperature and 37°C.

In an attempt to get sufficient yield for stitching, overnight binding and 4 hour elution
incubation times were applied to batch serial purification of the (1+2) and (3+4)
fragments in separate tubes. The resin amounts used were increase to 150 µl and 125 µl,
FITC and digoxigenin respectively, in case there was any notion of insufficient binding
sites. The purification samples are shown in Figure 5-12. The yield is only marginally
improved as even overnight binding of these longer genes did not result in a significant
decrease in post-bind samples.

This implies that the binding may have reached

equilibrium and nothing short of greatly increasing the number of binding sites would
alter the outcome. Regardless, after concentrating with the Amicon kit the yield was at
least better than in previous tests. Given the slight increase in template concentration,
stitching was possible with these immunoaffinity purified products (Figure 5-12
“Stitch”). The stitching product was still inferior to unpurified product stitching due to
the decreased template concentration, but at least demonstrated some measure of success.

(3+4)

fE2

1

dE2

fE1
dE1

fW2

fW3
dW3

fW1

dW2

fP
dP

(1+2)

dW1

fF

fE2
dE2

fE1
dE1

fW3
dW3

fW2
dW2

fW1
dW1

fP
dP

fF
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Stitch

Figure 5-12 Batch testing with long incubation times [(1+2) and (3+4)] with serial
purification with FITC then digoxigenin, and subsequent stitching (Stitch, lane 1) of the
purified products.
f: FITC; d: digoxigenin; F: feed; P: post-bind supernatant; W: wash (three washes); E:
elution (two elution fractions).

5.3.5 mWAP-hPC sequencing results
Difficulties arose in the cloning of gel-purified (1+2) and (3+4) synthetic fragments.
While the exact reason for the lack of clones was not determined, the presence of repeat
sequences within the genes was identified as one possible cause.

As such, direct

sequencing of the PCR products was performed to, at the very least, provide a basic
understanding of the constructed sequences. The sequencing results for the (1+2) and
(3+4) genes are given in Appendix 5A.3 and 5A.4, respectively. It is important to
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recognize that the sequencing data is not “clean” due to the residual presence of assembly
products and superimposition of peaks.

The sequencing results of gene (3+4) show that the desired gene was successfully
constructed. The sequencing data matches the reference sequence very closely, with only
a number of base pair positions in question . It can be seen that in nucleotide positions
where an error may be present, the improper “G” generated in the data is flanked by
repeat “A” nucleotides (indicating confounding sequence signal overlap). Thus, there is a
high level of confidence that the (3+4) gene was successfully constructed, barring typical
error rates that one would expect from the PCA process.

It is more difficult to draw definite conclusions regarding the accurate synthesis of gene
(1+2) from the sequencing data. The synthetic sequence matches the reference sequence
by and large over the first 800 bp and from 1300 to 1903 bp. However, the sequencing
data appears corrupted in the middle, starting at the presence of a problematic repeat
“GAGA…” section in the mWAP region starting at position 760. This repeat region
compromised the data from the F2 sequencing primer. Thus, the relative correctness of
this middle portion cannot be unequivocally stated.

The correct size construct as determined by gel electrophoresis for not only (1+2) and
(3+4) but also for each of the four ~ 950 bp fragments. Additionally, the correct 3.8 kb
band was produced in the stitching reactions from both 4 fragments and 2 fragments. The
production of the desired sizes in all these cases from a pool of oligos without actual

assembly of the basic desired sequences would defy logic.
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With these considerations

and the current sequencing data, there is strong evidence that the individual fragments
and the entire 3810 bp mWAP-hPC was constructed. It is certainly true that errors are
likely present. However, the isolation of error-free clones for the entire 3.8 kb gene was
not the immediate objective of the work at the onset given typical error rates observed in
PCA-based synthesis. It was expected that intermediate screening of fragments would be
necessary before stitching the full-length construct, but in this case difficulties in cloning
presents a hurdle to overcome in future work. With the failure of the ~ 1.9 kb cloning
efforts, the next logical step would be to attempt cloning and sequencing of the four ~
950 bp fragments. If error-free clones can be isolated for these fragments, stitching of
these isolates and subsequent cloning/sequencing of the full-length gene should give
definitive proof of success.

A further discussion of strategies that may be explored to

construct and isolate error-free sequences for longer genes is presented in Chapter 6.

5.4 Summary & Conclusions
A convergent gene synthesis strategy was developed in which rapid PCR thermocycling
was employed to construct longer gene sequences not amenable to direct synthesis. In
the technique, rapid 2-step PCA-PCR is recommended for the initial synthesis of
sequence fragments that can be readily constructed.

Each fragment contains

hybridization overlap with adjacent sequence fragments such that the fragments can
hybridize with each other in the annealing PCR step. Thus, a second stitching reaction by
rapid integrated PCA-PCR assembles these fragments with simultaneous amplification of
the full-length gene.
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The rapid convergent strategy was applied to the synthesis of a 3.8 kb mWAP-hPC gene
sequence. Either two (~1.9 kb) or 4 (~950 bp) fragments were easily constructed from
short single-stranded assembly oligos in the first round reactions. Direct stitching of
these fragments using 1 µl each as templates successfully generated a band at the desired
3.8 kb length. Due to anticipated error rates, intermediate screening of the two ~1.9 kb
fragments was attempted.

However, problems arose in cloning of these fragments.

Direct sequencing of these fragments (after gel-purification) revealed that, to the
exclusion of some errors, the desired fragments were generated. The success of the
convergent strategy is given strong supporting evidence from these direct sequencing
results and the gel electrophoresis band lengths obtained.

Serial immunoaffinity purification in the workstation was explored for utility in the rapid
convergent synthesis technique, both as 1) post-synthesis purification of the full-length
gene, and 2) intermediate purification of fragments prior to stitching. With respect to the
latter, the hypothesis was that the stitching reaction would benefit from higher purity
template fragments. However, a by-product of the purification was a lower template
concentration in stitching. For this particular gene, these lower template concentrations
proved lethal to stitching success. Only under overnight batch incubation times could
enough fragment concentration be achieved after serial purification to successfully
generate the 3.8 kb band (and even then inferior to direct stitching).

Note that other

sequence synthesis may not be susceptible to this issue, and purification may prove
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beneficial in other cases. As a basic demonstration, gel-purified fragments at comparable
template concentrations to direct PCR products resulted in higher yield.

For flow-through post-purification of the full-length gene, an insufficient yield was
obtained to detect by gel electrophoresis. Based on flow-through testing and batch
competitive binding testing between DNA of different lengths, it is believed that the
immunocapture yield was highly dependent on gene length. Shorter fragments (> 1kb)
had relatively acceptable binding levels, whereas binding amounts were substantially
reduced for longer products.

While the current immunoaffinity purification can be

considered acceptable for shorter gene purification, future improvements to the
chromatographic performance for longer genes are recommended.

Since elevated

temperatures did not increase binding, the main parameters for optimization of the
existing FITC and digoxigenin systems are ligand concentration, total ligand amount, and
residence time in the flow-through system.

An important aspect of the synthesis of longer genes is that many of the processes therein
on the fragments can be done in parallel. Multiple reaction capillaries (one for each
fragment) may be processed simultaneously during PCA and PCR thermocycling. This
would require that all fragments may be acceptably processed under the thermocycling
conditions, most notably the annealing temperature. To accomplish this, the melting
temperatures of hybridization overlaps are reasonably matched to one another during the
oligo design. Likewise, the fragments may be purified simultaneously in the affinity
columns; that is, the synthesis reaction products combined in the feed to result in a
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purified mixture of the fragments in the final effluent. Such parallel approaches would
significantly reduce the time requirements when compared to separate sequential
processing.
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6 Summary, Analysis and Future Work
6.1 Rapid PCA-based gene synthesis
6.1.1 Summary
Based upon the initial work of Mamedov and others (2007), the rapid PCA platform and
methodologies further developed in this work offer an advantageous pathway for the fast
and accurate synthesis of genes. In comparison to PCA with traditional heat-block
cyclers (Stemmer and others 1995), PCA synthesis times are reduced from typically from
several hours down to less than 30 minutes (for two thermocycling protocols comprising
2-step PCA with follow-up PCR amplification). The reduction in run-times can be
considered more than just a speed novelty. As noted by others, fast thermocycling
protocols lead to a reduction in error rates attributable to thermal damage (Pienaar and
others 2006). Another advantage of rapid PCR over traditional PCR is that the short
annealing times used in the former can provide higher fidelity of hybridization/annealing
events (Wittwer and Garling 1991). An increase in the accuracy of synthesis implies that
less

downstream

efforts

are

needed,

such

as

site-directed

mutagenesis

or

cloning/sequencing screening efforts (Kodumal and others 2004). Lastly, rapid PCR
presents advantages over longer runtimes when optimization of reaction conditions are
required since testing of different conditions can be completed relatively quickly.

While rapid PCA does provide these advantages, it should be noted that PCA with
conventional block cyclers has been routinely used for successful synthesis of genes
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(Czar and others 2009). Recently, PCA was utilized to construct small building blocks
used to assemble the complete 582,970 bp genome for Mycoplasma genitalium by
recombination techniques (Gibson and others 2008). It was obviously not the objective,
nor fiscally conscionable, to compete in a race for length. Currently, PCA is a primary
synthesis technique for sequences ranging from several hundred bp to several kb—above
this level typically requires pairing with recombination techniques. Thus, the primary
concern was to demonstrate rapid PCA within this stratum as a robust and accurate
technique.

In this work, rapid PCA was utilized for the synthesis of seven different gene sequences
ranging from 612 bp to 3.8 kb in length, not including shorter sequence fragments
therein. The variety of sequences and relative ease by which these were assembled
demonstrate the robustness of the approach.
follow-up PCR process was employed.

In most instances, a 2-step PCA with

In Chapter 3, a rapid integrated PCA-PCR

approach was developed in which genes up to approximately 1 kb in length (starting from
~ 40 bp assembly oligos) could be synthesized in a single reaction. In Chapter 5, a novel
convergent approach for the rapid synthesis of longer gene sequences was disclosed. In
the convergent technique, shorter sequence fragments are assembled by 2-step rapid
PCA-PCR, and then stitched together in a subsequent reaction using rapid integrated
PCA-PCR. A 3.8 kb mWAP-hPC gene sequence—the largest constructed to date by
rapid thermocycling methods—was stitched from either two or four first-round synthetic
fragments.
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6.1.2 Impact of assembly oligo length
As part of the research scope for this work, the length of the assembly oligos was limited
to roughly 40 bp each. The rationale was that shorter assembly oligos possess fewer
errors, as the error rate from automated phosphoramidite chemistry is around 0.3%
(McClain and others 1986).

Thus, limiting the assembly oligo length aided in

preservation of the sequence quality without requiring any extraneous quality control.
Even still, Smith and others (2003) ascertained that each 42-mer used in their synthesis
contained ~50% truncated species, implying a higher error rate.

Additionally,

hybridization among oligos was specified so that no gaps were allowed between
neighboring oligos on the same strand. This oligo design strategy allowed for some
discrimination at annealing to exclude oligos with deletions present, albeit resulting in a
highly oligo-dense PCA reaction.

While the short assembly oligo approach with standard desalting purification proved
adequate for the most part in this work, revisiting of the assembly oligo length is
recommended. In many instances, especially for the chimeric genes, deletions were
present in the sequencing data. While stringent PCA hybridization should have limited
the incorporation of deletions, the quality of oligo building blocks does impact the end
results. Linshiz and others (2008) provide a unique recursive strategy for the synthesis of
DNA from error-prone oligos that is akin to the convergent approach. Instead of “onepot” assembly and cloning, the divide and conquer recursion sought to optimize synthesis
steps to generate an error-free clone.

However, the recursive technique was only

demonstrated for a trivial 768 bp GFP sequence. Smith and others (2003) increased the
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quality of the oligo pool by first conducting gel purification prior to ligation/PCA to
construct a 5,386 bp ΦX174 bacteriophage.

If longer assembly oligos may be employed, it is expected that longer genes may be more
readily constructed. For example, a 4 kb gene synthesized from ~40 bp assembly oligos
(20 bp hybridization units) would require roughly 200 oligos at the current specification.
If 100-mers can be employed, the number of oligos needed would be reduced to
approximately 50 oligos if 20 bp overlaps are used. The reservation arising with the
latter is that gaps will be present between hybridization sections—there will be no
hybridization screening process for elimination of nucleotide deletions in these regions.
Using the trivial equation

a 40-

mer synthesis will be 67% full-length, whereas a 100-mer has a mere 36% yield,
assuming a 99% efficiency. It is therefore certain that standard desalting with longer
oligos should not be used directly due to the majority of oligos being in the truncated
form; the oligos must be of the high purity with truncated species removed.

Integrated

DNA Technologies currently offers DNA oligos up to 200bp in length (“ultramers”,
Allen and others 2009) with optional PAGE purification to remove truncated species. If
the quality of 100-mers (or even longer) can be assured to a reasonable level, then this
approach becomes feasible. Returning to the 4 kb example, a 50-oligo PCA reaction to
directly construct the full-length gene would seem within reason.

6.1.3 Oligo design flexibility with longer assembly oligos

144
Another benefit of utilizing longer assembly oligos is the design flexibility. In the no-gap
approach, hybridization units were interdependent.

Adjusting the length of one

hybridization unit affected the others, resulting in the need for global optimization
strategies of the complete sequence hybridization map in order to match melting
temperatures (Rouillard and others 2004; Louw and others 2010).

Condoning gaps

allows for a more flexible design strategy since each hybridization overlap can essentially
be designed independently. Nucleotides can be added or subtracted at whim for each
hybridization region to obtain desired Tm (melting temperature) values. This is expected
to result in a more straightforward design of oligos with improved matching of Tm values.
One can proceed in a more linear progression from one hybridization unit to the next. An
illustration of an example oligo map is given in Figure 6-1. Note that the oligo lengths
need not be exactly the same length, and that typically one oligo (i.e. towards the 3’ end)
may be much shorter than others dependent on the sequence and desired oligo lengths.

0

100

200

300

400

~20 bp overlaps

500

600

~60 bp gaps

Figure 6-1 Oligo map for an example 600 bp sequence employing 100-mers with gaps
allowed.
~20 bp overlaps can be increased or decreased for optimal melting temperatures. Note
the short oligo at the 3’ end.
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6.1.4 Economic considerations
PAGE purification is known to be the method of choice for purifying longer oligos with
unit-base resolution, overcoming a key technical hurdle.

The other consideration is the

economic cost of the longer oligo approach. The current cost of an ultramer from IDT is
$0.75/base on a 4 nmole scale compared to $0.35/base for standard DNA oligos. The
scale is more than sufficient, and even smaller miniaturization of oligo synthesis amount
is an outstanding economic barrier for gene synthesis (Tian and other 2004). Note that
the presence of gaps significantly reduces the number of total nucleotides synthesized by
phosphoramidite chemistry (5,000 bp vs 8,000 bp for a 4 kb sequence). 200-mers would
require approximately 4,500 nucleotides. The other economic element is the cost of the
PAGE purification—currently retailing at $105 (for a single oligo, the price of a larger
volume order is expected to be discounted significantly).

Smith and others (2003)

utilized a pooled oligo approach that also could be employed to reduce purification costs.
Thus, while a premium will be paid for the longer oligo approach, any cost premium
would be entirely justifiable if labor costs are reduced in downstream steps, and most
importantly produces the desired construct more efficiently.

The longer assembly oligo approach is not new—IDT offers gene synthesis services
using their ultramers. With a number of biotech companies offering gene synthesis, a
price war in the gene synthesis industry has been raging (Czar and others 2009).
Advertised prices are currently around $0.50 / bp, usually including insertion into a
plasmid vector, cloning and sequencing confirmation. With IDT for example, sequences
ranging from 400 bp to 1.5 kb are currently listed at a base price of $0.55 / bp including
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the extras listed. Note that this is less than what one can purchase only the ultramers
themselves for at retail ($0.75 / bp, and not too much more than regular $0.35 / bp
oligos). Due to the vertical integration of processes involved in the synthesis steps by
these larger companies and the aggressive pricing, individual researchers may be
discouraged that they will incur higher costs to perform the synthesis themselves since
the oligos themselves alone are priced comparably to a pre-assembled sequence.
However, additional charges are more often than not added for sequence complexity and
length, and for many sequences these companies fail to deliver or refuse to quote
altogether (Czar and others 2009).

6.1.5 Error Frequency Considerations

In this work, rapid PCA with a proof-reading KOD polymerase (Takagi and others 1997)
was demonstrated as a reliable technique for obtaining error-free clones. In Chapter 2,
the error rates for all four genes were less than 1 error / kb. This is compared to
approximately 2-5 errors / kb usually found in conventional PCA synthesis (Mamedov
and others 2007). In the case of the 1.4 kb chimeric genes (see Appendix 5B), error rates
were not calculated; yet error-free clones for each of the two variants was found after
screening of only ten clones each. Since error rates typically limit conventional PCA
synthesis length to 500-800 bp before a screening step is recommended, a small decrease
in error frequency can drastically reduce the cloning requirements (Kodumal and others
2004).

Next-generation sequencing methods such as emulsion PCR (Marguiles and

others 2005) that employ in vitro clonal amplification rather than molecular cloning may
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also reduce gene synthesis labor costs. While initial investigation into the 3.8 kb failed to
provide error-free clones in the fragments tested due to cloning issues, rapid PCA can be
viewed as a preferred technique for synthesis of genes.

The importance of gene synthesis error rate reduction cannot be over emphasized.
Kodumal and others (2004) conducted an in-depth study of gene synthesis error rates in
which over 1 million bp were sequenced. In confirmation with other conventional PCA
results, the error frequency was about 0.2% (1 error per 500 bp) or higher. Rapid PCA
synthesis in this work (see Chapter 2) and in Mamedov and others (2007) has yielded
error frequencies of about 0.1% (1 error per 1 kb). Following Kodumal and others
(2004), the error frequency in gene synthesis can be described as a Poisson distribution:

Where λ is the average number of outcomes (i.e. the error frequency, EF), t is the interval
(herein the gene length, L), and x is the # of outcomes. Since we are interested in
determining the fraction of clones, F, that are error-free (x=0), the equation reduces to
simply

. A graph of the fraction correct vs. gene length at different

error frequencies is shown in Figure 6-2.
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Figure 6-2 Fraction clones correct vs. gene length at different error frequencies as
estimated by the Poisson distribution.

The dramatic effect of a reduction in error rates is obvious from Figure 6-2.

In

conventional PCA with an EF ~0.2, Kodumal and others (2004) limited synthon
fragments to 500-800 bp to effectively screen error-free clones from unpurified oligos.
With a reduction by rapid PCA techniques to ~ 0.1%, error-free clones can be effectively
isolated with minimal screening up to about 1.5 kb with the employed unpurified oligos.
In this work, three different genes (TM-1, chimera #1, chimera #2) of ~1.4 to 1.5 kb in
length yielded error-free clones from just ten picked colonies, supporting the rapid PCA
fidelity.

6.1.6 Future Work with rapid PCA
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In general, future work with rapid PCA is recommended to focus on the above proposed
use of longer assembly oligos. The objectives therein would be three-fold: 1) investigate
the robustness of the process steps, particularly with respect to elimination of truncated
assembly oligos and deletion error avoidance, 2) demonstrate the capacity to synthesize
longer constructs in each PCA reaction for both single and convergent strategies, and 3)
statistical comparison of the error rates when employing either rapid or conventional
thermocyclers. Such efforts could further cement the superiority of rapid PCA for fast
and accurate synthesis of genes many kb in length with minimal cloning burden to isolate
an error-free clone.

With regards to the specific gene syntheses presented in this work, there are several areas
for future work. For the error-free clones of the two chimeric gene sequences isolated in
Appendix 5B, the next step is to conduct protein expression of the chimeric genes and
activity assays of the EPCR and TM-2 domains to determine if the chimeric gene yields
improved activity. Of course, success of protein expression and particularly protein
folding is not a guarantee especially in the case of the “flipped” TM-2 region in chimera
#1. The determination of the optimal linker region for synergistic EPCR and TM activity
by construction of variants would also serve as an interesting endeavor. In the case of the
3.8 kb gene sequence pursued in Chapter 5, more work is recommended to generate an
error-free clone. The initial step would be to attempt cloning of the four ~950 bp part
fragments in the hopes that cloning proceeds properly. Given the difficulties in cloning
of the longer sequences it may very well turn out that problems arise again, but at the
very least provide some direction for the next steps. If troublesome regions become
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apparent that cannot be readily fixed by site-directed mutagenesis or the recursive
strategy of Linshiz and others (2008), then the recommendation would be to pursue the
longer oligo assembly strategy from 100+-mers.

6.2 Affinity purification of synthetic genes
6.2.1 Summary
The companion affinity workstation developed in this work facilitated the purification of
full-length synthetic genes from unwanted assembly oligos and incomplete reaction
products. Labels were incorporated into the gene during the PCR amplification process
by the use of primers labeled on the 5’ ends. Since only the full-length gene is expected
to contain both labels, the serial immunoaffinity purification resulted in only the fulllength product in the final effluent (acknowledging that some non-specificity may exist).
The immunoaffinity purification was meant to serve as an alternative to manuallyintensive (and possibly error-generating) gel purification typically performed prior to
cloning and sequencing.

In Chapter 2, four different genes were tested against a serial affinity arrangement with
anti-BrdU and Streptavidin (genes labeled with iminobiotin) columns. A bread-board
hardware mock-up was used to implement the serial purification.

The 929 bp β-

lactamase gene clearly proved the concept, while the 1548 bp TM-1 gene was also
successfully purified but at low levels. The short puc19 ori and EPCR genes (612 and
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648 bp, respectively) were also successfully purified to some extent, but slight issues
with labeled PCR amplification prevented clear analysis of the affinity purifications.
Since the anti-BrdU column did demonstrate some non-specificity, in Chapter 4 a next
generation platform was developed.

FITC and digoxigenin proved to be the best

candidates compared to BrdU, TRITC, and desthiobiotin options. The serial anti-FITC
and anti-digoxigenin immunoaffinity purification was implemented in an improved
hardware and process. This final workstation configuration was validated using a 1.4 kb
chimeric gene sequence. In Chapter 5, this immunoaffinity workstation was employed
for the purification of mWAP-hPC gene sequences—a mixture of ~950 bp fragments, a
mixture of ~1.9 kb fragments, and the full 3.8 kb gene sequence.

6.2.2 Impact of labeling DNA
While the immunoaffinity purification did show isolation of full-length products, there
are several considerations for the long-term adoption of this technique.

First, one

drawback of the affinity purification is that the necessary labels are present in the isolated
product. As such, typically another PCR amplification thereon with regular amplification
primers was performed for cloning functionality, thereby obviating much of the benefit of
the affinity purification. Now, insertion of labeled product into a cloning vector has not
been attempted to date, but the ligation reaction is expected to be inhibited by the label
presence on the 5’ end. Alternatively, shifting of the labels into a middle location of the
primer may help or a simple cleavage reaction to remove the labels (i.e. restriction
enzyme cutting of the ends) can be envisaged.
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6.2.3 Affinity purification yield
Likely the largest short-coming of the current affinity workstation was its relatively low
yield. The flow-through purification performed relatively well for genes under 1kb, but
as the length of the sequence increased the yield was substantially reduced. Even batch
purification of longer gene sequences failed to produce stellar binding. This is indicative
of a larger Kd (dissociation constant) as the gene length increased. The other primary
parameters for future optimization with the existing FITC and dixogenin columns to
increase the yield are the antibody to label ratio, the ligand concentration, and residence
time in the flow-through system. It would be advantageous to decrease the processing
time in the workstation given that slow flow rates were employed to date.

One possible explanation for low binding amounts in the affinity purification is the size
of the target DNA. In Chapter 5, it appeared that as the gene length increased, the
binding amount decreased. Taking the average molecular weight of each base pair at 660
Da, a 1kb gene is approximately 660 kDa which is fairly large by protein purification
standards. For example, BSA and fibrinogen are two commonly purified proteins with
molecular weights of approximately 67 kDa and 340 kDa, respectively.

While the

immunoaffinity purification provided fairly good yield of products up to 1kb, the binding
amounts were noticeably reduced for the 1.9 kb (~1254 kDa) and no product visible on
the gel for the 3.8 kb gene (~2508 kDa). It is believed that steric hindrance reduced the
binding as the gene length increased due to limited accessibility of the labels and ligand
binding sites. Thus, it is not difficult to rationalize the low yields obtained for longer
genes, and thus limiting the recommended maximum gene length in the current
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purification system to ~ 1 kb. Of course, this is not to say that higher molecular weight
products cannot be successfully purified in high yield after continued optimization of the
existing chromatography. Also note that multiplication of yields from the consecutive
columns further complicated matters by reduction of overall yield in the final effluent.

As gel electrophoresis was a necessary, but highly unreliable quantitation, detection
method in the initial workstation development, calculations of the disassociation constant
(Kd) was not worthwhile. Additionally, the impure nature of the synthesis mixtures did
not allow for direct Kd measurements with respect to gene length. Given the preliminary
implications of gene length on binding, a thorough quantitative investigation of Kd is
warranted. It is apparent that the antibodies possessed high affinity for the free label
from the use of biospecific competitive binding in the elution step. Tethering of a DNA
chain of specific lengths impacts the epitope binding site either directly from the
attachment or via steric hindrance. Quantitiative assay schemes applied against the free
label and labeled DNA of known pure length would be advantageous to fully understand
the phenomena.

6.2.4 Economic considerations
Another barrier to adoption of the immunoaffinity purification is the cost-effectiveness of
the approach. In this work, primers unique to each synthetic gene were employed at an
approximate cost of $70 each from IBA GmbH (Göttingen, Germany). The average cost
of each purification was about $17 per run, assuming the columns can be acceptable
regenerated for three total uses (not including labeled primers or labor costs). The bulk
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of the economics is dominated by the cost of the FITC and digoxigenin antibodies. Of
course, more column regenerations would significantly amortize the cost per test. For
example, 10 column uses before replacement would reduce the cost to around $5 per test.
Additionally, miniaturization of the purification scale, particularly the feed load, would
further reduce the amount of antibodies used per test. However, primer labeling still adds
unattractive costs to the purification.

6.2.5 Future work with generic labeled primers
A possible solution to reduce purification costs is to tailor the synthesis of genes to use
generic labeled primers that can be used for all synthetic genes by adding flanking 5’ and
3’ sequences that are not specific to the gene. An option is the His-tag-Stop-NotI
sequence employed on the 3’ end of the chimeric gene sequences (see Appendix 5B). On
the 5’ end, an additional flanker could consist of the XhoI plus additional outer
nucleotides (similar for the 3’ primer if the His-tag is not desired). The restriction
enzyme sites facilitate direct cleavage of the labels post-purification for insertion into a
complementary cloning vector (i.e. pPICZαA for Pichia pastoris). An example of the
generic flanker regions is given in Figure 6-3 without the His-tag as part of the generic 3’
sequence.

A variety of generic primer options can be envisioned to select from

depending on the desired restriction enzyme sites and avoidance of internal sequence
commonality in the dummy sequence flankers—the objective is just to stream-line and
reduce costs of the purification.
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Generic Primer
GCATTCAGTACCATCTCGAG

Dummy
Sequence

Generic Primer

Desired Sequence

TAACGCCGGCGAATTTAATT

XhoI
site

Stop

NotI
site

Dummy
Sequence

Figure 6-3 The addition of dummy 5’ and 3’ flanker sequences allows for generic
labeled primers to be used for many different synthetic genes.
Example XhoI and NotI sites allow for cleavage of the labels prior to vector insertion.

6.2.6 Future work with FITC detection
To date, approximately 100 µl of product (combined four separate PCR reaction
volumes) in the feed was in part a necessity as gel electrophoresis was the specified
means for detection.

It is known that absorbance (UV/Vis) detectors are generally

limited in sensitivity to about an LOD of 10-8 to 10-7 M (Moser and Hage 2006),
precluding the use of these detectors in the current workstation. With the labeled PCR
concentration at 700 nM, it can be expected that the full-length PCR product is only a
fraction of this amount. Further dilution upon feed mixing, reduced yield through two
columns, and dilution in final effluent, is estimated to put the final concentration at ~10-9
or less.

One of the reasons that FITC was chosen for use in the final configuration of the
workstation was for its fluorescent characteristics and subsequent LOD when used with
fluorescent detectors (Moser and Hage 2006). Various types of fluorescence detectors
and flow cells capable of detecting the amounts observed in the workstation could
thereby be used to track the FITC-labeled products. While laborious sampling of effluent
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fractions and gel analysis thereon was performed in the development, only monitoring of
the effluent from the digoxigenin column would be necessary to automatically switch the
corresponding 3-way valve to collect the final product. A sensitive fluorescent detection
scheme would support reduction of feed loads and column sizing, important to the
economics of the purification step.

6.2.7 Future work with other affinity columns
Alternatives to the FITC and digoxigenin serial purification may be a worthwhile future
endeavor.

As noted in Chapter 4, any number of affinity-based separations may prove

suitable for purifying hapten-tagged synthetic genes in addition to antibody-antigen
systems. Also discussed briefly in Chapter 4, the iminobiotin label with streptavidin
binding may be particularly advantageous as the second stage in a serial purification
arrangement with an antibody-based system. Unlike Chapter 2, future work would center
on testing both columns directly in series or even embodied as a single column packed
with two distinct matrix layers of the respective ligands. There are two aspects to this
arrangement that need explored: 1) the labeled product will successfully bind in the first
stage under streptavidin elution conditions so that all products not captured by the first
column do not bind to the streptavidin (i.e. first column binding buffer at pH 4.0), and 2)
the elution buffer from the first column is at the proper binding pH for the streptavidin
(i.e. pH 10). After sufficient washing of the first stage antibody column, a transition step
is likely to be recommended to transition the pH of the streptavidin to 10 prior to FITC
elution and product loading to the streptavidin. The process is illustrated in Figure 6-4,
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noting that a pH transition step between buffers 1 and 2 and a regeneration step are not
shown. Also, the optimal salt concentrations for each buffer are not listed.

pH 4

Binding to Ab-FITC

FITC-labeled
product elutes

Iminobiotin-labeled
product binds

Elute Ab-FITC/
bind Streptavidin

Strept
avidin

Iminobiotin-labeled
product washes
through

Strept
avidin

Strept
avidin

FITC-labeled
product binds at
pH 4

Ab-FITC

Buffer 3

Free FITC
pH 10

Ab-FITC

Buffer 2

pH 4

Ab-FITC

Buffer 1

Iminobiotin-labeled
product elutes

Elute Streptavidin

Figure 6-4 Illustration of an integrated Ab-FITC/streptavidin column.
Refer to the text for a description of the process.

6.2.8 Broader applications of purification of labeled DNA
Even if the serial immunoaffinity purification does not establish strong roots for isolating
synthetic genes, the incorporation of labels via PCR amplification primers for subsequent
isolation of DNA may of generic benefit for a myriad of other uses. For any application
that employs the hybridization of an oligo to a target sequence, the presence of a label on
the hybridized oligo facilitates affinity purification of the target sequence. For instance,
simple purification or detection of PCR amplicons generated with labeled primers may be
performed. Another obvious application of the labeled-DNA purification is the screening
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of cDNA libraries (Tagle and others 1993). In that light, individual label purification is
sufficient rather than the serial arrangement with two different target labels. Even for the
isolation of synthetic genes it is not an absolute truth that complete resolution of the fulllength product from unwanted oligos is needed for downstream processing—the base
objective is to increase the signal-to-noise ratio. Sole utilization of just one of the
purification steps for synthetic genes may be adequate since all inner intermediate
products that have not been assembled to completion in the chosen strand direction would
be washed away, representing the vast majority of unwanted products. It is easy to see
that the developed immunoaffinity workstation can be modified with little effort to a
single-stage platform.

6.3 Closing thoughts
The capacity to create genes de novo is undoubtedly a major advancement in
biotechnology.

While conceptually there are no natural limitations on the exact

sequences that may be constructed, many technical challenges abound. The research
presented herein served to demonstrate rapid PCA and subsequent affinity purification of
synthetic genes as valuable tools for researchers.

A rapid thermocycler can be

characterized as generally superior to the use of conventional instrumentation for PCAbased gene synthesis, particularly advantageous due to high fidelity with reduced error
rates. The affinity purification of synthesized DNA to isolate the full-length gene from
its reaction background has been proven a useful alternative to gel purification. Still,
researchers are advised to select among available techniques for particular applications
given the infinite diversity of sequences and lengths that one may desire. Especially as
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the synthesis projects grow in sequence and length complexity, there will become a
growing need to combine rapid PCA and affinity purification with other techniques to
tailor strategies that give the highest probability of success.
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Appendix 5A- mWAP-hPC sequence information
5A.1

Sequence information

gaattctttcactgctaaaacagggcgggaggagtccagagccctgccactgggtgcagaacatgaagaccccttgagtggaaaggggtta
tacagctggacagtggtggcgcacacctttaatcccagcactcgggaggcagaggcagacggatctctgagttcgaggccagcctggtcta
cagaatgagttccgggacagccagggccacacagagaaactcttgtctcgaaaaaccaaaaaaaaacaaaaaaggaaaggggttacaca
acagagactcaggtcacagctacccatcacacacaggatacacatacaaaggtgttcacaggcagatgaggaacgaggagaaggggctc
aagcaagggcctaaagtttctttttttttttttcttctttttttttttccctgtggcctagagtttcaagaggctgaggacctaggcatgaaccaagagg
ggccaaaccacttcaagaagcagggggtagcagcagaatctcactatcagccttgagcacagctgggaaggagatccatggaaacaacc
aagaaagagctgaaaggggctggagagatggctcagcagttaagagcactgagtgctcttccgaagtcctagattcaaatcccagcaacca
tatggtgggtcacaaccatctgtaatgagatctgatgccctcttctggtgtgtctgaagacagctacagtgtacttatgtataataaataaataaat
ctttagaaagggagggggggagagagagagagagagagagagagagagagagagagagagagagagagagagagagctggaaga
gggagatctgggaagtctgctggctttatatgctgaccatatatagtcacctgtgtttacacactgtgctcatcactttgaaatctcagtggtttctt
ctttgagcctgtgtctgtaagttcaccaggagagtggtacataggcaagaataacagccagtgggcataggacacagagtgcatgggcccc
agcaagactgtagagagaacagagctctggctcctaagacatagggccttctgggaaactcaagcagccaagcaaccctagccagcccttt
cctggtggccctccttctgttccagcaaaggcggaaatgggaacaggggtggaagcagagcattggcagagcataggtatgacttagtcttg
actaacacaagcatggcagtagcctgacagtggcctaaatgtggggatgactgccttagatggggatgactgccttagatgggcatgactgc
cttagatggggatgactgccttagatggggatgactgccttagatggaacaacaaacatctatgggcatgctgtggaacactggcccacaca
cggaactgaaggcactggcaatttccatagggcagttaaacctaaaagcatgctcacactcaacaggctgccggaatctcatgagacacctg
gaatagacgaatgtagaaacagagcagagagttggttgccaaggtctgggggctcagaggacaagcaagaggcgcggctttcctttgggg
ctggcatgaaaggaaatatcgaggttacagcctgagagggcttcccctgacacttcgtattcaaagaggccatgggcaccagtgaagacaa
aggagtatggcctgcaccacaggctggcnctgacagtcagtaagcacacagtcactctgggtcatcccatccccttccttgcaagagaaatc
aaggaaatgtcccgagaacaatggggcacagtgccagcaggacatctcttcctgcccatggcaccctttggcacggtatgggcccttctgg
gaaggtggccttccaaattgctctgcacaggcagctccttttcaatgtatgcccgacactctctacatggagcaagcgcctccacactcttaga
agaattttagaaaactccagaaaagcaccaggagaagtcaccctcagatgtagcccggactcgagccttgctcaaaacctcctgtcttgttttc
tatgtgacctgtacaaatttggagctcagaattgcctttgtctgtgatgggttccaacccaaccactcaaagtgacacttgtcacatttgtcactga
tcctatttcttctttttctgctccttcattttctccgctttcataataaacaagtattactttttaagtgggggaaaaaatgaccacccttacaaaggact
ttttaaaaatggcctccattgtggcccttgttcctggcagcctgggcctgctctctctgtgtggccaagaaggaagtgttgtagcccatctagag
ctgtgccagcctcttcccccaccccacccccaaagtcttcctcctgtgggtcctttaaatgcatcccagacactcagacagccatcagtcactt
gcctgacaccggtaccatgtggcagctcacaagcctcctgctgttcgtggccacctggggaatttccggcacaccagctcctcttgactcagt
gttctccagcagcgagcgtgcccaccaggtgctgcggatccgcaaacgtgccaactccttcctggaggagctccgtcacagcagcctgga
gcgggagtgcatagaggagatctgtgacttcgaggaggccaaggaaattttccaaaatgtggatgacacactggccttctggtccaagcac
gtcgacggtgaccagtgcttggtcttgcccttggagcacccgtgcgccagcctgtgctgcgggcacggcacgtgcatcgacggcatcggc
agcttcagctgcgactgccgcagcggctgggagggccgcttctgccagcgcgaggtgagcttcctcaattgctcgctggacaacggcggc
tgcacgcattactgcctagaggaggtgggctggcggcgctgtagctgtgcgcctggctacaagctgggggacgacctcctgcagtgtcacc
ccgcagtgaagttcccttgtgggaggccctggaagcggatggagaagaagcgcagtcacctgaaacgagacacagaagaccaagaaga
ccaagtagatccgcggctcattgatgggaagatgaccaggcggggagacagcccctggcaggtggtcctgctggactcaaagaagaagc
tggcctgcggggcagtgctcatccacccctcctgggtgctgacagcggcccactgcatggatgagtccaagaagctccttgtcaggcttgg
agagtatgacctgcggcgctgggagaagtgggagctggacctggacatcaaggaggtcttcgtccaccccaactacagcaagagcacca
ccgacaatgacatcgcactgctgcacctggcccagcccgccaccctctcgcagaccatagtgcccatctgcctcccggacagcggccttgc
agagcgcgagctcaatcaggccggccaggagaccctcgtgacgggctggggctaccacagcagccgagagaaggaggccaagagaa
accgcaccttcgtcctcaacttcatcaagattcccgtggtcccgcacaatgagtgcagcgaggtcatgagcaacatggtgtctgagaacatgc
tgtgtgcgggcatcctcggggaccggcaggatgcctgcgagggcgacagtggggggcccatggtcgcctccttccacggcacctggttcc
tggtgggcctggtgagctggggtgagggctgtgggctccttcacaactacggcgtttacaccaaagtcagccgctacctcgactggatccat
gggcacatcagagacaaggaagccccccagaagagctgggcaccttag
Note 1: mWAP sequence in black, hPC sequence in red
Note 2: n at position represents ambiguous nucleotide
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5A.2

Oligo Hybridization Map

GAATTCTTTCACTGCTAAAACAG-GGCGGGAGGAGTCCAGAG CCCTGCCACTGGGTGCAG-AACATGAAGACCCCTTGA
CTTAAGAAAGTGACGATTTTGTC CCGCCCTCCTCAGGTCTC-GGGACGGTGACCCACGTC TTGTACTTCTGGGGAACT
59.82
67.70
69.62
59.381
GTGGAAAGGGGTTATACAGC-TGGACAGTGGTGGCGCAC ACCTTTAATCCCAGCACT-CGGGAGGCAGAGGCAGAC G
-CACCTTTCCCCAATATGTCG ACCTGTCACCACCGCGTG-TGGAAATTAGGGTCGTGA GCCCTCCGTCTCCGTCTG-C
62.627
69.41
59.464
68.64
5
GATCTCTGAGTTCGAGG-CCAGCCTGGTCTACAGAA TGAGTTCCGGGACAGCCA-GGGCCACACAGAGAAACT CTTGT
CTAGAGACTCAAGCTCC GGTCGGACCAGATGTCTT-ACTCAAGGCCCTGTCGGT CCCGGTGTGTCTCTTTGA-GAACA
9.81
62.017
67.19
63.310
59.20
CTCGAAAAACCAAAA-AAAAACAAAAAAGGAAAGGGG TTACACAACAGAGACTCAGG-TCACAGCTACCCATCACA CA
GAGCTTTTTGGTTTT TTTTTGTTTTTTCCTTTCCCC-AATGTGTTGTCTCTGAGTCC AGTGTCGATGGGTAGTGT-GT
60.494
61.16
61.618
60
CAGGATACACATACAAAGG-TGTTCACAGGCAGATGAG GAACGAGGAGAAGGGGCT-CAAGCAAGGGCCTAAAGT TTC
GTCCTATGTGTATGTTTCC ACAAGTGTCCGTCTACTC-CTTGCTCCTCTTCCCCGA GTTCGTTCCCGGATTTCA-AAG
.90
60.61
64.86
61.27
59.
TTTTTTTTTTTTTCTTCTTTTTT-TTTTTCCCTGTGGCCTAG AGTTTCAAGAGGCTGAGG-ACCTAGGCATGAACCAAG
AAAAAAAAAAAAAGAAGAAAAAA AAAAAGGGACACCGGATC-TCAAAGTTCTCCGACTCC TGGATCCGTACTTGGTTC
00
60.54
60.215
60.29
AGGGGCCAAACCACTTCA-AGAAGCAGGGGGTAGCAG CAGAATCTCACTATCAGCCT-TGAGCACAGCTGGGAAGG A
-TCCCCGGTTTGGTGAAGT TCTTCGTCCCCCATCGTC-GTCTTAGAGTGATAGTCGGA ACTCGTGTCGACCCTTCC-T
65.39
64.90
60.803
65.82
6
GATCCATGGAAACAACCA-AGAAAGAGCTGAAAGGGG CTGGAGAGATGGCTCAGC-AGTTAAGAGCACTGAGTGC TCT
CTAGGTACCTTTGTTGGT TCTTTCTCGACTTTCCCC-GACCTCTCTACCGAGTCG TCAATTCTCGTGACTCACG-AGA
0.689
60.215
63.26
61.4
60.
TCCGAAGTCCTAGATTC-AAATCCCAGCAACCATATG GTGGGTCACAACCATCTG-TAATGAGATCTGATGCCCT CTT
AGGCTTCAGGATCTAAG TTTAGGGTCGTTGGTATAC-CACCCAGTGTTGGTAGAC ATTACTCTAGACTACGGGA-GAA
43
59.59
61.658
59.2
62.
CTGGTGTGTCTGAAGAC-AGCTACAGTGTACTTATGTATAAT AAATAAATAAATCTTTAGAAAGGGAG-GGGGGGAGAG
GACCACACAGACTTCTG TCGATGTCACATGAATACATATTA-TTTATTTATTTAGAAATCTTTCCCTC CCCCCCTCTC
44
60.27
59.74
63.27
AGAGAGAG AGAGAGAGAGAGAGAGAGAG-AGAGAGAGAGAGAGAGAGAG AGAGCTGGAAGAGGGAGA-TCTGGGAAGT
TCTCTCTC-TCTCTCTCTCTCTCTCTCTC TCTCTCTCTCTCTCTCTCTC-TCTCGACCTTCTCCCTCT AGACCCTTCA
60.43
60.43
62.7
65.50
CTGCTGGC TTTATATGCTGACCATATATAGTCA-CCTGTGTTTACACACTGTG CTCATCACTTTGAAATCTCAG-TGG
GACGACCG-AAATATACGACTGGTATATATCAGT GGACACAAATGTGTGACAC-GAGTAGTGAAACTTTAGAGTC ACC
60.81
60.36
59.10
60.
TTTCTTCTTTGAGCCT GTGTCTGTAAGTTCACCAG-GAGAGTGGTACATAGGCAA GAATAACAGCCAGTGGGC-ATAG
AAAGAAGAAACTCGGA-CACAGACATTCAAGTGGTC CTCTCACCATGTATCCGTT-CTTATTGTCGGTCACCCG TATC
9
59.4
60.21
62.13
60.9
GACACAGAGTGCATG GGCCCCAGCAAGACTGTA-GAGAGAACAGAGCTCTGG CTCCTAAGACATAGGGCC-TTCTGGG
CTGTGTCTCACGTAC-CCGGGGTCGTTCTGACAT CTCTCTTGTCTCGAGACC-GAGGATTCTGTATCCCGG AAGACCC
0
65.52
60.054
59.479
60.05
AAACTCAAGCA GCCAAGCAACCCTAGCCA-GCCCTTTCCTGGTGGCCC TCCTTCTGTTCCAGCAAA-GGCGGAAATGG
TTTGAGTTCGT-CGGTTCGTTGGGATCGGT CGGGAAAGGACCACCGGG-AGGAAGACAAGGTCGTTT CCGCCTTTACC
66.55
69.74
60.05
64.8
GAACAGG GGTGGAAGCAGAGCATTG-GCAGAGCATAGGTATGACT TAGTCTTGACTAACACAAGC-ATGGCAGTAGCC
CTTGTCC-CCACCTTCGTCTCGTAAC CGTCTCGTATCCATACTGA-ATCAGAACTGATTGTGTTCG TACCGTCATCGG
62.442
60.368
59.3
62.816
TGACAG TGGCCTAAATGTGGGGAT-GACTGCCTTAGATGGGGA TGACTGCCTTAGATGGGC-ATGACTGCCTTAGATG
ACTGTC-ACCGGATTTACACCCCTA CTGACGGAATCTACCCCT-ACTGACGGAATCTACCCG TACTGACGGAATCTAC
62.0
61.78
62.82
59.72
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GG GATGACTGCCTTAGATGGG-GATGACTGCCTTAGATGGA ACAACAAACATCTATGGGC-ATGCTGTGGAACACTGG
CC-CTACTGACGGAATCTACCC CTACTGACGGAATCTACCT-TGTTGTTTGTAGATACCCG TACGACACCTTGTGACC
61.36
60.29
59.82
64.40
C CCACACACGGAACTGAAG-GCACTGGCAATTTCCATA GGGCAGTTAAACCTAAAAGC-ATGCTCACACTCAACAGG
G-GGTGTGTGCCTTGACTTC CGTGACCGTTAAAGGTAT-CCCGTCAATTTGGATTTTCG TACGAGTGTGAGTTGTCC61.9
59.32
61.58
60.94
CTGCCGGAATCTCATGAG-ACACCTGGAATAGACGAAT GTAGAAACAGAGCAGAGAGT-TGGTTGCCAAGGTCTGGG G
GACGGCCTTAGAGTACTC TGTGGACCTTATCTGCTTA-CATCTTTGTCTCGTCTCTCA ACCAACGGTTCCAGACCC-C
61.24
59.822
60.94
66.
6
GCTCAGAGGACAAGCAA-GAGGCGCGGCTTTCCTTT GGGGCTGGCATGAAAGGA-AATATCGAGGTTACAGCCT GAGA
CGAGTCTCCTGTTCGTT CTCCGCGCCGAAAGGAAA-CCCCGACCGTACTTTCCT TTATAGCTCCAATGTCGGA-CTCT
3.36
67.48
66.2
59.58
65.2
GGGCTTCCCCTGAC-ACTTCGTATTCAAAGAGGC CATGGGCACCAGTGAAGA-CAAAGGAGTATGGCCTGC ACCACAG
CCCGAAGGGGACTG TGAAGCATAAGTTTCTCCG-GTACCCGTGGTCACTTCT GTTTCCTCATACCGGACG-TGGTGTC
6
59.22
63.39
61.820
63.641
GCTGGCNCTGA-CAGTCAGTAAGCACACAGT CACTCTGGGTCATCCCAT-CCCCTTCCTTGCAAGAGA AATCAAGGAA
CGACCGNGACT GTCAGTCATTCGTGTGTCA-GTGAGACCCAGTAGGGTA GGGGAAGGAACGTTCTCT-TTAGTTCCTT
61.35
62.1
62.687
60.76
ATGTCCCGA-GAACAATGGGGCACAGTG CCAGCAGGACATCTCTTC-CTGCCCATGGCACCCTTT GGCACGGTATGGG
TACAGGGCT CTTGTTACCCCGTGTCAC-GGTCGTCCTGTAGAGAAG GACGGGTACCGTGGGAAA-CCGTGCCATACCC
62.6
60.77
66.94
68.78
CCCTT-CTGGGAAGGTGGCCTTCC AAATTGCTCTGCACAGGC-AGCTCCTTTTCAATGTATGC CCGACACTCTCTACA
GGGAA GACCCTTCCACCGGAAGG-TTTAACGAGACGTGTCCG TCGAGGAAAAGTTACATACG-GGCTGTGAGAGATGT
66.25
62.69
60.724
60.13
TGG-AGCAAGCGCCTCCACACT CTTAGAAGAATTTTAGAAAACTCC-AGAAAAGCACCAGGAGAA GTCACCCTCAGAT
ACC TCGTTCGCGGAGGTGTGA-GAATCTTCTTAAAATCTTTTGAGG TCTTTTCGTGGTCCTCTT-CAGTGGGAGTCTA
68.53
59.10
59.719
60.45
GTAGC-CCGGACTCGAGCCTTGCTC AAAACCTCCTGTCTTGTTTT-CTATGTGACCTGTACAAATTTG GAGCTCAGAA
CATCG GGCCTGAGCTCGGAACGAG-TTTTGGAGGACAGAACAAAA GATACACTGGACATGTTTAAAC-CTCGAGTCTT
69.29
59.98
60.143
60.89
TTGCCTTTG-TCTGTGATGGGTTCCAACC CAACCACTCAAAGTGACAC-TTGTCACATTTGTCACTGATC CTATTTCT
AACGGAAAC AGACACTACCCAAGGTTGG-GTTGGTGAGTTTCACTGTG AACAGTGTAAACAGTGACTAG-GATAAAGA
63.718
60.66
61.31
61.88
TCTTTTTCTGCTCCT-TCATTTTCTCCGCTTTCATA ATAAACAAGTATTACTTTTTAAGTGG-GGGAAAAAATGACCAC
AGAAAAAGACGAGGA AGTAAAAGAGGCGAAAGTAT-TATTTGTTCATAATGAAAAATTCACC CCCTTTTTTACTGGTG
59.401
60.148
59.89
CC TTACAAAGGACTTTTTAAAAATGG-CCTCCATTGTGGCCCTTG TTCCTGGCAGCCTGGGCC-TGCTCTCTCTGTGT
GG-AATGTTTCCTGAAAAATTTTTACC GGAGGTAACACCGGGAAC-AAGGACCGTCGGACCCGG ACGAGAGAGACACA
59.96
64.51
71.54
65.46
GGCC AAGAAGGAAGTGTTGTAGC-CCATCTAGAGCTGTGCCA GCCTCTTCCCCCACCCCA-CCCCCAAAGTCTTCCTC
CCGG-TTCTTCCTTCACAACATCG GGTAGATCTCGACACGGT-CGGAGAAGGGGGTGGGGT GGGGGTTTCAGAAGGAG
59.060
62.49
70.26
63.09
C TGTGGGTCCTTTAAATGCA-TCCCAGACACTCAGACAG CCATCAGTCACTTGCCTG-ACACCGGTACCATGTGGC A
G-ACACCCAGGAAATTTACGT AGGGTCTGTGAGTCTGTC-GGTAGTCAGTGAACGGAC TGTGGCCATGGTACACCG-T
61.31
61.60
61.73
66.17
6
GCTCACAAGCCTCCTGC-TGTTCGTGGCCACCTGGG GAATTTCCGGCACACCAG-CTCCTCTTGACTCAGTGT TCTCC
CGAGTGTTCGGAGGACG ACAAGCACCGGTGGACCC-CTTAAAGGCCGTGTGGTC GAGGAGAACTGAGTCACA-AGAGG
6.18
68.86
62.74
59.15
68.8
AGCAGCGAGCGTG-CCCACCAGGTGCTGCGGA TCCGCAAACGTGCCAACT-CCTTCCTGGAGGAGCTCC GTCACAGCA
TCGTCGCTCGCAC GGGTGGTCCACGACGCCT-AGGCGTTTGCACGGTTGA GGAAGGACCTCCTCGAGG-CAGTGTCGT
71.34
66.97
64.95
67.1
GCCTGGAGC-GGGAGTGCATAGAGGAGA TCTGTGACTTCGAGGAGG-CCAAGGAAATTTTCCAAAATGT GGATGACAC
CGGACCTCG CCCTCACGTATCTCCTCT-AGACACTGAAGCTCCTCC GGTTCCTTTAAAAGGTTTTACA-CCTACTGTG

165
61.12

61.67

61.086

63.392

ACTGGCCTT-CTGGTCCAAGCACGTCGA CGGTGACCAGTGCTTGGT-CTTGCCCTTGGAGCACCC GTGCGCCAGCCTG
TGACCGGAA GACCAGGTTCGTGCAGCT-GCCACTGGTCACGAACCA GAACGGGAACCTCGTGGG-CACGCGGTCGGAC
66.04
66.38
67.23
71.04
TGCTG-CGGGCACGGCACGTGCAT CGACGGCATCGGCAGCTT-CAGCTGCGACTGCCGCAG CGGCTGGGAGGGCCGCT
ACGAC GCCCGTGCCGTGCACGTA-GCTGCCGTAGCCGTCGAA GTCGACGCTGACGGCGTC-GCCGACCCTCCCGGCGA
73.05
69.8
70.68
74.18
T-CTGCCAGCGCGAGGTGAG CTTCCTCAATTGCTCGCT-GGACAACGGCGGCTGCAC GCATTACTGCCTAGAGGA-GG
A GACGGTCGCGCTCCACTC-GAAGGAGTTAACGAGCGA CCTGTTGCCGCCGACGTG-CGTAATGACGGATCTCCT CC
69.79
61.4
70.99
59.39
75
TGGGCTGGCGGCGCTG TAGCTGTGCGCCTGGCTA-CAAGCTGGGGGACGACCT CCTGCAGTGTCACCCCGC-AGTGAA
ACCCGACCGCCGCGAC-ATCGACACGCGGACCGAT GTTCGACCCCCTGCTGGA-GGACGTCACAGTGGGGCG TCACTT
.83
67.64
67.95
69.83
60.46
GTTCCCTTGTGG GAGGCCCTGGAAGCGGAT-GGAGAAGAAGCGCAGTCA CCTGAAACGAGACACAGA-AGACCAAGAA
CAAGGGAACACC-CTCCGGGACCTTCGCCTA CCTCTTCTTCGCGTCAGT-GGACTTTGCTCTGTGTCT TCTGGTTCTT
68.13
63.39
60.214
59.26
GACCAAGTA GATCCGCGGCTCATTGAT-GGGAAGATGACCAGGCGG GGAGACAGCCCCTGGCAG-GTGGTCCTGCTGG
CTGGTTCAT-CTAGGCGCCGAGTAACTA CCCTTCTACTGGTCCGCC-CCTCTGTCGGGGACCGTC CACCAGGACGACC
64.02
66.31
68.70
65.0
ACTCA AAGAAGAAGCTGGCCTGC-GGGGCAGTGCTCATCCAC CCCTCCTGGGTGCTGACA-GCGGCCCACTGCATGGA
TGAGT-TTCTTCTTCGACCGGACG CCCCGTCACGAGTAGGTG-GGGAGGACCCACGACTGT CGCCGGGTGACGTACCT
64.09
66.94
67.62
69.7
T GAGTCCAAGAAGCTCCTT-GTCAGGCTTGGAGAGTAT GACCTGCGGCGCTGGGAG-AAGTGGGAGCTGGACCTG GA
A-CTCAGGTTCTTCGAGGAA CAGTCCGAACCTCTCATA-CTGGACGCCGCGACCCTC TTCACCCTCGACCTGGAC-CT
59.88
59.31
72.22
65.14
61
CATCAAGGAGGTCTTCG-TCCACCCCAACTACAGCA AGAGCACCACCGACAATG-ACATCGCACTGCTGCACC TGGCC
GTAGTTCCTCCAGAAGC AGGTGGGGTTGATGTCGT-TCTCGTGGTGGCTGTTAC TGTAGCGTGACGACGTGG-ACCGG
.5
64.3
63.73
67.45
77.0
CAGCCCGCCACCC-TCTCGCAGACCATAGTGC CCATCTGCCTCCCGGACA-GCGGCCTTGCAGAGCGCG AGCTCAATC
GTCGGGCGGTGGG AGAGCGTCTGGTATCACG-GGTAGACGGAGGGCCTGT CGCCGGAACGTCTCGCGC-TCGAGTTAG
62.845
67.71
73.88
69.08
AGGCCGGCC-AGGAGACCCTCGTGACGG GCTGGGGCTACCACAGCA-GCCGAGAGAAGGAGGCCA AGAGAAACCGCAC
TCCGGCCGG TCCTCTGGGAGCACTGCC-CGACCCCGATGGTGTCGT CGGCTCTCTTCCTCCGGT-TCTCTTTGGCGTG
66.90
68.65
67.67
63.703
CTTCG-TCCTCAACTTCATCAAGATTC CCGTGGTCCCGCACAATG-AGTGCAGCGAGGTCATGA GCAACATGGTGTCT
GAAGC AGGAGTTGAAGTAGTTCTAAG-GGCACCAGGGCGTGTTAC TCACGTCGCTCCAGTACT-CGTTGTACCACAGA
60.211
67.80
65.14
60.93
GAGA-ACATGCTGTGTGCGGGCA TCCTCGGGGACCGGCAGG-ATGCCTGCGAGGGCGACA GTGGGGGGCCCATGGTCG
CTCT TGTACGACACACGCCCGT-AGGAGCCCCTGGCCGTCC TACGGACGCTCCCGCTGT-CACCCCCCGGGTACCAGC
69.50
72.5
71.03
71.88
-CCTCCTTCCACGGCACCT GGTTCCTGGTGGGCCTGG-TGAGCTGGGGTGAGGGCT GTGGGCTCCTTCACAACT-ACG
GGAGGAAGGTGCCGTGGA-CCAAGGACCACCCGGACC ACTCGACCCCACTCCCGA-CACCCGAGGAAGTGTTGA TGC
67.95
69.04
69.50
63.31
62.
GCGTTTACACCAAAG TCAGCCGCTACCTCGACT-GGATCCATGGGCACATCA GAGACAAGGAAGCCCCCC-AGAAGAG
CGCAAATGTGGTTTC-AGTCGGCGATGGAGCTGA CCTAGGTACCCGTGTAGT-CTCTGTTCCTTCGGGGGG TCTTCTC
264
66.58
63.25
65.93
64.78
CTGGGCACCTTAG
GACCCGTGGAATC

5A.3 Sequencing Results for Gene (1+2)
Reference (desired) sequence either at top in light blue or as “gene1ref” in each section.
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5A.4 Sequencing Results for Gene (3+4)
Reference (desired) sequence shown as “gene2ref” in each section.
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Appendix 5B- Synthesis of chimeric gene sequences
The technique of rapid PCA has been employed for the de novo construction of chimeric
gene sequences encoding for both endothelial protein C receptor (EPCR) and
thrombomodulin (TM). A mutant of TM (TM-2) was employed due to its shortened gene
sequence but expected retention of high activity. Two different variants of the chimeric
gene were explored, one with the amino acid sequence of TM-2 in the standard
orientation and one with the amino acid sequence flipped due to the direction of the
native protein state with respect to the cell wall. Two different linker epitopes, myc or
flag, were incorporated into the genes. For facilitation of expression, restriction enzyme
sites and His-tags were included in the design of the sequences.

Both variants of the

approximately 1.4 kb chimeric genes were synthesized in high-yield, with error-free
clones isolated.

5B.1

Introduction

One of the most attractive advantages of PCA is the capacity to synthesize de novo
sequences that do not naturally occur. With no inherent constraints, these gene sequences
may encode for a protein that is devoid of any semblance of existing proteins. More
practically, researchers are more interested in extrapolation using natural protein
sequences as a basis for design. The construction of a sequence that encodes for two
unique proteins to be expressed in a single cohesive stretch (i.e. chimeric gene or
chimeric protein) is one such example. Even though the separate proteins are common,
an integrated protein containing both is certainly a conjured entity.
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Demonstration of how rapid PCA is particularly suited for synthesis of novel sequences,
the construction of chimeric gene sequences was undertaken. Endothelial protein C
receptor (EPCR, Genbank accession no. L35545) and the TM-2 mutant of
thrombomodulin (TM, TM-1, Genbank accession no. BC035602) were selected as the
two proteins of interest.

Two different variants including EPCR and TM-2 were

investigated—the primary difference between the two being the orientation of the TM-2
amino acid sequence. These chimeric genes serve as a reaffirmation of the rapid PCA
technique’s ability to construct high-fidelity de novo genes under extremely short
thermocycling run-times. As a basic test of the convergent rapid PCA synthesis strategy,
one of the gene sequences was synthesized from the stitching of two synthesized starting
fragments.

EPCR and TM work synergistically in the activation of protein C and surface coimmobilization strategies have been shown to increase the catalytic conversion (Kador
and Subramanian 2010). As an alternative approach, synthesis of a gene sequence that
integrates both into a single protein is a perfect candidate as the resulting recombinant
chimeric protein would be highly coveted if activities were retained (or even increased
due to inherent proximity of the two proteins). Due to the length of the TM-1 sequence
(1548bp), a shorter TM-2 sequence consisting of important domains was used that has
been shown to retain high activity (Shi and others 2005). In designing a chimeric gene
sequence including EPCR-1 and TM-2, there are two main considerations:

1) the

orientation of the TM-2 amino acid (AA) sequence and 2) the linker region joining the
two sequences.

In its native orientation, the N-terminus of the TM protein
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(corresponding to the 5’ end of cDNA) is opposite of the cell membrane. As a secondary
sequence in a chimeric gene retaining the AA order, the orientation of the AA sequence
will be opposite its native with respect to the cell membrane. An alternative is to flip the
AA sequence in the chimera (by reversing the cDNA), which conserves the AA
orientation with respect to the cell wall. Of course, protein expression and folding may
be adversely affected by this change.

The specific TM-2 for chimera #1 was extracted from the research of Shi and others
(2005) using residues from Ala224 to Cys462. Chimera #2 used residues Asp226 to Lys466.
The amino acid sequences were extracted from Suzuki and others (1987). Originally, an
EPCR and TM-2 chimeric sequence was designed with the TM-2 in standard sequence
orientation from prior research done by Tarlan Mamedov. However, difficulties arose in
purifying the expressed protein. Based on these findings, it was decided to include a HisTag on the C-terminus of the proteins to aid in protein purification.

Chimera #1
XhoI

EPCR-1

flag TM-2 (reversed AA) His-tag NotI

Chimera #2
XhoI

EPCR-1

myc TM-2 (normal AA)

His-tag NotI

Figure 5B-1 Illustration of the EPCR and TM-2 chimeric genes.
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The primary difference in the two versions of the chimera is the orientation of the TM-2
amino acids. The second aspect of the design difference is the linker between the EPCR1 and TM-2 fragments. It is hypothesized that spacing the two proteins apart an optimal
distance will result in the highest activity because of the synergy of the two proteins.
Two linkers were selected as candidates, a flag epitope (DYKDDDDK) (Hopp and others
1988) for chimera #1 and a myc epitope (EQKLISEEDL) (Evan and others 1985) for
chimera #2. Additionally, lysine residues flanking the flag epitope and also the end of
the TM-2 were added in an attempt to increase the efficacy of the expressed chimeric #1
protein. Flanking XhoI and NotI restriction sites were designed in the gene sequence to
facilitate direct insertion into pPICZαA vector for protein expression analysis in Pichia
pastoris.

5B.2

Chimeric genes: Design of sequence and assembly
oligonucleotides

First, the hybridization oligonucleotides and AA sequences were designed (see Appendix
5C). Gene Designer from DNA 2.0 (Villalobos and others 2006) was used in the design
and codon optimization of chimera #1. The codon optimization was done using a Pichia
pastoris codon table with the usage frequency threshold set at 25%. The Gene Designer
repeat minimization setting was specified to >9 bp, as this reduced sequence repeats that
may be troublesome for PCA. Since XhoI and NotI sites were included at the ends to
ligate the sequence into the pPICZαA vector, avoidance of these sites internal to the
sequence was also specified.

The main Gene Designer window of chimera #1 is shown

in Figure 5B-2 showing the pertinent segments.
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Figure 5B-2. Structure of chimera #1 as shown in Gene Designer software.

The output full nucleotide sequence for chimera #1 is shown in Appendix 5A.2.

The

basis for chimera #2 lacking a His tag was initially designed by Tarlan Mamedov in prior
research (see Appendix 5C.6 for corresponding hybridization oligo map lacking the Histag). Since the basis of the sequence was already designed, a slightly different approach
was used. The existing sequence was first forward translated to determine the resulting
AA sequence to verify the protein translation (see Appendix 5C.5). A modified oligo set
was then manually generated by simply redesigning several oligos towards the 3’ end of
the sequence to include the His tag.

Oligo design for chimera #2 was done with the Gene2Oligo software of Rouillard and
others (2004).

The oligo design for chimera #1 was performed using internally

developed oligo design software (Louw and others 2010). The oligo design hybridization
output maps for chimera #1 and chimera #2 are provided in the appendix (Appendix 5C.3
and 5C.6, respectively). 78 oligos were needed for chimera #1 for the 1416 bp sequence.
77 oligos were needed for chimera #2 for the 1395 bp sequence. Assembly oligos and
unlabelled primers were obtained from Integrated DNA technologies at 100 µM in
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nuclease-free water. The details of the chimeric gene sequences are shown in Table 5B1.

Table 5B-1. Gene synthesis details for the chimeric genes.

A modified 1377 bp chimera #2 (lacking the 3’ His-tag) synthesis was performed from
convergent stitching of fragments. The hybridization map shown in Appendix 5C-6
shows the oligos used in this synthesis (disregard addition of oligos notation at end). The
sequence was divided into an “A” fragment of 640 bp using the first 35 oligos, and a “B”
fragment of 753 bp using the last 42 oligos. Note that the A and B fragments overlap
each other, thus reconciling the length sum of the fragments being greater than the fulllength size. Please refer to Table 4-1 in Chapter 4 for details regarding this modified
chimera #2 and its fragments.

5B.3

PCA synthesis of chimeric genes

Each 25μl reaction mixture contained 200μM of each dNTP, 5 mM MgSO4, 400 μg per
ml non-acetylated BSA, and 0.5 unit KOD hot-start polymerase in 1x manufacturer’s
buffer obtained from Novagen (Madison, WI). 25 nM each oligonucleotide was used in
the equimolar PCA reaction. PCA was conducted under the following conditions: 30 s
hot start at 94°C, followed by 30 cycles of [94°C for 2 s and 56°C for 10 s and 72°C for
10 s] and a final extension at 72°C for 15 s. PCA product was subsequently PCR
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amplified using 2 μl of the PCA product as template and 0.7μM each primer. Note that
the same reverse primer was used for both sequences due to sequence commonality on
the 3’ end. PCR amplification was conducted under the following conditions: 30 s hot
start at 94°C, followed by 35 cycles of [94°C for 2 s and 58°C for 3 s and 72°C for 10 s]
and a final extension at 72°C for 15 s.

As a very basic test of the convergent synthesis approach, the A and B fragments of the
modified chimera #2 were constructed by 2-step PCA with follow-up PCR, and then
directly stitched together by rapid integrated PCA-PCR. The PCA and PCR reaction
compositions and thermocycling conditions were kept the same as for the full-length
sequence. Note that for the particular PCR products shown in Figure 5B-4, PCA of the
fragments was performed at 100 nM each oligo (done prior to Chapter 4 research). 1 µl
of each PCR product of the fragments was used as template for the stitching reaction.
Stitching was performed under the same reaction conditions as PCA of chimera #2,
except with 0.7 µM of the outer primers and 1 µl of each PCR product of the fragments
used as templates.

5B.4

Cloning & Sequencing

Gel-purified DNA from both chimera #1 and chimera #1 were ligated to TOPO vector
using Zero Blunt® TOPO® PCR Cloning Kit (Invitrogen, Carlsbad, CA). The ligated
plasmids were transformed into chemically competent cells of E. coli strain TOP-10
(Invitrogen); ten positive clones of each were selected. Purified plasmids from selected
clones were sequenced at the University of Nebraska-Medical Center sequencing facility
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using vector and gene specific primers.

Sequence analysis was performed using

ChromasPro v1.5 software.

5B.5

Results & Discussion

Both of the chimeric sequences were successfully assembled and amplified by rapid 2step PCA-PCR, as evidenced in the PCR products shown in Figure 5B-3. As can be seen
from these gel results, a high yield and relative purity of the desired products were
obtained using 25 nM each oligo for PCA and 2 µl of the PCA product as PCR
amplification template. The yield and purity under these conditions were dramatically
better than results obtained using 100 nM / 1 µl conditions (results not shown), in good
agreement with the conclusions drawn in Chapter 4.

L

1

2

Figure 5B-3. Gel electrophoresis results of the PCR products for the 1416 bp chimera #1
and the 1395 bp chimera #2 gene synthesis.

Since labeled primers were not procured, gel purification was performed on both
synthesized genes prior to cloning. Please refer to Chapter 4 that demonstrates the
immunoaffinity purification of the modified chimera #2. Sequencing results verified that
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the desired sequences were constructed.

For chimera #1, 1 out of 9 successfully

sequenced clones had no errors. For chimera #2, 3 out of 10 clones were error-free. This
is indicative of the fidelity of PCA synthesis by rapid thermocycling, especially given the
1.4 kb lengths of the genes. While some of the sequences suggested that mis-annealing
had occurred at the 3’ end of the sequence, the majority of errors present were deletions.
Deletions are primarily attributable to the quality of the phosphoramidite synthesized
oligos.

The actual experimental syntheses of the two chimeric genes were straightforward using
rapid 2-step PCA with follow-up PCR. The yield and purity using the optimized PCA
oligo concentration of 25 nM and PCR aliquot of 2 µl was dramatically improved over
other samples in which 100 nM each oligo was used for PCA and 1 µl each PCA product
used as template (results not shown). The bulk of the research effort was concentrated in
the actual design and post-sequencing analysis of the chimeric sequences. Given proper
oligo design and hybridization overlaps, optimization of reaction conditions after the
initial synthesis attempts was not necessary to produce error free clones for these two
genes. Although, it is likely that further optimization may have reduced the number of
errors by limiting mis-annealing or provide a higher discrimination of oligo deletions as
evidenced by some of the sequenced clones.

Figure 5B-4 shows that the full-length modified chimera #2 lacking the His-tag was
constructed by the convergent strategy. High yields of the A and B fragments were
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obtained after 2-step PCA-PCR. Using these products as templates in the final reaction,
the fragments successfully hybridized together coupled with amplification to construct
the full-length gene.

Note that a shorter fragment B band remains due to slight

imbalances of the templates or from slight differences in linear amplification of the
fragments with the respective primers. Not to be misleading, the final result should be
expected given the ability to synthesize the full-length gene directly by 2-step PCA-PCR.
However, this synthesis clearly serves as a basic example of the convergent synthesis
strategy outlined in Chapter 5.

A

B

L

L

F

Figure 5B-4 Convergent synthesis of a modified full-length 1377 bp chimera #2
(F) from 640 bp A fragment and 753 bp B fragment. L: 1kb ladder

5B.6

Conclusions

Rapid PCA in the workstation proved highly effective for the fast and accurate synthesis
of two de novo gene sequences. The two sequences designed consisted of chimeric
couplings of EPCR and TM-2 domains. The desired codon-optimized sequences for
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EPCR-myc-TM2 and EPCR-flag-TM2 (flipped) were synthesized facilely using rapid 2step PCA and PCR. Clones screened by DNA sequencing resulted in the isolation of
error-free sequences. His-tags and restriction sites were successfully included in the
chimeric genes to facilitate protein purification in future work. A variant of the EPCRmyc-TM2 gene lacking the His-tag was also successfully synthesized from two shorter
fragments, demonstrating the convergent strategy by rapid PCA proposed in Chapter 5.
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Appendix 5C: Details of Chimeric Sequences
5C.1 Chimera #1 Beginning Design
atctcgagaaaagaFCSQDASDGLQRLHMLQISYFRDPY
HVWYQGNASLGGHLTHVLEGPDTNTTIIQLQPLQEP
ESWARTQSGLQSYLLQFHGLVRLVHQERTLAFPLTI
RCFLGCELPPEGSRAHVFFEVAVNGSSFVSFRPERAL
WQADTQVTSGVVTFTLQQLNAYNRTRYELREFLED
TCVQYVQKHISAENTKGSQTSRSYTSKKRKKDYKD
DDDKKRKRKCDTGIHRVLASDPGCICEFTGPLNHCV
GSCFGGNECEDIDTCIFGDDLIYGEPCECSAQTNPDC
DAPCATQNCFMQCRHPEHPIPAFGEACVCLYSTQNL
PQCQYECNARFCPDVPEVCEGDVLDYNPYCHCEFG
GQTNVCRQPCPSPELICDDVDECRHQDAALRYGTEC
MCSYSGPQDPNPVCFHECLDNCSQTASATCSRGDAQ
LAAGAPCQCRPAGPIANCAHECGGNEVSCDWARKK
K R H H H H H H Stop g c g g c c g c t a

Legend
Lower-case: nucleotides

Upper Case: Amino Acids

Black- added sequence

Red- EPCR mature peptide

Green- Flag epitope

Blue- TM-2 (Ala224 to Cys462) flipped

Orange- His 6 tag

Underline-Xho1 and Not1 sites
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5C.2 Chimera#1 Resulting Sequence
ATCTCGAGAAAAGATTCTGCTCTCAAGATGCTTCTGATGGATTGCAAAGATTG
CATATGTTGCAAATTTCTTACTTCAGAGATCCTTACCACGTTTGGTACCAGGG
TAACGCTTCTTTGGGTGGACATTTGACTCACGTTTTGGAGGGTCCTGATACTA
ACACTACTATCATTCAATTGCAACCTTTGCAGGAACCTGAATCTTGGGCCAGA
ACCCAATCTGGATTGCAGTCTTACTTGTTGCAGTTTCATGGTTTGGTTAGATT
GGTTCACCAGGAGAGAACTTTGGCCTTTCCTTTGACCATTAGATGTTTCTTGG
GATGTGAATTGCCTCCAGAAGGTTCTAGAGCTCATGTTTTTTTCGAAGTTGCT
GTTAACGGTTCTTCTTTCGTTTCTTTCAGACCTGAGAGAGCCTTGTGGCAGGC
TGATACTCAGGTTACCTCTGGAGTTGTTACTTTCACCTTGCAACAGTTGAACG
CTTATAACAGAACCAGATATGAATTGAGAGAATTCTTGGAAGATACTTGTGT
TCAGTATGTTCAAAAGCACATTTCTGCCGAAAACACCAAGGGTTCTCAAACTT
CTAGATCTTACACCTCTAAGAAAAGAAAGAAGGATTACAAAGACGACGACG
ATAAGAAGAGAAAGAGAAAATGTGACACTGGTATCCACAGAGTTTTGGCTTC
TGACCCTGGATGCATTTGTGAGTTTACTGGACCTTTGAACCACTGTGTTGGTT
CTTGTTTTGGTGGTAACGAGTGTGAGGACATTGACACTTGCATTTTTGGAGAC
GATTTGATTTATGGTGAGCCATGCGAATGTTCTGCCCAAACTAACCCTGATTG
CGACGCCCCATGTGCCACTCAAAACTGTTTCATGCAGTGTAGACACCCTGAA
CATCCTATTCCAGCTTTCGGTGAAGCTTGCGTTTGTTTGTATTCTACTCAGAAC
TTGCCACAGTGCCAGTACGAGTGTAACGCTAGATTTTGCCCTGACGTTCCTGA
AGTTTGTGAGGGTGATGTTTTGGACTACAACCCATACTGTCATTGCGAATTCG
GTGGACAGACTAACGTTTGCAGACAACCTTGCCCTTCTCCAGAATTGATCTGT
GATGACGTTGATGAATGCAGACACCAGGATGCCGCCTTGAGATATGGAACCG
AATGTATGTGTTCTTATTCTGGTCCTCAAGATCCTAACCCAGTTTGTTTCCATG
AGTGCTTGGACAATTGTTCTCAGACCGCTTCTGCCACCTGTTCTAGAGGAGAT
GCCCAGTTGGCTGCTGGTGCTCCTTGCCAATGTAGACCTGCTGGTCCAATTGC
TAACTGTGCTCACGAATGTGGAGGTAATGAGGTTTCTTGTGACTGGGCTAGA
AAGAAGAAGAGACATCATCACCATCACCACTAAGCGGCCGCTA
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5C.3 Chimera #1 Oligo Design Hybridization Map
-----------------------------------------------------------------------------------------------------ATCTCGAGAAAAGATTCTGC TCTCAAGATGCTTCTGATG-GATTGCAAAGATTGCATATGT TGCAAATTTCTTACTTCAGAG-ATCCTTACCACGTTTGG
TAGAGCTCTTTTCTAAGACG-AGAGTTCTACGAAGACTAC CTAACGTTTCTAACGTATACA-ACGTTTAAAGAATGAAGTCTC TAGGAATGGTGCAAACC
T = 57.5795
T = 56.8179
T = 57.347
T = 56.1104
T = 56.5007
-----------------------------------------------------------------------------------------------------TACCAGGGTAACGCTT-CTTTGGGTGGACATTTGA CTCACGTTTTGGAGGG-TCCTGATACTAACACTACTATCA TTCAATTGCAACCTTTGC-AGGAACCTGAATCTTGGG
-ATGGTCCCATTGCGAA GAAACCCACCTGTAAACT-GAGTGCAAAACCTCCC AGGACTATGATTGTGATGATAGT-AAGTTAACGTTGGAAACG TCCTTGGACTTAGAACCC
T = 57.102
T = 57.5298
T = 57.2092
T = 57.3733
T = 56.9362
T = 58.9821
------------------------------------------------------------------------------------------------------------------CCAGAACCCAATCTGG-ATTGCAGTCTTACTTGTTGC AGTTTCATGGTTTGGTTAGA-TTGGTTCACCAGGAGA GAACTTTGGCCTTTCCT
-GGTCTTGGGTTAGACC TAACGTCAGAATGAACAACG-TCAAAGTACCAAACCAATCT AACCAAGTGGTCCTCT-CTTGAAACCGGAAAGGA
T = 56.6284
T = 58.8957
T = 56.8628
T = 56.8355
T = 57.0704
----------------------------------------------------------------------------------------------TTGACCATTAGATGTTTCTTGG GATGTGAATTGCCTCCA-GAAGGTTCTAGAGCTCATG TTTTTTTCGAAGTTGCTGTT-AACGGTTCTTCTTTCGTT
AACTGGTAATCTACAAAGAACC-CTACACTTAACGGAGGT CTTCCAAGATCTCGAGTAC-AAAAAAAGCTTCAACGACAA TTGCCAAGAAGAAAGCAA
T = 58.5048
T = 56.9309
T = 57.0395
T = 56.7238
T = 56.8126
----------------------------------------------------------------------------------------------------TCTTTCAGACCTGAGAGA-GCCTTGTGGCAGGCTG ATACTCAGGTTACCTCTGG-AGTTGTTACTTTCACCTTGC AACAGTTGAACGCTTATAACA
-AGAAAGTCTGGACTCTCT CGGAACACCGTCCGAC-TATGAGTCCAATGGAGACC TCAACAATGAAAGTGGAACG-TTGTCAACTTGCGAATATTGT
T = 56.401
T = 64.6309
T = 57.7534
T = 58.4542
T = 57.8503
---------------------------------------------------------------------------------------------------GAACCAGATATGAATTGAGAGA ATTCTTGGAAGATACTTGTGT-TCAGTATGTTCAAAAGCACA TTTCTGCCGAAAACACC-AAGGGTTCTCAAACTTCTAG
CTTGGTCTATACTTAACTCTCT-TAAGAACCTTCTATGAACACA AGTCATACAAGTTTTCGTGT-AAAGACGGCTTTTGTGG TTCCCAAGAGTTTGAAGATC
T = 57.2631
T = 56.7984
T = 57.4075
T = 58.0436
T = 56.7413
--------------------------------------------------------------------------------------------------------ATCTTACACCTCTAAGAAAAGA-AAGAAGGATTACAAAGACGA CGACGATAAGAAGAGAAAGA-GAAAATGTGACACTGGTATC
-TAGAATGTGGAGATTCTTTTCT TTCTTCCTAATGTTTCTGCT-GCTGCTATTCTTCTCTTTCT CTTTTACACTGTGACCATAG
T = 56.0439
T = 56.3014
T = 56.5821
T = 56.2353
---------------------------------------------------------------------------------------------------------------CACAGAGTTTTGGCTTCT-GACCCTGGATGCATTT GTGAGTTTACTGGACCTT-TGAACCACTGTGTTGG TTCTTGTTTTGGTGGTAACG-AGTGTGAGGACATTGACA
-GTGTCTCAAAACCGAAGA CTGGGACCTACGTAAA-CACTCAAATGACCTGGAA ACTTGGTGACACAACC-AAGAACAAAACCACCATTGC TCACACTCCTGTAACTGT
T = 57.408
T = 56.4857
T = 56.0704
T = 56.3341
T = 58.7302
T = 58.1244
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------CTTGCATTTTTGGAGACG-ATTTGATTTATGGTGAGCCA TGCGAATGTTCTGCCC-AAACTAACCCTGATTGCG ACGCCCCATGTGCCAC
-GAACGTAAAAACCTCTGC TAAACTAAATACCACTCGGT-ACGCTTACAAGACGGG TTTGATTGGGACTAACGC-TGCGGGGTACACGGTG
T = 56.8992
T = 57.5142
T = 60.409
T = 57.6783
T = 66.7021
-------------------------------------------------------------------------------------------------TCAAAACTGTTTCATGCAG TGTAGACACCCTGAACA-TCCTATTCCAGCTTTCGG TGAAGCTTGCGTTTGT-TTGTATTCTACTCAGAACTTGC
AGTTTTGACAAAGTACGTC-ACATCTGTGGGACTTGT AGGATAAGGTCGAAAGCC-ACTTCGAACGCAAACA AACATAAGATGAGTCTTGAACG
T = 56.3193
T = 56.9429
T = 59.0842
T = 56.942
T = 57.8555
-------------------------------------------------------------------------------------------------------------CACAGTGCCAGTACGA-GTGTAACGCTAGATTTTGC CCTGACGTTCCTGAAG-TTTGTGAGGGTGATGTTT TGGACTACAACCCATACT-GTCATTGCGAATTCGGT
-GTGTCACGGTCATGCT CACATTGCGATCTAAAACG-GGACTGCAAGGACTTC AAACACTCCCACTACAAA-ACCTGATGTTGGGTATGA CAGTAACGCTTAAGCCA
T = 58.6769
T = 56.7828
T = 56.4518
T = 56.5278
T = 56.9998
T = 58.0003
------------------------------------------------------------------------------------------GGACAGACTAACGTTTGC-AGACAACCTTGCCCTT CTCCAGAATTGATCTGTGA-TGACGTTGATGAATGCA GACACCAGGATGCCGC
-CCTGTCTGATTGCAAACG TCTGTTGGAACGGGAA-GAGGTCTTAACTAGACACT ACTGCAACTACTTACGT-CTGTGGTCCTACGGCG
T = 58.3361
T = 58.1022
T = 56.4545
T = 56.5597
T = 63.9534
----------------------------------------------------------------------------------------------------CTTGAGATATGGAACCGAA TGTATGTGTTCTTATTCTGGT-CCTCAAGATCCTAACCCA GTTTGTTTCCATGAGTGC-TTGGACAATTGTTCTCAGA
GAACTCTATACCTTGGCTT-ACATACACAAGAATAAGACCA GGAGTTCTAGGATTGGGT-CAAACAAAGGTACTCACG AACCTGTTAACAAGAGTCT
T = 56.5937
T = 56.5149
T = 58.0162
T = 56.7897
T = 56.3285
---------------------------------------------------------------------------------------------------------CCGCTTCTGCCACCTG-TTCTAGAGGAGATGCCC AGTTGGCTGCTGGTGC-TCCTTGCCAATGTAGAC CTGCTGGTCCAATTGC-TAACTGTGCTCACGAATG
-GGCGAAGACGGTGGAC AAGATCTCCTCTACGGG-TCAACCGACGACCACG AGGAACGGTTACATCTG-GACGACCAGGTTAACG ATTGACACGAGTGCTTAC
T = 63.8609
T = 57.2886
T = 63.5895
T = 56.1306
T = 58.506
T = 57.2194
---------------------------------------------------------------------------------TGGAGGTAATGAGGTTTCT-TGTGACTGGGCTAGAA AGAAGAAGAGACATCATCAC-CATCACCACTAAGCGG CCGCTA
-ACCTCCATTACTCCAAAGA ACACTGACCCGATCTT-TCTTCTTCTCTGTAGTAGTG GTAGTGGTGATTCGCC-GGCGAT
T = 57.7677
T = 56.5621
T = 56.554
T = 57.0889
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5C.4 Chimera #2 Starting original nucleotide sequence
ATCTCGAGAAAAGATTTTGTAGTCAAGATGCTTCTGATGGTCTACAAAGATTG
CATATGTTGCAAATCTCTTACTTTCGTGATCCTTATCATGTTTGGTACCAAGGT
AATGCTTCTTTGGGTGGACATTTGACTCATGTTTTGGAAGGTCCAGATACTAA
TACTACTATCATTCAATTGCAACCTTTGCAAGAACCTGAAAGTTGGGCTCGTA
CTCAAAGTGGTTTGCAATCTTACTTGTTACAATTTCATGGTCTAGTTCGTTTGG
TTCATCAAGAACGTACTTTGGCTTTTCCTTTGACTATCCGTTGTTTTTTGGGTT
GTGAATTGCCTCCTGAAGGTTCTAGAGCTCATGTTTTTTTTGAAGTTGCTGTTA
ATGGTAGTTCTTTTGTTAGTTTTCGTCCAGAAAGAGCTTTGTGGCAAGCTGAT
ACTCAAGTCACCTCTGGAGTTGTCACCTTTACCTTGCAACAATTGAATGCTTA
CAATCGTACTCGTTATGAATTACGTGAATTTCTTGAAGATACTTGTGTTCAAT
ATGTTCAAAAACATATTTCTGCTGAAAATACTAAAGGTAGTCAAACTAGTCG
TTCTTACACTTCTGAACAAAAACTCATCTCAGAAGAGGATCTGAATAGCGCC
GTCGACTGTTCTGTTGAAAATGGTGGTTGTGAACATGCTTGTAATGCTATTCC
AGGTGCTCCAAGATGTCAATGTCCAGCTGGTGCTGCTTTGCAAGCTGATGGTA
GATCTTGTACTGCTTCTGCTACTCAATCTTGTAATGATTTGTGTGAACATTTCT
GTGTTCCAAATCCAGATCAACCAGGTTCTTATTCTTGTATGTGTGAAACTGGT
TATAGATTGGCTGCTGATCAACATAGATGTGAAGATGTTGATGATTGTATTTT
GGAACCATCTCCATGTCCACAAAGATGTGTTAATACTCAAGGTGGTTTCGAAT
GTCATTGTTATCCAAATTATGATTTGGTTGATGGTGAATGTGTTGAACCAGTT
GATCCATGTTTCAGAGCTAATTGTGAATATCAATGTCAACCATTGAATCAAAC
TTCTTATTTGTGTGTTTGTGCTGAAGGTTTCGCTCCAATTCCACATGAACCACA
TAGATGTCAAATGTTCTGTAATCAAACTGCTTGTCCAGCTGATTGTGATCCAA
ATACTCAAGCTTCTTGTGAATGTCCAGAAGGTTATATTTTGGATGATGGTTTC
ATTTGTACTGATATTGATGAATGTGAAAATGGTGGTTTCTGTTCTGGTGTTTG
TCATAATTTGCCAGGTACTTTCGAATGTATTTGTGGTCCAGATTCTGCTTTGGT
TAGACATATTGGTACTGATTGTGATTCTGGTAAGCATCATCACCATCACCACT
AAGCGGCCGCTA
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5C.5 Resulting Forward Translation of Chimera #2
a t c t c g a g a a a a g a FCSQDASDGLQRLHMLQISYFRDPYHV
WYQGNASLGGHLTHVLEGPDTNTTIIQLQPLQEPESWART
QSGLQSYLLQFHGLVRLVHQERTLAFPLTIRCFLGCELPP
EGSRAHVFFEVAVNGSSFVSFRPERALWQADTQVTSGVV
TFTLQQLNAYNRTRYELREFLEDTCVQYVQKHISAENTK
GSQTSRSYTSEQKLISEEDLNSAVDCSVENGGCEHACNAI
PGAPRCQCPAGAALQADGRSCTASATQSCNDLCEHFCVP
N P D Q P G S Y S C Met C E T G Y R L A A D Q H R C E D V D D C I L E P S P C P
QRCVNTQGGFECHCYPNYDLVDGECVEPVDPCFRANCEY
Q C Q P L N Q T S Y L C V C A E G F A P I P H E P H R C Q Met F C N Q T A C P A
DCDPNTQASCECPEGYILDDGFICTDIDECENGGFCSGVC
H N L P G T F E C I C G P D S A L V R H I G T D C D S G K H H H H H H Stop
gcggccgcta

Legend
Lower-case: nucleotides

Upper Case: Amino Acids

Black- added sequence

Red- EPCR mature peptide

Green- Flag epitope

Blue- TM-2 (Asp226 to Lys466) normal

Orange- His 6 tag

Underline-Xho1 and Not1 sites
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5C.6 Chimera #2 Oligo Design Hybridization Map
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Note that the above does not contain the His tag. Manual addition resulted in the
following three oligos substituted at the 3’ end.
R1343his 5’ TGATGCTTACCAGAATCACAATCAGTACCAATATGTCTAA 3’
F1364his 5’ GTGATTCTGGTAAGCATCATCACCATCACCACTAAGC 3’
R1383his 5’ TAGCGGCCGCTTAGTGGTGATGGTGA 3’

